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Abstract 
This PhD research focuses on understanding a maternal pregnancy condition 
known as pre-eclampsia. This condition contributes to around 14 % of the 
global burden of maternal mortality and fivefold of perinatal mortality in 
developing countries. Genetic, environmental, nutritional and socioeconomic 
factors are thought to disproportionately affect the burden of pre-eclampsia in 
low and middle-income countries (LMIC). 
The first chapter gives an overview; it introduces pre-eclampsia and outlines 
its contribution to the burden of maternal and infant mortality and morbidity. It 
summarises all chapters in this thesis. 
The second chapter gives the background of the literature review. This 
chapter describes pre-eclampsia in the context of hypertensive disorders of 
pregnancy. It then explains some of the risk factors of pre-eclampsia, the 
natural history of the disease and the health system response: current 
modalities in screening, the evolution of the definition pre-eclampsia, 
diagnosis, prevention and management. 
The third chapter describes the scoping study, which aims at summarising 
explored risk factors in Africa, to identify potential gaps and the feasibility of 
conducting a systematic review. Its results showed that there were twenty 
studies done in Africa that had explored relatively few risk factors. These 
studies had methodological limitations of size and rigour, hence produced 
conflicting and inconclusive associations between pre-eclampsia outcome 
and most explored risk factors, including malaria infection. They also showed 
a gap in the literature regarding models built by risk factors that attempted to 
classify pre-eclampsia outcome in African populations.  
The fourth chapter describes the systematic review that explores the 
relationship between malaria infection and gestational hypertension (GH) 
with proteinuria (pre-eclampsia) or without. It considers two pathways that 
malaria possibly exert its effect on causing gestational hypertension. One 
pathway being through a dysfunctional placenta and the other pathway is by 
  
endothelial inflammation of blood vessels from malaria toxins. The result of 
the meta-analysis was a pooled odds ratio (OR) of 2.6, 95 % confidence 
interval (CI) 1.5 to 4.5. The odds of pre-eclampsia among pregnant women 
with malaria infection were 2.6 times than pregnant women without malaria 
infection. 
The fifth chapter describes the analysis of secondary data from Tanzania. 
This data analysis has four objectives. The sixth chapter describes the 
results of the four objectives, while chapter Seven presents the discussions 
of the four objectives. This data analysis used data from two sources: a 
hospital maternity register from northern Tanzania and a clinical trial in Dar 
es Salaam, Tanzania. The data analysis had four objectives; objective one 
determined the incidence pre-eclampsia to be 1.9 %, 95 % CI 1.3 % to 2.2 % 
in Dar es Salaam city, Tanzania. Objective two describes the 
sociodemographic characteristics of women with pre-eclampsia compared 
with those without pre-eclampsia in northern Tanzania population. Pre-
eclampsia was more frequent among women with age above 35 years, single 
and tertiary level education.  
Objective three aimed to identify biomedical risk factors for pre-eclampsia 
among women in northern Tanzania. Then, I used these identified risk factors 
to build prediction models for pre-eclampsia. I later assessed the ability of 
these models to classify women with and without pre-eclampsia. Maternal 
age, weight before pregnancy, contraceptive intrauterine device (IUD) use, a 
diagnosis of malaria, diagnosis of infections, history of hypertension and HIV 
treatment were statistically significant predictors in some of my models. My 
final models in predicting pre-eclampsia in all deliveries, term and preterm 
delivery subgroups produced an area under the curve of 69.4 %, 71.2 % and 
66.9 % respectively. The points of maximum sensitivity and specificity 
produced sensitivity values of 65 %, 65 % and 59 % respectively, while also 
producing specificity values of 63 %, 65 % and 66 % respectively. The risk 
factors and the prediction models were developed on a hospital-based 
register where the incidence of pre-eclampsia was 3.5%. Since hospital 
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estimates tend to overestimate the incidence compared to population survey, 
the results of my prediction models will differ in women populations with a 
high risk of pre-eclampsia.  
The fourth objective describes the pregnancy outcome of women with pre-
eclampsia compared to women without pre-eclampsia. The results showed 
there were more stillbirths among women with pre-eclampsia. The odds of 
stillbirth were 4.8 (95 % CI 3.7 – 6.3) times among women with pre-
eclampsia than women without pre-eclampsia in all deliveries. Upon 
stratifying by term and preterm deliveries the odds were 2.6 (95 % CI 1.6 – 
4.3) and 2.9 (95 % CI 2.0 – 4.1) respectively. The surviving offspring have 
worse developmental indicators compared to their counterparts in terms of 
low a Apgar score at 1-minute, low birth weight, small head circumference 
and short birth length. The odds of a low Apgar score (0 – 3) baby was 4.3 
times (95 % CI 3.4 - 5.4) among pre-eclampsia women in all deliveries 
compared to normal Apgar score (4 – 10) babies. The association was 
maintained in the subgroups of term and preterm delivery (OR = 2.3, 95 % CI 
1.5 – 3.5 and 2.8, 95 % CI 2.0 - 3.9 respectively). 
Chapter Eight covers the conclusion and recommendations of this thesis, 
which are: (i) Few studies that explored risk factors in Africa, more studies 
are needed to resolve conflicting and inconclusive findings from these 
studies. (ii) Malaria infection is associated with pre-eclampsia and gestational 
hypertension in malaria endemic regions. Malaria control should be 
intensified among pregnant women and further studies should explore the 
causal mechanisms. (iii) The incidence of pre-eclampsia should be tracked to 
observe changes in its trends in the evolving urban populations of LMIC. (iv) 
Affordable and feasible prediction models for pre-eclampsia should be 
developed and assessed for performance to enable identification and 
provision of prevention services on women with a high risk of developing pre-
eclampsia. (v) Women with pre-eclampsia should receive appropriate 
treatment to mitigate the negative impact on their pregnancy outcome. 
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Lay Summary 
This PhD research aims to contribute to our understanding of a maternal 
condition called pre-eclampsia in low and middle-income countries (LMIC). 
This condition is defined by the international society for the study of 
hypertension in pregnancy (ISSHP) as a rise in blood pressure during 
pregnancy that may occur at 20 weeks onwards accompanied by either 
proteinuria or other organ damage. It is reported as one of the top causes of 
maternal and infant death. National, regional and global targets have been 
set in an attempt to reduce maternal and infant death. Despite the decline, 
some causes of maternal death have persisted in some regions of the world. 
I believe researching in this area would uncover the problems and pave the 
way for designing preventive strategies. 
The World Health Organisation (WHO) reports that two-third of maternal 
death occur in Sub-Saharan Africa. Sub-Saharan Africa has certainly not 
made sufficient progress in reducing maternal deaths compared to other 
regions. WHO reported that from 2000 to 2017 maternal mortality dropped by 
40% in Sub-Saharan Africa, while in Southern Asia it dropped by 60 %. What 
is holding back this region and what are the causes of these deaths in the 
region? Most maternal deaths arise from preventable causes such as; 
bleeding during and after delivery, hypertensive disorders of pregnancy, 
infections, obstructed labour and unsafe abortions. Unlike the above causes, 
deaths from hypertensive disorders of pregnancy seem more difficult to 
address especially in LMIC. A successful reduction of maternal deaths in 
LMIC has to include addressing hypertensive disorders of pregnancies, 
which account 14 % of global maternal deaths according to WHO data. If 
progress is to be made on the reduction of global maternal mortality ratios, it 
is important to improve our understanding of the occurrence of hypertensive 
disorders of pregnancy focusing on pre-eclampsia in low-income settings. 
This PhD research aims to contribute knowledge in this field. 
Chapter One and Two sets out a general literature review on what is known 
about the occurrence, causes, outcomes and management of hypertensive 
  
disorders of pregnancy, with a focus on pre-eclampsia. It outlines the 
complexity of this subject and then highlights the implications of this 
complexity for the prevention and management of this condition in low- 
income countries such as Tanzania, which is the case study of this PhD.  
Chapter Three covers a scoping review on risk factors of pre-eclampsia in 
Africa; the purpose of the scoping review was to summarise existing 
evidence of risk factors for pre-eclampsia in Africa, identify gaps in the 
literature and identify a suitable systematic review topic and assess the 
feasibility of undertaking it. The results showed risk factors for pre-eclampsia 
have not been adequately explored in the African population, marked by the 
relatively few studies reported from my search. My literature search suggests 
local risk factors such as malaria infection during pregnancy may drive pre-
eclampsia condition in this region. I observed a gap in lack of literature that 
shows how well risk factors can classify women with pre-eclampsia in African 
populations. Following these identified gaps, my data analysis explored 
malaria as a local risk factor for pre-eclampsia alongside other risk factors 
that are prevalent globally such as chronic hypertension. I have also 
assessed how prediction models build from the identified risk factors can 
classify pre-eclampsia outcome in northern Tanzania population. 
Chapter Four is a systematic review and meta-analysis on the relationship 
between malaria infection and gestational hypertension with or without 
proteinuria. My findings from the meta-analysis showed that malaria infection 
was associated with gestational hypertension [with proteinuria (pre-
eclampsia) and without]. Thus, I was able to suggest the potential 
contribution of malaria infection in the overall burden of hypertensive 
disorders of pregnancy in Africa. 
Chapter Five covers the analysis of secondary data on risk factors for pre-
eclampsia in Tanzania. I first estimated the incidence of pre-eclampsia in the 
urban settings of Dar es Salaam city. My age-adjusted incidence estimate 
(1.9 %, 95 % CI 1.3 % - 2.2 %) was similar to global estimates of pre-
eclampsia. Second, I described the sociodemographic characteristics of 
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women with pre-eclampsia. Pre-eclampsia appeared to be more frequent 
among women with older age and tertiary level education in northern 
Tanzania. Third, I used modelling to identify risk factors of pre-eclampsia in a 
population of singleton women from northern Tanzania. I examined the 
performances of these models in classifying women with or without pre-
eclampsia using area under the curve, sensitivity and specificity values. My 
findings showed there were differences in risk factors that predicted pre-
eclampsia outcome in the term and preterm deliveries subgroups. Fourth, I 
described the pregnancy outcomes of women with pre-eclampsia. My 
findings showed that infant deaths were high in women with pre-eclampsia. 
Surviving offspring of women with pre-eclampsia had poor indicators of 
physical and mental health. Therefore, efforts to avert pre-eclampsia may 
have a potential change with lifelong impact in improving the survival and 
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Chapter 1 Thesis Overview. 
This PhD research focuses on understanding a maternal pregnancy condition 
known as pre-eclampsia. This condition contributes to around 14 % of the 
global burden of maternal mortality and increases the risk of perinatal 
mortality fivefold in low and middle-income countries (LMIC) (López Jaramillo 
et al. 2009, Say et al. 2014). The World Back categorises countries with 
gross national income per capita (United States dollars-USD) of ≤ 1,025 as 
low income, 1,026 – 3,995 as lower middle income, 3,996 – 12,375 as upper 
middle income and ≥ 12,376 as high-income countries. There is a 
considerable body of research knowledge suggesting the association 
between pre-eclampsia and a range of genetic, environmental, nutritional and 
socioeconomic factors (López-Jaramillo et al. 1997, Williams and Morgan 
2012, Elongi Moyene et al. 2016). These factors are thought to 
disproportionately affect the burden of pre-eclampsia in LMIC as observed in 
the difference in the burden of pre-eclampsia and eclampsia across world 
regions (Firoz et al. 2011), (Abalos et al. 2013).  
In this thesis, I start by introducing my research on risk factors for pre-
eclampsia in LMIC focusing on pre-eclampsia in the context of the wider 
problem of hypertensive disorders of pregnancies. The term hypertensive 
disorders of pregnancy (HDP) refers to a group of distinct diseases that 
includes; white coat hypertension, pre-eclampsia gestational hypertension, 
and chronic hypertension (Tranquilli et al. 2014). There are two important 
challenges in conducting research into pre-eclampsia, particularly in low 
resource settings. The first is that, as I explain later, the aetiology and 
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pathogenesis of pre-eclampsia and the other hypertensive disorders of 
pregnancy are not fully understood. It is unclear whether early onset and late 
onset pre-eclampsia share the same risk factors in LMIC populations. The 
second challenge is that the different hypertensive disorders of pregnancy 
are not always accurately diagnosed and distinguished from each other, 
particularly in resource-poor settings (Abalos et al. 2013). The risk of 
misclassification is therefore significant. 
This thesis focuses on understanding the risk factors for pre-eclampsia, 
which is a subject of growing public health concern. It deserves increased 
attention due to ongoing lifestyle changes across populations in Sub-Saharan 
Africa, because of globalisation and urbanisation which affect environmental, 
nutritional and socioeconomic factors. I have described the epidemiology of 
the condition and the evolving health system response. This sets the scene 
for the potential contribution of my research in advancing knowledge of the 
condition in LMIC.  
Pre-eclampsia is one of the leading global causes of maternal and infant 
mortality. National, regional and global targets have been set in an attempt to 
reduce maternal and infant death, but despite declines in global maternal 
mortality ratio by half (from 1990 to 2015, as seen below), some causes of 
maternal death have persisted in some regions of the world. Maternal deaths 
due to hypertensive disorders (including pre-eclampsia) have persisted 
around 15 % from 1994 to 2014 (as seen below). More research on 
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understanding the risk factors for pre-eclampsia in LMIC is an essential first 
step in designing effective preventive strategies. 
Global maternal mortality ratios have fallen sharply over the last quarter-
century. The global maternal mortality ratio (MMR) fell from 385 deaths per 
100,000 live births (80 % Confidence Interval (CI), 359 to 427 per 100,000 
live births) in 1990, to 216 (80 % CI, 207 – 249) deaths per 100,000 live 
births in 2015. However, there is marked variation between countries, the 
MMR still being high in many low-income countries. In 2015 the MMR ranged 
from 12 deaths per 100 000 live births (95 % confidence interval (CI), 11 to14 
per 100,000 live births) for high-income regions to 546 (95 % CI, 511 – 652) 
for Sub-Saharan Africa (Alkema et al. 2016). Sub-Saharan Africa has 
certainly not made sufficient progress in reducing maternal deaths. What is 
holding back this region and what are the causes of these maternal deaths in 
the region? Most maternal deaths arise from preventable causes such as 
haemorrhage during and after delivery, hypertensive disorders of pregnancy 
(including pre-eclampsia), infections, obstructed labour and unsafe abortions 
(Say et al. 2014). In low-income countries between 1991 and 2014, maternal 
deaths attributable to sepsis and infections fell steeply in absolute values (20 
% to 10.7 %). There was a moderate decline in maternal deaths from 
haemorrhage (30 % to 27.1 %) while maternal death from hypertensive 
disorders (15 % to 14 %) remained fairly constant (Abouzahr et al. 1994, Say 
et al. 2014). The decline in deaths due to infection can be accounted for by 
antibiotic use, which has reduced maternal deaths due to infections and 
abortions (Maine and Rosenfield 1999). Obstructed labour has been 
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addressed through improvements in obstetric care by the deployment of 
skilled health care workers and the establishment of referral mechanisms 
(WHO 2004b). Provision of blood services and uterotonic drugs has reduced 
deaths due to haemorrhage (Kuzume et al. 2017). Unlike the above causes, 
deaths from hypertensive disorders of pregnancy seem more difficult to 
address. This is partly because of complexity: this group of conditions 
encompasses several sub-categories that can be challenging to distinguish 
from one another, particularly in low-income settings, thus presenting 
difficulties in specifying the diagnosis and in choosing the correct 
management path. The relative intractability of this problem may also be 
impacted by broader changes to population health affecting LMIC. Growing 
urbanization and adoption of western diet and lifestyle in these settings is 
thought to drive an increase in cardiovascular disease (CVD). In 2016, CVD 
was the third highest cause of death in Sub-Saharan Africa, up from 5th in 
1990 (IHME 2016). Similar to this, a successful reduction of maternal 
mortality in LMIC has to include addressing hypertensive disorders of 
pregnancies, which account for 14 % of global maternal deaths (Say et al. 
2014). If progress is to be maintained on the reduction of global maternal 
mortality ratio, it is important to improve our understanding of the 
epidemiology of hypertensive disorders of pregnancy in general, and pre-
eclampsia in particular, in low-income settings. This PhD research project 
aims to contribute knowledge in this field. 
Chapter Two sets out a general literature review on what is known about the 
epidemiology, aetiology, outcomes and management of hypertensive 
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disorders of pregnancy, with a focus on pre-eclampsia. It outlines the 
complexity of this subject and then highlights the implications for the 
prevention and management of this condition in low-income countries such 
as Tanzania, which is the case study of this PhD research.  
Chapter Three is a scoping review on risk factors for pre-eclampsia in Africa. 
The purpose of the scoping review was to summarise existing evidence of 
risk factors for pre-eclampsia in Africa, identify gaps in the literature and 
identify a systematic review topic and assess the feasibility of undertaking it 
(Arksey and Malley 2005). The results showed risk factors for pre-eclampsia 
have not been adequately explored in the African population, marked by the 
relatively small number of studies identified. This scoping review suggests 
that locally relevant risk factors such as malaria infection during pregnancy 
may drive pre-eclampsia in Sub-Saharan Africa. 
In addition to the scoping review of literature, I observed a gap in the general 
literature of pre-eclampsia in African populations. There are no studies on the 
performance of prediction models using biomedical risk factors to classify 
women with pre-eclampsia in African populations. We do not know how well 
we can predict and classify pre-eclampsia outcome among African women. 
Following these identified gaps, my analysis of secondary data explored 
malaria as a regional specific risk factor for pre-eclampsia alongside other 
risk factors that are prevalent globally such as chronic hypertension. I have 
also assessed how models built from the identified risk factors can classify 
pre-eclampsia outcome in northern Tanzania population. 
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Chapter Four is a systematic review and meta-analysis of the association 
between malaria infection and gestational hypertension with or without 
proteinuria. My findings from the meta-analysis showed that malaria infection 
was associated with gestational hypertension (with proteinuria/pre-eclampsia 
and without). The strength of this association was a pooled odds ratio (OR) of 
2.6, 95 % CI 1.5 to 4.5). Thus, I was able to suggest the potential contribution 
of malaria infection in the overall burden of hypertensive disorders of 
pregnancy in Africa. 
Chapter Five is an analysis of secondary data on risk factors for pre-
eclampsia using two data sets from Tanzania. Chapter Six is the result of the 
data analysis in Chapter Five, while chapter Seven is the discussion of the 
results in Chapter Six. The data analysis covers four objectives. I first 
estimated the incidence of pre-eclampsia in the urban settings of Dar es 
Salaam city using a data set from a clinical trial. This data set is described in 
detail in Chapter Five, section 5.5.3. The age-adjusted incidence estimate of 
pre-eclampsia was 1.9 % (95 % CI 1.3 % - 2.2 %) which was similar to global 
estimates of pre-eclampsia 2 % to 8 % (Abalos et al. 2013). I used a second 
data set (a hospital registry data set, which is described in Chapter Five, 
section 5.5.2) to describe the sociodemographic characteristics of women 
with pre-eclampsia. Pre-eclampsia appeared to be more frequent among 
women with older age and tertiary level education in northern Tanzania. A 
multivariable logistic regression model of all sociodemographic 
characteristics showed that women with age 36 - 40 and ≥ 41 years were 
statistically significantly associated with having pre-eclampsia (OR = 1.8 [95 
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% CI, 1.2 – 2.8] and 2.6 [95 % CI, 1.4 – 4.6] respectively). Independent of 
age, women with tertiary level education were associated with having pre-
eclampsia (OR = 1.34, 95 % CI 1.06 - 1.69). Thirdly, I used logistic 
regression modelling to identify risk factors for pre-eclampsia in a population 
of singleton women from northern Tanzania. I examined the performance of 
these logistic regression models in classifying women with or without pre-
eclampsia using area under the curve, sensitivity and specificity values. My 
analysis further included two sub-groups: women who delivered their babies 
at term and women who had preterm deliveries. My findings show there were 
differences in the set of risk factors that predicted pre-eclampsia outcome in 
the subgroups. Pre-eclampsia in term deliveries was predicted by; maternal 
age, the number of pregnancies, weight before pregnancy, history of 
hypertension, HIV treatment, contraceptive IUD use, diagnosis of infections 
and diagnosis of malaria. While pre-eclampsia in preterm delivery was 
predicted by; maternal age, history of hypertension, diagnosis of infections 
and weight before pregnancy. Fourthly, I described the pregnancy outcomes 
of women with pre-eclampsia. My findings showed that the rate of stillbirths 
was higher in pre-eclampsia pregnancies, compared with normal 
pregnancies (OR = 4.874, 95 % CI 3.75 – 6.331). Surviving offspring of pre-
eclampsia pregnancies had poor indicators of physical and mental health.  
• Offspring survival 
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o The odds of stillbirth were 4.8 (95 % CI 3.7 – 6.3) times among 
women with pre-eclampsia than women without pre-eclampsia in all 
deliveries.  
• Mental and physical wellbeing of newborn 
o Pre-eclampsia was associated with a low Apgar score (OR = 4.3, 
95 % CI 3.4 - 5.4) in all deliveries. 
• Physical wellbeing of newborn 
o The odds of low birth weight baby were 6.4 (95 % CI 5.3 – 7.6) 
times among women with pre-eclampsia than women without pre-
eclampsia in all deliveries. 
o In all deliveries, newborns of pre-eclampsia women were shorter in 
birth length than their counterparts, mean difference of 1.92cm, 95 
% CI 1.54 - 2.29, p < 0.001. This difference was observed in both 
term (0.40cm, 95 % CI 0.18 - 0.63, p < 0.001) and preterm 
subgroups (3.72cm, 95 % CI 2.83 - 4.62, p < 0.001. 
Literature in this area suggests these features indicate fetal programming in 
pre-eclampsia newborns thus placing the surviving newborns into health risks 
in their adult life (Rogvi et al. 2012, Palinski 2014, Ashtin et al. 2019). 
Therefore, efforts to avert pre-eclampsia may potentially improve the survival 
and wellbeing of newborn infants. Chapter Eight presents the conclusion and 
recommendation from the data analysis. This chapter also shows my plans/ 
way forward after completion of this research work. 
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Chapter 2 Background Literature Review. 
This general review of the literature on pre-eclampsia is divided into the 
following sections: 
• Hypertensive disorders of pregnancy: an overview 
• Pre-eclampsia: an overview 
• Prevalence, temporal trends and geographical distribution of pre-
eclampsia 
• The natural history of pre-eclampsia 
• Risk factors for pre-eclampsia 
• Global, national and health system responses to pre-eclampsia 
2.1 Hypertensive disorders of pregnancy: an 
overview  
Pre-eclampsia is a subcategory within a broad collection of conditions known 
as hypertensive disorders of pregnancy. High blood pressure (BP) during 
pregnancy encompasses several different conditions: chronic hypertension; 
transient gestational hypertension; gestational hypertension; pre-eclampsia; 
white coat hypertension and masked hypertension. Pre-eclampsia may 
progress to Eclampsia and  HELLP (Hemolysis, which is the breaking down 
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of red blood cells; Elevated Liver enzymes; Low Platelet count) and pre-
eclampsia may superimpose on chronic hypertension (Brown et al. 2018).  
Chronic hypertension is a preexisting condition of elevated systolic/diastolic 
blood pressure (≥ 140/90 mmHg) prior to pregnancy, which does not resolve 
within 12 weeks after delivery. This condition results from factors that are 
often unrelated to pregnancy (e.g. obesity, genetic factors) and is a lifelong 
condition. It is detected by high blood pressure before 20 weeks of gestation 
and its persistence 12 weeks after delivery. The prevalence of chronic 
hypertension is estimated to be 5 % of all pregnancies (Mammaro et al. 
2009). Although unrelated to pregnancy, pregnancy tends to affect the 
control of chronic hypertension; hence, women with this condition require 
extra consideration on their management when they become pregnant. It is 
reported that women with severe chronic hypertension, SBP ≥ 160mmHg or 
DBP ≥ 110mmHg, within the first 12 weeks of pregnancy are at 50 % 
increased risk of developing pre-eclampsia superimposed on chronic 
hypertension. 
Gestational hypertension is a new onset of elevation of blood pressure, 
without proteinuria, that occurs during pregnancy from 20 weeks onwards 
and persists throughout pregnancy only to subside after delivery. This 
condition occurs in women who were not previously hypertensive (Brown et 
al. 2018). 
Transient gestational hypertension is a new onset of elevated blood pressure 
arises at any gestation and resolves without treatment during pregnancy 
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hence the name transient. It too is not characterised by proteinuria (Brown et 
al. 2018). White-coat hypertension means elevated blood pressure (≥140/ 90 
mmHg) taken at health facility but normal blood pressure when measured at 
home or work (< 135/85 mmHg); it is not an entirely benign condition it 
indicates an increased risk for pre-eclampsia (Brown et al. 2018). 
Masked hypertension is another form of hypertension, more challenging to 
diagnose. It is characterised by blood pressure that is normal at a health 
facility visit but elevated at other times, most typically diagnosed by 24 hours 
ambulatory blood pressure monitoring (ABPM) or automated home blood 
pressure monitoring (HBPM) (Brown et al. 2018). 
The current advice is regardless of the hypertensive disorder of pregnancy, 
blood pressures consistently ≥ 140/90 mmHg in health facility visit or ≥ 
135/85 mmHg at home should be treated. The treatment should aim for a 
target diastolic blood pressure of 85 mmHg in the health facility (and systolic 
blood pressure of 110–140 mmHg) to lower the likelihood of developing 
severe maternal hypertension and other complications (Brown et al. 2018). 
The sub-categories of high blood pressure during pregnancy can easily be 
confused with each other and pose some challenges in their diagnosis. Each 
category has a unique management path; thus, misdiagnosis can result in 
mismanagement of the condition. The potential misclassifications of these 
sub-categories make it difficult to achieve exact confirmation of the cause of 
maternal death from hypertensive conditions (Duley 1992). This impairs the 
validity of aggregated data from lower level health facilities (which often do 
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not have the technology and expertise to make a precise diagnosis) to 
national level health facilities in many LMIC, thus making it difficult to 
establish the burden of each subcategory of hypertensive disorders of 
pregnancy (Firoz et al. 2011, Bilano et al. 2014). 
 
2.2 About pre-eclampsia: an overview 
Pre-eclampsia is a hypertensive condition that arises after the 20th week of 
gestation. It can occur in a non-hypertensive woman or it may be 
superimposed on preexisting chronic hypertension. In the former scenario, it 
is characterised by persistent high systolic (≥ 140 mmHg) or diastolic (≥ 90 
mmHg) blood pressure and organ damage/proteinuria. Proteinuria levels of ≥ 
0.3 g/24 hours or a dipstick result of  ≥ 1 +, equivalent to 30 mg/dl in a single 
urine sample or spot urine protein/ creatinine ratio ≥ 30 mg protein/mmol 
creatinine, of new onset after 20 weeks of gestation (Tranquilli et al. 2014). 
For preexisting chronic hypertension, the blood pressure is exacerbated, and 
a new onset of proteinuria is observed after the 20th week of gestation. To 
diagnose pre-eclampsia, one requires the gestational age at the onset of high 
blood pressure and proteinuria. Clinical skills and tools such as 
sphygmomanometer (for blood pressure) and urine dipstick are necessary to 
obtain this diagnosis. Routine screening for blood pressure and proteinuria is 
necessary prior to the 20th week to pick up the new onset of these key signs. 
Over time, the definition of pre-eclampsia has evolved, to match with our 
increasing recognition of its systemic nature and its heterogeneous clinical 
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presentation. For example, a significant proportion of women develop severe 
pre-eclampsia without proteinuria being detectable while having other signs 
of organ damage (Barton et al. 2001). As a result, the Canadian hypertensive 
disorders of pregnancy working group reflected this change in its report. This 
change has led to a revised definition of pre-eclampsia to include the 
presence of severe features with or without proteinuria (Magee et al. 2014). 
The recommendations from different countries lead to the 2014 revised 
recommendations by the International society for the study of hypertension 
which also viewed some subcategories of hypertensive disorders of 
pregnancy as a spectrum rather than discrete entities (Tranquilli et al. 2014). 
However, the adoption of these new definitions depends on the ability of 
different national health systems to operationalise the definition in their 
settings. Most LMIC have continued to use the rather simple definition stated 
above.  
The aetiology of pre-eclampsia is still unknown. There are several theories 
attempting to explain its causation. This lack of clear understanding of its 
aetiology has deterred efforts to diagnose, prevent and treat the condition 
effectively. Some theories have classified pre-eclampsia based on its onset 
during gestation, early onset (≤ 34 weeks) and late onset (≥ 34 weeks). The 
onset classification is useful in guiding management since early onset is 
associated with worse outcomes (Phipps et al. 2016). An alternative 
classification is based on the severity of raised blood pressure: mild (BP < 
160/110mmHg), severe (BP ≥ 160/110mmHg). Severe pre-eclampsia is also 
accompanied by worse outcomes (Phipps et al. 2016). 
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It is hypothesised that not all pre-eclampsia cases have the same causal 
origin. Early onset pre-eclampsia is thought to differ from late onset pre-
eclampsia in its risk factors. Therefore, to be able to effectively predict and 
screen pre-eclampsia of different onsets, we would require different 
prediction models for late and early pre-eclampsia onset types (Scazzocchio 
and Figueras 2011). Early onset pre-eclampsia (occurring in ≤ 34 weeks of 
gestation) is most closely associated with inadequate placentation and may 
well be associated with alterations in angiogenic balance. Late pre-eclampsia 
(occurring > 34 weeks of gestation) is most commonly associated with 
normal placental development and is believed to be predicted by factors 
associated with long term cardiovascular risk, such as obesity, diabetes and 
chronic hypertension (Kleinrouweler et al. 2012). This suggests that there 
may be inappropriate use of risk factors in developing pre-eclampsia 
prediction models if they do not consider the variations between early and 
late pre-eclampsia. In addition, risk factors are thought to vary across 
ethnicity. Davies-Tuck et al. (2016) showed that obesity resulted in different 
pregnancy complication in Australian women of European descent compared 
to those of South-East Asia descent. A particular risk factor may exert 
different outcomes in different ethnicities. Hence, it is necessary to determine 
what risk factors are linked to the early and late onset of pre-eclampsia in 
diverse ethnic groups of Africa. A clear understanding of risk factors involved 
in Africa will enable appropriate assignment of risk factors in the screening of 
early and late onset pre-eclampsia. We plan to use data from northern 
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Tanzania to explore these risk factors for this subpopulation of African 
women. The results may be generalizable to other subpopulations of LMIC.  
Pre-eclampsia may progress to eclampsia, which is characterised by the 
onset of generalised seizures in women with pre-eclampsia, on condition that 
the tonic-clonic seizures are not due to other causes (e.g. epilepsy). Similar 
to pre-eclampsia, the pathogenesis of eclampsia is not fully known. 
Eclampsia data show it disproportionately complicates the pregnancies in 
LMIC. Five to eight percent of women with pre-eclampsia end up presenting 
with full blown eclampsia in LMIC (WHO 2011). In the developed countries of 
North America and Europe, the incidence of eclampsia is estimated to be 5-7 
cases per 10,000 deliveries, while that of developing counties is much higher 
and varies widely from 1 case per 100 pregnancies to 1 case per 1700 
pregnancies (WHO 2004a, Shah 2009). These incidence differences may be 
due to the efficiency of health service delivery or genetic susceptibility in 
converting to eclampsia among these populations. It also demonstrates that 
within developing countries there is significant variation in the distribution of 
eclampsia. Eclampsia is associated with worse pregnancy outcomes and 
higher mortality compared to pre-eclampsia. Eclampsia is an obstetric 
emergency and requires immediate intervention to save lives of the mother 
and, before birth, her unborn child. 
HELLP syndrome occurs in 10 % – 20 % of women with severe pre-
eclampsia and is associated with substantial, widespread endothelial 
damage. HELLP is a life and death situation. Often blood leaks from the 
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blood vessels and accumulates into spaces such as the brain ventricles or 
the liver. It may also complicate to disseminated intravascular coagulopathy 
(DIC), which is often fatal. The management of eclampsia and HELLP is 
complex and requires skilled health care workers (HCW) who are scarce in 
rural settings of developing countries. Therefore, eclampsia and HELLP 
syndrome remain as important predictors of further organ dysfunctions and 
mortality (WHO 2011). 
Gestational hypertension, pre-eclampsia, eclampsia and HELLP are viewed 
as a continuous spectrum of severity in organ dysfunction and involvement 
rather than distinct conditions. This view has resulted in the redefinition of 
pre-eclampsia to encompass its systemic organ involvement. As described 
above, before 2013 the presence of proteinuria was essential to a diagnosis 
of pre-eclampsia. In the revised definition of pre-eclampsia, the borders that 
separate pre-eclampsia from other conditions on the spectrum of 
hypertensive diseases of pregnancy have shifted. However, this shift comes 
with cost and operational challenges. New tools and expertise are required to 
make an accurate diagnosis of pre-eclampsia. This poses very real 
challenges to resource-poor settings in LMIC and has limited the extent to 
which the new broad definition of pre-eclampsia in the absence of proteinuria 
has been adopted in some countries (Brown et al. 2018). 
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2.3 Prevalence, temporal trends and geographical 
distribution of pre-eclampsia  
Pre-eclampsia is known to occur across all populations in the world. 
However, there are regional variations from the reported data. The highest 
prevalence among pregnant women estimates is in Africa (AFRO) region 5.6 
% (3.6 % – 11.3 %) while the lowest prevalence estimates were in Eastern 
Mediterranean (EMRO) region 1.0 % (0.1 % – 2.6 %) (Abalos et al. 2013). 
This apparent variation in its distribution may be a result of variation in 
susceptibility or the distribution of risk factors. Furthermore, it could be a 
result of variations in diagnostic capabilities and reporting systems across 
regions. This section describes the prevalence of pre-eclampsia among 
pregnant women, evidence of temporal trends and geographical distribution 
across populations. 
Pre-eclampsia is estimated to occur in 2 % to 8 % of all pregnancies 
worldwide (WHO 2011); however, there are noticeable regional variations. A 
systematic review estimated the regional point prevalence of pre-eclampsia 
among pregnant women (95 % CI) in WHO regions of Africa (AFRO), 
America (AMRO) and south-east Asia (SEARO) to be 5.6 % of deliveries (95 
% CI 3.6 % - 11.3 %), 3.0 % (95 % CI 1.5 % - 5.2 %) and 5.1 % (95 % CI 1.9 
% - 10.9 %) respectively (Abalos et al. 2013). Most of the estimates in this 
review were hospital-based which often overestimates the incidence of pre-
eclampsia. Another limitation of the regional estimate is the paucity of 
datasets involved and their high heterogeneity. The number of datasets and 
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heterogeneity (I2) for WHO regions were: 11 (I2 = 85 %) in Africa (AFRO), 5 
(I2 = 97 %) in America (AMRO) and 5 (I2 = 95 %) South-east Asia (SEARO) 
(Abalos et al. 2013). This limits the comparison of the observed regional 
estimates. 
The trend and distribution of gestational hypertension, pre-eclampsia and 
eclampsia have been studied in high-income countries. Findings from a study 
conducted in the USA from 1987 to 2004 showed an increase in the 
incidence of gestational hypertension by 183 % (annual incidence rates per 
1,000 deliveries of 10.5 (8.2 - 12.9) to 29.7 (25.4 – 33.9)) and pre-eclampsia 
by 28 % (annual incidence rates per 1,000 deliveries of 25.1 (21.5 – 28.6) to 
32.1 (27.6 – 36.6)) during the 18-year span. The study suggested the 
following plausible contributors to this large increase: population level 
increases in known risk factors for pre-eclampsia such as pre-pregnancy 
overweight and obesity, diabetes, multiple births, and maternal age (Wallis et 
al. 2008). However, a study by Roberts et al. (2011) that explored the trend 
of gestational hypertension and pre-eclampsia in Australia, North Europe, 
North America from 1997 to 2007, showed surprisingly that contrary to 
expectation, there was a decrease in these conditions in all countries except 
in the USA. The observed increased prevalence in risk factors such as 
diabetes, nulliparity and maternal age was expected to result in an increase 
in these conditions over time (Roberts et al. 2011). The authors attributed 
their findings to the increased utilization of intervention services such as early 
elective delivery, use of low dose aspirin, calcium and vitamin 
supplementation. They also pointed out the limitation of changes in 
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diagnostic criteria from ICD9 to ICD10 that may decrease the proportion of 
pre-eclampsia cases over the years. These findings may also be influenced 
by these countries experiencing a decreased fertility rate, furthermore, 
women with pre-eclampsia have even lower subsequent pregnancies. These 
factors may confound the nature of observed results. 
In LMIC, the trend of pre-eclampsia seems to be on the rise. A hospital-
based study in Ethiopia showed the proportion of women with pre-eclampsia 
was 2.2 % of pregnancies (95 % CI 1.9 % - 2.5 % in 2009, increasing by 154 
% to 5.58 % of all pregnancies (95 % CI 5.3 % - 5.8 %) in 2013 (Wagnew et 
al. 2016). However, it is uncertain whether these results are a true increase 
in cases in the population or are the result of increased awareness and 
utilization of maternity services.  
2.4 Natural history of pre-eclampsia  
Pre-eclampsia often results in catastrophic outcomes, if the natural history of 
the disease is left without intervention. It accounts for about 14 % of maternal 
mortality and fivefold of perinatal mortality across the globe (Khan et al. 2006, 
López Jaramillo et al. 2009). It increases the risk of CVD for the surviving 
mother (Bellamy et al. 2007). Surviving infants are also prone to increased 
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Image 1: Pathogenesis of pre-eclampsia. 
 
Genetic factors, maternal factors and immunological factors interact to cause 
placental dysfunction (Phipps et al. 2019).  
2.4.1 Maternal and Infant Mortality 
Pre-eclampsia can progress to a more severe form, such as eclampsia or 
HELLP, which have far worse outcomes for maternal and fetal mortality. Pre-
eclampsia leads to intrauterine fetal growth restriction of the fetus and is also 
thought to cause stillbirths, premature delivery and low weight babies 
(Backes et al. 2011). As a result, pre-eclampsia accounts for a fivefold 
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pregnancies (López Jaramillo et al. 2009). Pre-eclampsia risk is threefold in a 
woman’s first pregnancy compared to multiparous women (Hartikainen et al. 
1998). A meta-analysis by Bartsch et al. (2016) showed first pregnancy has 
the highest population attributable risk (PAR) for pre-eclampsia among all 
other risk factors in their study (32.3 %, 95 % CI 27.4 % to 37 %). PAR of a 
given risk factor is the proportion of the incidence of the disease in the 
population that is due to the particular exposure. Although the risk of 
developing pre-eclampsia is markedly different between nulliparous and 
parous women, once they develop pre-eclampsia their pregnancy outcomes 
do not seem to differ. In a middle-income country of Jordan, Badria and 
Amarin (2005) showed that there was no statistically significant difference in 
proportions of stillbirth, neonatal deaths, assisted deliveries or low birth 
weight between nulliparous women with pre-eclampsia and parous women 
with pre-eclampsia. 
Hypertensive disorders of pregnancy (including pre-eclampsia) are estimated 
to account for maternal deaths by 9.1 %, 95 % CI 3.9 % – 21.9 % in Africa 
and 9.1 %, 95 % CI 2.0 % - 34.3 % Asia, while accounting for 25.7 %, 95 % 
CI 7.9 % - 52.4 % of maternal deaths in Latin America and the Caribbean 
(Khan et al. 2006). These estimates show a wide confidence interval due to 
uncertainty from the small studies that were used to arrive at the estimates. 
Lack of data due to weak health information systems especially in rural parts 
of Africa and Asia can explain the uncertainty in their estimates. If true, the 
true incidence might be beyond the upper limit of the 95 % CI of the estimate 
based on the available data.  
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2.4.2 Fetal programming effect 
Apart from causing infant mortality, there is growing evidence of possible 
intergenerational effects from maternal pre-eclampsia status, leading to an 
increased risk of CVD in the offspring of pre-eclampsia women in adult life. 
Fetal programming is thought to occur during the development of the embryo 
and fetus. At this stage, important physiological parameters can be reset by 
environmental factors. The local fetal cellular environment can alter gene 
expression during the developmental construction of tissues and organs, and 
these alterations can result in lasting consequences for the function of those 
tissues and organs during childhood and adulthood (Palinski 2014). This fetal 
programming effect is thought to be mediated through fetal growth restriction 
in the first trimester and abnormal offspring blood pressure and birth weight 
(Palinski 2014). Women born preterm or with inappropriate weight for 
gestational age were found to be at increased risk of gestational diabetes 
and pre-eclampsia in their adult life (Rogvi et al. 2012). 
A few studies have suggested that maternal smoking, hypercholesterolaemia 
and obesity could cause fetal programming (Cederqvist et al. 1984, Noakes 
et al. 2003). They are thought to exert their programming effect partly by 
increased oxidative stress. Common mechanisms may also include immune 
programming. Smoking during pregnancy is associated with increased levels 
of immunoglobulins M and A in cord blood which is thought to affect fetal 
immune responses to allergens (Cederqvist et al. 1984, Noakes et al. 2003). 
This evidence links the association between early fetal programming to later-
life risk of disease. As part of this thesis, I will describe the characteristics of 
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newborns of women with pre-eclampsia. These offspring may possess 
features suggestive of having experienced aversive utero environment, which 
may programme them to have increased health risks in later life.  
2.4.3 Late effects of Maternal CVD and Cancer 
Evidence from systematic reviews suggests that women who suffer from pre-
eclampsia/eclampsia are at an increased risk of developing CVD in later life 
(Bellamy et al. 2007, Wu et al. 2017, Thilaganathan and Kalafat 2019). CVDs 
are a range of diseases that affect the cardiovascular system i.e. the heart, 
the blood vessels and blood dynamics. After a mean follow up of 14.5 years, 
the review found that mortality was higher in the group who had pre-
eclampsia/eclampsia, relative to those who did not, the odds ratio was 1.49 
(95 % CI 1.05 to 2.14) (Bellamy et al. 2007). However, the potential causal 
association of pre-eclampsia to CVD is debated. Other studies suggest that 
the two are not causally linked; rather they share common risk factors 
(Magnussen et al. 2007, Romundstad et al. 2010). Increasingly studies have 
suggested that pre-eclampsia is an independent risk factor for maternal 
cardiovascular disease (Mongraw-Chaffin et al. 2010). This evidence has 
been adopted by the Guideline of the American Health Association/American 
Stroke Association (Goldstein et al. 2011). 
There is also conflicting evidence on the potential association between pre-
eclampsia and cancer. In Israel, a 12 years cohort study by Calderon 
Margalit et al found that women with pre-eclampsia were at increased risk of 
going on to develop cancer (hazard ratio 1.23, 95 % CI 1.05 to 1.45) 
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(Calderon-Margalit et al. 2009). This is biologically plausible, given that pre-
eclampsia is mediated by proinflammatory cytokines such as (TNFα) which is 
also among the markers of breast cancer (Reyes-Lopez et al. 2012, Weel et 
al. 2016). However, in contrast to this evidence, two meta-analyses showed 
pre-eclampsia was not significantly associated with the development of 
cancer: any cancer (relative risk 0.96, 95 % CI 0.73 - 1.27) (Bellamy et al. 
2007) and breast cancer (RR = 0.93, 95% CI 0.82–1.06, p = 0.27)(Sun et al. 
2018). Gestational hypertension also showed no significant association (RR 
= 0.95, 95% CI: 0.81–1.12, p = 0.54) (Sun et al. 2018). Therefore, there is 
insufficient epidemiological evidence linking pre-eclampsia to cancer.  
2.5 Risk factors for pre-eclampsia  
This section describes the commonly explored risk factors for pre-eclampsia. 
The study of risk factors has been influenced by the diversity in geographical 
location and ethnicity of the researched populations. There is regional 
inequality in the published research exploring pre-eclampsia risk factors, 
where the LMIC have been under-researched. Some risk factors have been 
consistent across different populations while others have shown inconclusive 
results. Below is a summary of risk factors commonly described in the 
literature and some plausible hypothesised mechanisms of action. 
Obesity is among the modifiable risk factors associated with the development 
of pre-eclampsia. There is a growing epidemic of obesity in high-income 
countries and this is rapidly extending to LMIC (Misra and Khurana 2008). In 
the USA from 1970 to 2004, the percentage of women who are obese (BMI > 
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30) or overweight (BMI > 25) had increased almost by 60 % (Wang et al. 
2008). A study based on the pregnant population in Pittsburgh showed a 
threefold increase in the risk of pre-eclampsia associated with obesity 
(Bodnar et al. 2005). A narrative review of the literature of articles from 1994 
to 2011 involving 28 articles also showed an association of obesity and pre-
eclampsia (Salihu et al. 2012). A 2019 published meta-analysis of 16 papers 
involving 5,946 women showed pre-eclampsia was associated with BMI 
(Kg/m2). Healthy women had mean BMI of 25.13 (95 % CI: 23.52 - 2.74), 
women with mild pre-eclampsia their mean BMI was 27.42 (95 % CI: 24.4 - 
30.34) while those with severe pre-eclampsia had a mean BMI of 26.33 (95 
% CI: 24.52 - 28.13) (Motedayen et al. 2019). However, none of the included 
papers in the above meta-analysis was from the African population. It is still 
of interest to find the association of obesity and pre-eclampsia among African 
populations. 
A possible mechanism linking obesity with hypertension is through 
asymmetric dimethyl arginine (ADMA). ADMA is an endogenous inhibitor of 
nitric oxide synthase (NOS), an enzyme that produces nitric oxide, a potent 
vasodilator. High circulating plasma ADMA concentrations are also found in 
obese subjects (Eid et al. 2004, Krzyzanowska et al. 2004, Marliss et al. 
2006, McLaughlin et al. 2006). While the exact mechanism for the increase in 
plasma ADMA in people with obesity is unknown, it may be mediated in part 
by a change in dimethyl arginine dimethyl amino hydrolase (DDAH), which is 
the key enzyme in the main pathway for degrading ADMA in the body. 
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Diabetes mellitus is a chronic disease that has long been associated with the 
development of pre-eclampsia. A meta-analysis of cohort studies by Bartsch 
et al. (2016) showed pre-gestational diabetes was associated with pre-
eclampsia with a relative risk of 3.7, 95 % CI 3.1 to 4.3. While this association 
has long been established, there is also growing evidence suggesting pre-
eclampsia is a risk factor of diabetes mellitus in later life. A meta-analysis by 
Wu et al. (2016) showed pre-eclampsia is associated with two-fold increase 
in the risk of diabetes after adjusting for BMI and gestational diabetes in later 
life. However, there is concern that the preclinical diabetic state could have 
existed prior to pre-eclampsia. (Weissgerber and Mudd 2015). It is, therefore, 
necessary to further research the relationship of diabetes mellitus and pre-
eclampsia in different African populations to uncover their temporal 
relationship in these populations.  
The prevalence of diabetes is increasing globally, initially in high-income 
countries, but also in LMIC (WHO 2017a). Insulin is now known to play a role 
in the regulation of the angiogenic processes through regulating endothelial 
cell migration proliferation (Escudero et al. 2017). Insulin exerts its signaling 
through endothelial cells and pericytes, therefore insulin may affect the 
formation of placental blood vessels and thus contribute to the development 
of pre-eclampsia.  
Hyperemesis gravidarum is a clinical condition that occurs in the first 
trimester of pregnancy. It is characterised by severe nausea and vomiting; 
weight loss and dehydration may occur. It is more severe than morning 
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sickness commonly experienced during pregnancy. It is thought to be caused 
by an increase in human chorionic gonadotrophin hormone level during 
pregnancy. Studies have shown it is associated with a twofold increase in the 
occurrence of late pre-eclampsia among pregnant women who develop it 
(Bolin 2012). This clinical condition can be exploited in predicting high-risk 
pregnancies in LMIC. Currently, there are no systematic reviews that have 
examined the association of hyperemesis gravidarum and pre-eclampsia.   
Severe anaemia (< 8.5gm/dl) is associated with an increased risk of pre-
eclampsia. On the other hand, elevated levels of haemoglobin more than 
14.5 gm/dl and ferritin have also been associated with poor fetal outcomes 
and pre-eclampsia (Gonzales et al. 2012). A study in Pakistan showed 
haemoglobin, haematocrit, serum iron, serum ferritin and transferrin 
saturation are increased in pregnant women at 28 – 34 weeks gestation, who 
later develop pre-eclampsia (Zafar and Iqbal 2008). Another study only 
showed serum iron concentration, ferritin, and percent saturation of 
transferrin to be higher among pre-eclampsia cases than controls at mean 
gestation age 33 weeks (Rayman et al. 2002). Free iron radicals are 
postulated as a casual factor in oxidative stress that leads to pre-eclampsia. 
Both studies recommend that the iron status of pregnant women should be 
assessed before giving iron supplements, as these may cause more harm to 
high-risk pre-eclampsia women. This shows that not all forms of anaemia are 
associated with pre-eclampsia; rather the haemolytic anaemias that release 
free iron radicals may be the culprit. We also know that the placenta tends to 
overgrow in size to maximise oxygen and nutritional supply to the fetus, in 
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anaemic and malnourished women. This compensatory mechanism may 
confound any potential association between nutritional related anaemias with 
pre-eclampsia. There are no systematic reviews associating anaemia with 
pre-eclampsia, however, a WHO multicountry study in LMIC that showed 
severe anaemia was associated with pre-eclampsia after adjusting for 
antenatal clinic visits, urinary tract infections, gestational diabetes, chronic 
hypertension, age, BMI and marital status (AOR: 2.98; 95 % CI 2.47 – 3.61) 
(Bilano et al. 2014). The clinical perspective regards anaemia as a symptom 
of an underlying disease. In tropical settings, it is meaningful to try to 
associate pre-eclampsia with the possible underlying disease such as 
malaria rather than the mere symptom of anaemia. 
The prevalence of placental malaria is estimated to be 16 – 63 % among 
primigravidae and much less among multigravidae 12 – 33 % (Darmstadt et 
al. 2011). While malaria infection is estimated to affect 11.1 million 
pregnancies in Sub-Saharan Africa (WHO 2019b). A case-control study in 
Sudan established an association between placental malaria and pre-
eclampsia (Adam et al. 2011). Another study in The Gambia showed a 5.4-
fold increase in maternal death due to eclampsia during the malarial rainy 
seasons. This study also concluded that placental malaria infection is 
associated with non proteinuric hypertension in women living in hypo-
endemic malaria areas, however in this study proteinuria values ≤ 2 were 
regarded as non proteinuric, this may have categorised mild pre-eclampsia 
as non proteinuric hypertension (Ndao et al. 2009). Hypo endemic areas 
have low and periodic/seasonal transmission of malaria infection. Malaria 
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infection during pregnancy is known as a major cause of maternal anaemia 
and low birth weight babies. Malaria has the potential of being an important 
risk factor in Africa since it is very prevalent and commonly affects women 
during the vulnerable period of pregnancy. The mechanism by which malaria 
may cause pre-eclampsia is through the damage of the placenta during 
placental malaria infection (Adam et al. 2011). An alternative pathway 
mechanism is through the haemolysis of red blood cells and the release of 
free radicals that damage blood vessels endothelia (Rayman et al. 2002, 
Zafar and Iqbal 2008). There are no meta-analyses studies showing the 
association of malaria infection with pre-eclampsia. I plan to explore further 
this relationship in the next chapters to understand malaria’s potential 
association with pre-eclampsia in Africa. 
Cigarette smoking may have a paradoxical effect on pre-eclampsia. Studies 
have shown that smoking reduces the occurrence of pre-eclampsia by 50 % 
in a dose dependent manner (Lucinda 2007). A meta-analysis involving 28 
studies with 833,714 women showed there is a 32 % risk reduction of pre-
eclampsia 95 % CI 31 % - 33 % among smokers (Conde-Agudelo et al. 
1999). This finding was also echoed by another meta-analysis by Wei et al. 
(2015) which showed a 0.67-fold lower risk of pre-eclampsia in women who 
smoke regularly. Women who smoke in early pregnancy and quit do not have 
a reduced risk, whereas those who start smoking in late pregnancy and those 
who smoke throughout pregnancy are protected (Wikström et al. 2010). 
Exposure to nicotine, carbon monoxide, stimulation of nitric oxide production, 
lowering of antiangiogenic factors, or a decreased immune response have 
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been advanced as possible explanations for this observation (Conde-
Agudelo et al. 1999, Bainbridge et al. 2005, Beste et al. 2005). Interestingly, 
women who smoke and develop pre-eclampsia seem to have a poorer 
outcome than women with pre-eclampsia who do not smoke (Salafia and 
Shiverick 1999). This observation suggests either a synergy between 
smoking and pre-eclampsia or that smoking may be masking the symptoms 
of pre-eclampsia in these women (Magnussen et al. 2007).  
Pre-eclampsia has also been shown to have a seasonal variation in its 
occurrence. Studies done in the USA suggest that the increased prevalence 
of pre-eclampsia among pregnant African Americans women living in the 
south could be due to vitamin D deficiency, which fluctuates seasonally 
(Wallis et al. 2008). The potential mechanism for the role played by Vitamin D 
in causing pre-eclampsia is still not well understood; however, a proposed 
mechanism is that Vitamin D3 acts as an inhibitor for placental cytochrome 
P450scc preventing the production of lipid peroxides and excess 
progesterone, both of which may contribute to the etiopathogenesis of pre-
eclampsia (Zabul et al. 2015). A prospective cohort study showed black 
women are at an increased risk of pre-eclampsia compared with white 
women (Knuist et al. 1998). This could be due to inherent genetic differences 
or due to vitamin D absorption through the skin. It is known that skin pigment 
causes a difference in Vitamin D concentration level between white and black 
people (Atkinson et al. 2014). There is no meta-analysis evidence to show 
the pooled estimate of the association between vitamin D and pre-eclampsia. 
The existing narrative review by Christesen et al. (2012) suggested vitamin D 
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is associated with pre-eclampsia in randomised clinical trial (RCT), cohort 
and case-control design studies. However, this association was not shown in 
some studies thus inviting suggestions that vitamin D works with other factors 
such as calcium in bringing out the effect (Christesen et al. 2012). 
Pre-eclampsia risk is threefold in a woman’s first pregnancy compared to 
parous women (Hartikainen et al. 1998). A meta-analysis by Bartsch et al. 
(2016) showed first pregnancy has the highest population attributable risk for 
pre-eclampsia among all other risk factors in their study (32.3 %, 95 % CI 
27.4 % to 37 %). Pregnancy is viewed as a physiological stressor on the 
cardiovascular system. Women who fail to cope with these changes end up 
developing pre-eclampsia, those who pass this stress test on their first 
pregnancy are deemed fit and suffer less from pre-eclampsia in their 
subsequent pregnancies. However, having a previous pre-eclampsia 
pregnancy is associated with 7 – 15 % higher risk of pre-eclampsia in 
subsequent pregnancies (Hernandez-Diaz et al. 2009, McDonald et al. 
2009), while women who did not have pre-eclampsia in the previous 
pregnancies have only a 1 % chance of developing it in their subsequent 
pregnancies. It is hypothesised that the risk in first pregnancy may occur 
more among women who have limited exposure to their partner’s sperm. In 
support of this argument, women who had a short duration of cohabitation, 
those who used barrier contraception and those who used donor sperm have 
been seen to be most affected (Hutcheon et al. 2011).  
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Human immunodeficiency virus (HIV) infection is known to compromise the 
immune response. HIV affects the inflammatory process in the entire body, 
including blood vessels and the placenta. The introduction of highly active 
antiretroviral therapy (HAART) for treating HIV has posed a question about 
the role these drugs play in relation to developing pre-eclampsia among 
people with HIV. Small studies have presented conflicting evidence, some 
suggesting that HIV is a risk factor while others show HIV has a protective 
role against developing pre-eclampsia. A systematic review and meta-
analysis looking at HIV status and use of HAART concluded that there is 
insufficient evidence to show the direction of the effects of HIV and HAART 
on pre-eclampsia (Adams et al. 2016). It is important to understand any 
potential associations since most of the HIV global burden is in Sub-Saharan 
Africa. 
Micronutrient deficiency has been associated with increased risk of 
development of pre-eclampsia. A randomised double-blind controlled clinical 
trial conducted among Ecuadorian pregnant teenagers, where the population 
average daily calcium intake is 51 % of the daily requirement showed calcium 
(2 g/day) supplementation reduced the risk of pre-eclampsia by 3.2 % 
(12.35% in the treatment group versus 15.5% in the placebo group). The 
study concluded that calcium supplementation during pregnancy in a calcium 
deficient population reduces the risk of pre-eclampsia (López-Jaramillo et al. 
1997). It is therefore important that future research explore the role of 
micronutrients in the development of pre-eclampsia in LMIC where 
malnutrition still prevails.  
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Advanced maternal age is a risk factor for pre-eclampsia according to several 
studies across different populations (Bilano et al. 2014, Tessema et al. 2015, 
O'Gorman et al. 2016). The association between maternal age and pre-
eclampsia has been suggested to follow a U shape (Kumari 2016). Thus, 
women with lower age (< 20 years) are at higher risk and at the other end of 
the age spectrum, women aged above 35 years are also at a higher risk. 
However, this U shaped relationship is widely to be confounded by 
primiparity (Kumari 2016). Pre-eclampsia is more common among women in 
their first pregnancy (primiparous) and hence it corresponds to women with 
younger age. Upon removal of this confounding nature of primiparity in the > 
20 years age group, pre-eclampsia appears to be at a higher rate in the > 35 
years age group. This is in line with the recommendation by the National 
Institute of Health and Care Excellence (NICE) guideline that states that 
women in their first pregnancy and women above 35 years are at higher risk 
of pre-eclampsia (NICE 2019). There is scarce evidence from meta-analysis 
studies showing the association between maternal age and pre-eclampsia. 
However, a WHO multicountry survey by Bilano et al. (2014) showed the 
odds ratio for pre-eclampsia among women aged ≥ 35 years compared to 
those aged 20 - 35 years was 1.7, 95 % CI 1.6 - 1.9. 
Prior history of hypertension is a known risk factor for pre-eclampsia. 
Concurrently, previous pre-eclampsia leads to a higher risk of developing 
pre-eclampsia in the subsequent pregnancies (M J. Mahande et al. 2013). A 
meta-analysis by Bartsch et al. (2016) showed prior pre-eclampsia and 
chronic hypertension were the first and second factors with a highest pooled 
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relative risk for pre-eclampsia, (8.4, 95 % CI 7.1 to 9.9) and (5.1,95 % CI 4.0 
to 6.5) respectively. This association has been claimed to result from shared 
pre-pregnancy risk factors. Pre-pregnancy cardiovascular risk factors such as 
triglycerides and cholesterol levels have shown an association with pre-
eclampsia (Magnussen et al. 2007). Several observational studies have 
echoed a similar association between prior history of hypertension and pre-
eclampsia (Anorlu et al. 2005, Kiondo et al. 2012, Bilano et al. 2014). This 
strong relationship has even produced a specific subcategory in the 
hypertensive disorders of pregnancy known as pre-eclampsia superimposed 
on chronic hypertension (Tranquilli et al. 2014). Women with severe chronic 
hypertension within 12 weeks of gestation have been seen to be at a 50 % 
higher risk of developing superimposed pre-eclampsia (Mammaro et al. 
2009). 
2.6 Global, national and health system responses to 
pre-eclampsia  
Over the years, our scientific understanding of the aetiology and 
pathogenesis of pre-eclampsia has advanced. There has also been a global 
political demand for improvement in maternal health care delivery. The 
United Nations through its Millennium Development Goal (MDG) number five 
that promoted maternal health has vividly described the call for maternal 
health improvement. The current Sustainable Development Goals (SDGs) 
have continued to highlight this as a priority through goal number three on 
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good health and wellbeing, and goal number five on gender equality (United 
Nations 2015).  
2.6.1 Diagnosis, Prevention and Management of pre-
eclampsia 
As described above, low-income countries such as Tanzania are still using 
the previous definition of pre-eclampsia stated by ISSHP (2001). Thus, 
characterizing pre-eclampsia by persistent high systolic (≥ 140 mmHg) or 
diastolic (≥ 90 mmHg) blood pressure and proteinuria only. Proteinuria levels 
of ≥ 0.3 g/24 hours or a dipstick result of  ≥ 1 +, which is equivalent to 30 
mg/dl in a single urine sample or spot urine protein/ creatinine ratio ≥ 30 mg 
protein/mmol creatinine, of new onset at 20 weeks onwards of gestation 
(Brown et al. 2001). Although this ISSSP report had considered situations 
where high blood pressure could occur with other haematological features in 
the absence of proteinuria, this did not form an essential part of the definition. 
In recognition of the syndromic nature of pre-eclampsia, the diagnosis of pre-
eclampsia by the ISSHP 2014 report revised its definition of pre-eclampsia to 
include all the above features in the ISSHP 2001 report, plus any of the 
additional features. The additional features are: haematological, renal and 
hepatic changes, the presence of utero placental dysfunction (fetal growth 
restriction) and a more explicit list of neurological complications (examples 
include eclampsia, altered mental status, blindness, stroke, or more 
commonly hyperreflexia when accompanied by clonus, severe headaches 
when accompanied by hyperreflexia, persistent visual scotomata) (Tranquilli 
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et al. 2014). This broad definition of pre-eclampsia is unlikely, to be adopted 
and operationalised successfully in resource-limited countries, as they 
require the support of laboratory and sonographic tests, which in most LMIC 
settings are absent or inaccessible. 
The lack of appropriate technologies and other resources is a barrier for 
LMIC to detect and manage pre-eclampsia appropriately. This situation 
widens the inequality in service delivery between women who access to 
these modern services in urban areas from those residing in the rural. It also 
presents policy challenges calling for further investment into health budgets 
in rural areas to bridge the gap of inequality in health care.  
2.6.2 Screening of pre-eclampsia 
Improvement in the screening of high-risk women for pre-eclampsia has 
enabled the timely provision of preventive services in high-income countries. 
The United Kingdom NICE guideline on hypertension in pregnancy has 
outlined criteria for high risk women, defined as having any of the following 
conditions: hypertensive disease during a previous pregnancy, type 1 or type 
2 diabetes, chronic hypertension, chronic kidney disease and autoimmune 
diseases such as systemic lupus erythematosis or antiphospholipid 
syndrome (NICE 2019). A woman is categorised as at moderate risk of 
hypertension in pregnancy if she has more than one of the following factors: 
first pregnancy; multiple pregnancies; pregnancy interval of more than 10 
years; body mass index (BMI) of 35 kg/M2 or more at first visit; family history 
of pre-eclampsia; age ≥ 40 years. However, the categorization into high and 
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moderate risk using the above risk factors may not be applicable universally 
across all populations. Regionally specific identification and classification of 
risk factors should be done to arrive at better guidelines for managing pre-
eclampsia in LMIC. 
In LMIC, screening for pre-eclampsia and other hypertensive disorders of 
pregnancy is done during routine antenatal clinic (ANC) visits. Pregnant 
women, among other things, are monitored for their blood pressure and 
protein levels in urine. The screening process is compromised by delay and 
lack of booking to ANC by some women. Shortage of skilled staff, tools and 
supplies to measure blood pressure and detect proteinuria contribute to low 
rates of pre-eclampsia detection.  
Prevention of pre-eclampsia in pregnant women at high risk of pre-eclampsia 
is mainly through the administration of low dose aspirin (Firoz et al. 2011). 
The efficacy of aspirin in the reduction of preterm pre-eclampsia varies 
across maternal characteristics groups (Poon et al. 2017). Early identification 
of high-risk pregnancies through screening so that administration of low dose 
aspirin can be started promptly has been shown to result in better outcomes. 
A meta-analysis showed that aspirin started at 16 weeks or earlier in 
pregnancy was associated with a significant and greater reduction in pre-
eclampsia (relative risk = 0.47, 95 % CI 0.34 - 0.65, prevalence of 9.3 % in 
the treated compared with 21.3 % in the control group) in women with 
moderate or high-risk pregnancies than aspirin started after 16 weeks of 
gestation (Bujold et al. 2010). 
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The mechanism of aspirin in preventing pre-eclampsia is still debated. Over 
time, our understanding of the mechanism of action of aspirin has evolved to 
enable us to explain its effects. The first pathway is that low dose aspirin 
(75mg-100mg per day) is able to irreversibly inhibit enzyme cyclooxygenase-
1, thus inhibiting platelets to produce thromboxane A2, resulting in the 
antithrombotic effect of aspirin i.e. prevention of blood clotting by the 
aggregation of platelets (Cadavid 2017). The second pathway is that a 
moderate dose of aspirin (650 mg – 4 g per day) inhibits both enzymes 
cyclooxygenase-1 and 2, resulting in inhibition of prostaglandins production, 
which is a pro-inflammatory compound. In doing so, aspirin prevents 
inflammation in the body. A third mechanism is through generation of pro-
resolving lipid mediators from arachidonic acid, called aspirin-triggered 
lipoxins. This compound gives aspirin further ability to resolve inflammation. 
Other mechanisms have been put forward, suggesting that aspirin causes 
anti-inflammatory effects via the induction of nitric oxide. Despite these 
mechanisms, epidemiological studies have shown inconsistency in the 
effectiveness of aspirin in preventing pre-eclampsia. Rossi and Mullin (2011) 
conducted two meta-analyses examining the effect of aspirin in groups of 
women with low risk and high-risk of pre-eclampsia. They found no 
statistically significant effect. Concurrently, apart from the side effects of 
gastric bleeding due to aspirin, there is growing concern about the effects of 
aspirin resistance, aspirin treatment failure and aspirin low response in study 
populations, aspirin resistant effect is thought to confound the effects of 
aspirin in the prevention of pre-eclampsia (Navaratnam et al. 2016). This 
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area requires further research, taking into account the confounding effect of 
aspirin resistance.  
Prevention modalities may change as our understanding of pre-eclampsia 
develops. The hypothesis that pre-eclampsia arises because of imbalances 
of the factors responsible for the formation of new blood vessels has gained 
acceptance (Ahmed 1997). It has been shown that loss of vascular 
endothelial growth factor (VEGF) activity as a result of the increase in the 
levels of endogenous soluble(s) VEGFR-1(also known as soluble fm like 
tyrosine kinase-1 (sFlt-1)) antagonises the beneficial effects of VEGF 
(Ahmed 1997). The imbalance in anti-angiogenic factors is most strongly 
associated with the clinical signs of pre-eclampsia. Anti-angiogenic factors, 
sVEGFR-1 and soluble endoglin (sEng), also known as CD105, are 
increased before the clinical onset of pre-eclampsia (Levine et al. 2006). 
Thus current researchers are proposing the use of pravastatin, which is 
known to reduce the levels of sVEGFR-1 and thus promoting VEGF (Ahmed 
and Ramma 2015). This newly proposed drug for prevention is being studied 
further in clinical trials to evaluate its safety during pregnancy. Pravastatin is 
preferred to other statins as it is thought to be associated with fewer 
congenital anomalies (Esteve-Valverde et al. 2018). Statin drugs are 
contraindicated during pregnancy for their association with congenital 
anomalies. Statins are thought to decrease cholesterol synthesis. It is 
through this mechanism that statins may affect fetal growth to cause 
congenital anomalies (BMA et al. 1966). 
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Once pre-eclampsia is evident, treatment is through the administration of 
antihypertensive drugs. If eclampsia is already evident or develops 
regardless of the administration of antihypertensive drugs, the recommended 
management is provision of magnesium sulphate followed by delivery of the 
baby, the definitive treatment. There is a dilemma in deciding to induce 
delivery on the grounds of maternal wellbeing, especially when delaying 
delivery would increase the survival of the foetus. Guidelines have been 
developed to assist physicians in making such management decisions, with 
the intention of maximizing the chances of survival for both the mother and 
the foetus whenever possible. However, in resource-limited settings, it is 
difficult to adhere to such guidelines, where premature care is often absent or 
not sufficiently comprehensive to enable the survival of premature babies. In 
such settings, the entire process of treatment is subject to multiple barriers 
caused by a weak health system. Limited access to antenatal care, shortage 
of skilled health workers, inappropriate skill mix and lack of pharmaceutical 
support are some of the barriers to access and provision of quality prevention 
and treatment services for the mother and the premature baby in many LMIC 
(Firoz et al. 2011).  
The mechanism of action of magnesium sulphate is not clearly understood 
and hence its use needs to be weighed against potential risks. The risks 
involved include the development of toxicity, which is more common in 
women with renal failure. Toxicity leads to respiratory arrest, which can be 
reversed with intravenous calcium gluconate. A patellar reflex test is used to 
assess the consciousness level, which tends to be impaired by the toxicity. 
  [Risk factors for pre-eclampsia] 
[Analysis of risk factors]  41 
Absence of the reflex warrant administration of calcium gluconate. In 
declined consciousness, intubation should be performed to maintain airway 
patency (Anthony et al. 2016). Therefore, the effective control of eclampsia 
requires skilled personnel and equipped facilities, which are often lacking in 
LMIC settings. 
The complexity in diagnosis and treating the sub-categories of hypertensive 
disorders of pregnancy is a major challenge. The management of 
hypertension during pregnancy is different from the management of 
hypertension in women who are not pregnant. This is due to the extra 
consideration of the foetus’ wellbeing. It is not desirable to rapidly reduce 
maternal blood pressure because this may affect the placental blood 
perfusion, which may pose grave consequences for the foetus. Use of 
angiotensin converting enzyme inhibitors is also limited during pregnancy 
since this is associated with poor fetal outcome. Beta-blocker drugs are also 
relatively contraindicated, being regarded as an independent risk factor for 
the development of intrauterine growth restriction. This situation ends up 
narrowing the options of drugs that can be used to treat hypertension during 
pregnancy. 
Labetalol is the recommended drug of choice in treating hypertension during 
pregnancy in the UK (NICE 2019). It has dual effects, acting as an alpha (α1) 
and beta (β1/β2) adrenergic receptor blocker. In the short term, it decreases 
blood pressure by decreasing systemic vascular resistance with little effects 
on stroke volume, heart rate and cardiac output (MacCarthy and Bloomfield 
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1983). In the long term, it reduces the heart rate while maintaining cardiac 
output by increasing stroke volume (Louis et al. 1984). In most LMIC settings 
methyldopa is the drug of choice (Anthony et al. 2016). It is a central acting 
drug and is documented to be safe during pregnancy; however, it should be 
avoided in women at risk of depression. Calcium channel blockers can also 
be used to manage hypertension in pregnancy; however, when given with 
magnesium sulphate in eclampsia they rarely can interact to cause prolonged 
neuromuscular blockage (Magee et al. 1996, Berdai et al. 2016). However, 
the recommended doses in common practice show nifedipine and 
magnesium sulphate when prescribed together do not increase the risk of 
magnesium sulphate side effects (Magee et al. 2005). The contraindication of 
these drugs to subgroups of women with specific challenges narrow their 
scope of use. It also complicates the skills required by HCWs to safely use 
them in the indicated subgroup of women. In addition to this mix of barriers, 
some LMIC do not have the pre-eclampsia related drugs in their National 
essential drugs list (Lalani et al. 2013). Lack of availability of these drugs in 
low levels health facilities in LMIC contributes to ineffective management of 
the condition, thus leading to poor outcomes. Clinicians in many LMIC are 
routinely faced with all these difficult choices of using what is available at that 
moment to address the challenges of HDP. 
2.7 Summary  
Pre-eclampsia’s contribution to the burden of maternal and infant mortality 
places it as a condition of public health importance in LMIC. Most of the 
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research aiming to understand and tackle this problem has been done in 
high-income countries. Thus, the recommendations drawn from these studies 
may not be applicable or implementable in LMIC settings. 
LMICs are faced with several challenges in their response towards tackling 
pre-eclampsia. It is challenging to diagnose pre-eclampsia, since it 
resembles other hypertensive disorders of pregnancy. It thus requires skilled 
staff and equipment to detect increased blood pressure and proteinuria. The 
lack of skilled staff and equipment hampers effective and timely diagnosis. 
The process of screening, prevention and treatment of pre-eclampsia is 
faced with similar challenges. Shortage of drug supply in health facilities is a 
common barrier in service delivery. It is difficult to make progress because 
most LMICs lack accurate epidemiological data to inform researchers and 
decision makers about the scale of the problem. The demand side i.e. the 
pregnant woman is also faced with a lack of awareness of pre-eclampsia and 
access limitations to antenatal and delivery services. 
The LMIC of Africa experience high burdens of potential risk factors such as 
malaria infection and HIV that may be unique drivers in the region. 
Pregnancy increases women’s vulnerability to malaria and can complicate 
into placental malaria, which has even worse consequences. So far, there is 
inconclusive published evidence linking malaria with pre-eclampsia. Africa 
also bears most of the global HIV burden, which is important because of the 
potential of HIV to influence pre-eclampsia, although so far, there is 
conflicting evidence on the association between HIV and pre-eclampsia. In 
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this context, the Africa region requires attention to exploring the unique 
drivers for pre-eclampsia.  
In order to start to address these gaps in knowledge and response systems, 
we first need a better understanding of the risk factors for pre-eclampsia 
operating in the local settings of African populations. This thesis focuses on 
exploring risk factors in Tanzania, which has high maternal mortality, but very 
limited data on pre-eclampsia. The country is also experiencing population 
growth with rapid urbanization and transformation of lifestyle and diet. These 
factors are thought to increase the incidence of pre-eclampsia. Successful 
identification of specific risk factors will inform prevention strategies 
contributing to the reduction of maternal and infant mortality and attainment 
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Chapter 3 Scoping study on risk factors for 
pre-eclampsia in Africa. 
3.1 Background  
Pre-eclampsia is a complex and poorly understood condition, which 
contributes to a significant burden of maternal and infant mortality, 
particularly in LMIC (Say et al. 2014). There is a considerable body of 
research suggesting associations between pre-eclampsia and a range of 
genetic, environmental, nutritional and socioeconomic risk factors (López-
Jaramillo et al. 1997, Williams and Morgan 2012, Moyene et al. 2016). 
Although these factors are likely to vary between populations, most research 
has been conducted in high-income country populations. Little research has 
been done on this topic in African populations, and most systematic reviews 
exploring the risk factors for pre-eclampsia do not include primary research 
conducted in African populations. This may be due to the absence of primary 
studies or to the poor quality of studies that do exist. Because genetic, 
environmental and socioeconomic factors in African populations differ from 
those in high-income countries in Europe and north America, it is important to 
explore risk factors specific to the population in Africa. The first step in doing 
this is to assess the scope of available evidence from published quantitative 
papers that have investigated risk factors of pre-eclampsia in African 
populations. This chapter uses a systematic scoping review methodology to 
conduct such a scoping study (Arksey and Malley 2005). 
[Risk factors for pre-eclampsia] 
46  [Analysis of risk factors] 
Specifically, the purpose of this chapter is to conduct a structured review of 
the literature to identify and summarise current research into pre-eclampsia 
risk factors, conducted in African populations. Research questions addressed 
are: 
• What research has been conducted in African populations on the risk 
factors for pre-eclampsia?  
• Are there any significant gaps in the research literature? 
• Based on this analysis, can a suitable topic be identified which could 
be further explored through a systematic review and the meta-analysis 
of existing data sets?  
The advantage of using scoping review methodology over a narrative 
literature review is that a scoping review uses a rigorous, structured and 
systematic approach to searching and documenting retrieved literature. As 
such, it can provide a transparent, comprehensive,  and unbiased account of 
relevant studies (Arksey and Malley 2005). 
It is important to explore the risk factors for pre-eclampsia in LMIC, especially 
when Africa is undergoing rapid urbanisation and a transformation of 
lifestyles. Despite these changes, infectious disease burden still overwhelms 
the region. The dual burden of communicable and non-communicable 
diseases cripples the response of the health system. Research efforts in 
Africa are more inclined to conditions that have high direct mortality, like HIV 
and Ebola while leaving behind the slow killers like hypertensive diseases.  
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Hypertensive diseases are known to emerge and worsen during pregnancy. 
In most cases, hypertension will be a lifelong chronic condition that impairs 
quality of life. It is also a burden to the health system, which must support the 
individual for life. In LMIC, the chronic nature of hypertension has huge costs 
to the already heavily burdened health system (von Dadelszen and Magee 
2016). Hypertensive disease is predicted to increase in the coming years in 
Africa. In some settings, it has overtaken haemorrhage as the leading cause 
of maternal mortality (LEE et al. 2012); hence, it is vital to understand the risk 
factors to plan prevention strategies to reduce hypertensive conditions.  
It is not technically feasible to explore the risk factors for hypertensive 
disorders of pregnancy as one outcome because the subcategories within 
hypertensive disorders have different origins and hence different risk factors. 
Although there is an overlap of some risk factors there are distinct risk factors 
associated with each subcategory. Therefore, as seen in other literature; we 
must explore risk factors for each specific subcategory of HDP. My research 
focuses on exploring the risk factors for pre-eclampsia, a subcategory of 
hypertensive conditions during pregnancy. Women are a vulnerable group in 
terms of their health status, especially in LMIC, and the backbone of the 
society in providing health care. Therefore, a women’s health status has a 
direct influence on the heath of her family. Hypertensive disorders of 
pregnancy, especially pre-eclampsia, have been associated with poor 
outcomes and mortality to both mother and child (Lopez-Jaramillo et al. 2005, 
Say et al. 2014), and also associated with later life cardiovascular morbidity 
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of the surviving mother and the newborn (Bellamy et al. 2007, Palinski 2014, 
Wu et al. 2017, Thilaganathan and Kalafat 2019).  
I therefore aimed to explore the risk factors of pre-eclampsia in African 
populations currently documented in the literature. I have explored 
observational studies that have shown the statistical significance and the 
strength of the association between pre-eclampsia and the different risk 
factors. I have shown populations where the relationship was observed in an 
attempt to map out similarities and differences across different populations in 
African countries.  
3.2 Methods  
Arksey and Malley (2005) propose the use of scoping review studies as a 
methodology for summarising, disseminating and identifying gaps in a body 
of research literature. A scoping review is a more structured thus minimises 
bias compared to a narrative literature review. The process of conducting a 
scoping review is a highly iterative and flexible one, which is useful in the 
early stages of conducting a new research study. 
I searched for relevant literature in the following databases; EMBASE, WHO 
Global Index Medicus and Web of Science core collection. Full details of the 
search strategy for each data base are given in the appendix (see annex 5). I 
limited my search to English language and studies on humans. I did not limit 
the search by year of publication. My study populations were all pregnant 
women and my outcome characteristic was pre-eclampsia.  
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Criterion  Included Excluded 
Population  • Pregnant women in 
Africa 
• Non-African countries 
Exposure • Aetiology/ risk factors 







Outcome  • Pre-eclampsia   




controlled trial studies) 
  
 
• Qualitative studies, case series 
and ecological studies, Genetic 
studies, animal studies, studies 
on subpopulations of women with 
rare conditions such as renal or 
liver transplant (since their 
findings could not be 
generalisable to the population of 
all pregnant women) 
Language  • English   
Year of 
Publication  
• All    
 
Papers identified from the search strategies were exported to an EndnoteX7 
software library, where duplicates were removed automatically by matching 
papers by tittle, year of publication and author name. Then manually removal 
was done where titles, year of publication and author name varied though the 
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papers were still duplicate. The titles and abstracts of papers were then 
screened using the following inclusion and exclusion criteria.  
 
Inclusion criteria 
1. Epidemiological quantitative studies and randomised control trials 
exploring risk factors for pre-eclampsia  
2. Studies published in the English language 
3. Studies published in peer-reviewed academic journals 
 
Exclusion criteria 
1. Animal and laboratory (in vitro) studies  
2. Studies targeting non-African populations  
3. Studies that explored risk factors for pre-eclampsia in a 
subpopulation of women such as among women with rare 
conditions such as renal, liver transplant. This was because the 
associations observed in these subgroups could not be 
generalised to the general population. 
4. Studies that only examined risk factors for other hypertensive 
disorders of pregnancy, and not specifically pre-eclampsia 
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Full article reviews were then conducted to assess eligibility according to my 
inclusion and exclusion criteria. 
Unlike systematic review methodology, this scoping methodology is designed 
to be iterative: as the process unfolds and the researcher learns more about 
the topic, it is legitimate to revise the inclusion and exclusion criteria and to 
change the focus of the review. My initial search identified all relevant studies 
globally, it did not exclude studies out of Africa. However, later I focused my 
review search to studies conducted in African populations, by selecting 
studies from Africa from the initial worldwide search strategy that retrieved all 
studies across the globe.  
The following data from eligible papers was extracted: author, year of the 
study, country of the study, study design, sample size, key results of the 
study. Following the methodology of Arksey and Malley (2005), a formal 
process of assessing the quality of included studies was not carried out. The 
purpose of a scoping review is to summarise the volume, focus, study 
designs and general conclusions of the literature on a particular topic, and to 
identify any gaps in the research, rather than to answer a specific and 
narrowly focused research question (Arksey and Malley 2005). In this way, 
scoping review methodology differs from systematic review methodology 
although, as in this case, a scoping review may be conducted as a precursor 
to conducting a systematic review. Their value in this respect is that they can 
identify gaps in the existing literature in a highly systematic way.   
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3.3 Results  
This section covers the results of the literature search and the characteristics 
of the identified studies in terms of their study populations, study designs, 
sample sizes, risk factors investigated, their respective associations and 
statistical significance. It is split into two sections, section one presents the 
results of the literature search according to the preferred reporting items for 
systematic reviews and meta-analysis (PRISMA) guide. Section two 
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3.3.1 Results of the literature search 
The search yielded 10,182 papers, of which 858 were duplicates, 9,112 were 
rejected as ineligible after a title and abstract screen and 192 after full-text 
screening. Twenty papers were included in the final analysis. The results of 
the literature search are summarised in figure 1. 
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3.3.2 Results of literature analysis 
This section summarises the current published literature exploring the risk 
factors for pre-eclampsia in African populations. I identified 20 primary 
observational studies on risk factors for pre-eclampsia conducted in Africa, 
carried out in 11 countries out of the 54 countries that constitute the African 
region. Most of the studies (16 studies) were case-control by design. There 
were three cohort studies and one cross-sectional study. All twenty studies 
were small hospital-based studies covering a limited geographical area 
served by the health facility. There are no countrywide or multi-country 
studies identified. 
The results are presented in three parts. Table one lists the studies included 
in the review, showing the country where the study was conducted and the 
study design. Table two summarises the risk factors explored by the twenty 
studies and their statistical significance. Finally, Table 3 shows the strength 
of association of the risk factors, confounding factors addressed and 
limitation of each of the twenty studies. The synthesis of the results is 
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Table 2 shows the risk factors by study and country. It also indicates whether a statistically significant association was found 
between the risk factor and pre-eclampsia. Forty-five different risk factors have been explored in relation to pre-eclampsia in 
African populations. Most of the studies show an inconclusive association between risk factors and pre-eclampsia in the 
different countries where they were explored i.e. a risk factor showed association in one study but failed to show association in 
another study. The small number of risk factors that were investigated in more than one country show conflicting results. The 
inconclusive and conflicting results may be due to inherent differences in study populations or it may be due to insufficient 
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The above risk factors in table 3 can be grouped into seven major factors a) 
to f) summarised below.  
Sociodemographic factors  
Advanced maternal age was found to have a statistically significant 
association with pre-eclampsia in four case-control and one cohort studies 
(Adam et al. 2013, M J. Mahande et al. 2013, Tessema et al. 2015, 
Endeshaw et al. 2016a, Endeshaw et al. 2016b). 
Primiparity was found to have a statistically significant association with pre-
eclampsia in four case-control study (Adam et al. 2011, Adam et al. 2013, 
George et al. 2015, Ajah et al. 2016).  
High parity and being unmarried were found to have a statistically significant 
association with pre-eclampsia in a case-control study in Ethiopia (Tessema 
et al. 2015). 
Familial and medical factors 
Family history of hypertension was found to have a statistically significant 
association with pre-eclampsia in two case-controls and one cohort study. 
(Adam et al. 2011, Tessema et al. 2015, Endeshaw et al. 2016a). 
History of diabetes mellitus was statistically significant on a cohort study of 
recurrent pre-eclampsia in Tanzania and a case-control study in Ethiopia (M 
J. Mahande et al. 2013, Endeshaw et al. 2016a). 
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Lack of exercise and stressful environment were found to have a statistically 
significant association with pre-eclampsia in a case-control study in Nigeria 
(Anorlu et al. 2005). 
Infections 
Placental malaria was found to have a statistically significantly association 
with pre-eclampsia in two case-control studies in Senegal and Sudan 
(Sartelet et al. 1996, Adam et al. 2011) However, malaria was not found to be 
statistically significant associated with pre-eclampsia in a case-control in 
Ghana (Ephraim et al. 2014). 
Urinary tract infection (UTI) in pregnancy was found to have a statistically 
significant association with pre-eclampsia in a case-control study in Ethiopia. 
(Endeshaw et al. 2016a). 
Periodontal disease is inflammation of gums, it was found to have a 
statistically significant association with pre-eclampsia in a case-control study 
in Ethiopia (Endeshaw et al. 2016a). 
Micronutrient factors 
Low serum calcium and magnesium levels were found to have a statistically 
significant association with pre-eclampsia in three case-control studies 
(Ephraim et al. 2014, Richards et al. 2014, Elmugabil et al. 2016). 
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Environmental factors 
Heavy metals pollution such as Lead was found to have a statistically 
significant association with pre-eclampsia in a case-control study D.R 
Congo/Zaire (Elongi Moyene et al. 2016). 
Nutritional factors  
Anaemia was found to have a statistically significant association with pre-
eclampsia in three case-control studies (Adam et al. 2013, Elmugabil et al. 
2016, Endeshaw et al. 2016a) 
Obesity was found to have a statistically significant association with pre-
eclampsia in three case-control studies (Zimbabwe, South Africa and Nigeria) 
and one cohort study in Tanzania (Mahomed et al. 1998, Anorlu et al. 2005, 
M J. Mahande et al. 2013, Nieuwoudt et al. 2014). 
Evidence from cohort studies revealed the following findings. Two cohort 
studies had explored HIV and found no association between HIV and pre-
eclampsia (Frank et al. 2004, George et al. 2015). Another cohort study 
explored the recurrence of pre-eclampsia where previous pregnancy 
experience of pre-eclampsia, chronic hypertension, gestational hypertension 
and diabetes mellitus were associated with increased risk of pre-eclampsia in 
subsequent pregnancies (M J. Mahande et al. 2013). 
One study examined pre-eclampsia with severe features and eclampsia in 
Nigeria, where it showed severe pre-eclampsia and eclampsia were more 
[Risk factors for pre-eclampsia] 
78  [Analysis of risk factors] 
common among adolescents, rural dwellers, poorly educated, unemployed, 
unbooked antenatal visits and nulliparous women (Ajah et al. 2016). 
3.4 Discussion  
My scoping review has revealed a relatively small number of published 
papers exploring risk factors for pre-eclampsia in the African region. The list 
of risk factors explored was extensive, but the measures of association were 
not consistent in their statistical significance across studies from different 
countries. Lack of power in the small studies may have resulted in the 
inconclusive results observed in this review. The inconclusive evidence and 
small study sizes presented by some studies have led me to identify potential 
areas for carrying out a systematic review study to aggregate results. Most of 
the identified risk factors with inconclusive results have important clinical 
relevance since they affect a large proportion of the population. These results 
also underscore the need for doing more research in this area to build the 
epidemiological evidence base from robust study designs.  
The African region has a diverse ethnic population (over 115 ethnic groups) 
that is underrepresented based on my findings (Shoup 2011). My scoping 
review identified 20 papers from only eleven countries out of the 54 counties 
in the African continent. This suggests that the continent is underrepresented 
by the findings of these few represented countries. Africa has the highest 
global rates of maternal and infant mortality, yet few studies have been done 
to understand risk factors for pre-eclampsia, which is one of the major 
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contributors to maternal mortality (WHO 2016). This underscores the 
importance of conducting further research on this topic in the African region.  
The susceptibility to developing pre-eclampsia is thought to vary across 
genetically diverse populations (Williams and Morgan 2012). Hence, the 
findings of these few studies may not be generalizable to the diverse 
subpopulations in the continent. Most of the papers used a case-control 
design. This design has several advantages, including being relatively cheap 
and quick to conduct and being well suited to exploring multiple risk factors 
simultaneously; however, it is unable to establish a temporal relationship 
between the exposure/risk factor and the outcome disease. A temporal 
relationship is the sequential timing of the occurrence of the risk factors prior 
to the disease; it is important evidence in establishing causality. Sixteen out 
of the twenty papers were case-control by design, thus limiting the affirmation 
of the temporal relationship. This choice of design may also be a result of 
weakness in health information systems to enable cohort design studies from 
data collected routinely in antenatal services. 
Cohort studies produce a higher quality of evidence due to the ascertainment 
of the temporal relationship between the risk factor/exposure and the 
outcome. I identified two cohort studies that explored HIV as a risk factor and 
found no association with pre-eclampsia. The other cohort study explored the 
recurrence rate of pre-eclampsia. In this study, recurrence of pre-eclampsia 
in subsequent pregnancies was associated with a history of pre-eclampsia, 
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chronic hypertension, gestational hypertension and diabetes in the previous 
pregnancy. 
The results from table 2 show the different risk factors that have been 
examined in different countries. The table shows risk factors that were 
explored and the ones that were statistically significant in their association 
with pre-eclampsia. There is inconsistency in the significance of some key 
risk factors for pre-eclampsia such as obesity and malaria. Not all countries 
where obesity or malaria was examined showed consistency in whether there 
was a statistically significant association with pre-eclampsia. This may be 
due to variation in ethnic susceptibility towards these risk factors across the 
different populations. Another possible explanation could be methodological 
shortfalls of the studies such as small sample size. This observation warrants 
large studies to be done to confirm or refute these findings.  
Severe anaemia has been associated with pre-eclampsia (Adam et al. 2011, 
Elmugabil et al. 2016, Endeshaw et al. 2016b). However, we do understand 
that anaemia is often caused by underlying conditions such as malaria and 
other haemolytic infections. Therefore, malaria may be the underlying 
condition that is causally linked to pre-eclampsia. To explore this further, in 
the next chapter I will present the results of a systematic review study 
investigating the direct association between malaria and pre-eclampsia.  
Malaria infection is a potentially important risk factor in the region. Malaria is 
very common during pregnancy and thus affects a large population of 
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pregnant women in African countries. If malaria is found to be associated 
with pre-eclampsia, it may turn out to be a significant contributing factor to 
the burden of pre-eclampsia in Africa, due to the high prevalence of malaria 
in the region (Desai et al. 2007). In this scoping review, I have identified the 
possible association between malaria and pre-eclampsia to be a potential 
area for conducting a systematic review and a meta-analysis to aggregate 
evidence from different small studies to establish their association. 
Unlike malaria infection, family history of hypertension, a diagnosis of 
diabetes mellitus and low serum levels of calcium and magnesium have 
consistently been shown to be associated with the development of pre-
eclampsia in different studies. Antenatal care has been shown to have a 
protective role in developing pre-eclampsia, although not consistently in all 
the studies. Where there is consistency in the results across studies, the 
findings can be used to inform maternal health strategies. However, larger 
studies may still be required to confirm these observations.  
The strength of this study is that it provides transparency, reproducibility and 
an unbiased review of the literature, as a result of adopting the scoping 
literature review methodology, which also gives flexibility in focusing or 
widening the search scope based on the results obtained. Initially, I used a 
wide search strategy that retrieved all papers that examined risk factors for 
pre-eclampsia across the globe and later selected papers from the African 
region. This approach enabled me to target the population of interest in my 
study without bias from the retrieved papers. 
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A potential limitation is that my search strategy only covered EMBASE, Web 
of Science, WHO-GIM databases, the inclusion of more databases like 
MEDLINE may have yielded more articles. 
A limitation is in the few numbers of identified papers in Africa that restrict the 
generalization to the whole region. This may partly be a result of restricting to 
English language articles. However, this may not have made a substantial 
difference, as only approximately 2 % of retrieved papers were not in English. 
Another important limitation is that only peer-reviewed, published papers 
were included. A more comprehensive approach would involve a grey 
literature search and hand searching the reference lists of key papers. The 
reason this was not undertaken for this scoping review is that the purpose 
was to carry out a rapid review of the literature in order to inform a more in-
depth and comprehensive systematic review. 
There are limitations in the comparison of evidence presented by these 
papers due to differences in selection criteria of the study populations. Some 
studies excluded groups such as twin pregnancies and women with diabetes 
mellitus or chronic hypertension. The variations of study populations across 
studies due to different recruitment criteria limit the comparison for the 
observed association of some risk factors across study populations.  
Another limitation is that some studies did not adjust the association for 
possible confounding factors. A lack of recorded data for important potential 
confounding variables, possibly because of weak health information systems, 
  [Risk factors for pre-eclampsia] 
[Analysis of risk factors]  83 
 
could have led to failures in making necessary adjustments for the examined 
associations.  
There were limitations in the range of risk factor variables that were 
examined in the cohort studies. Two cohort studies in South Africa and 
Zambia had both explored HIV, which showed non statistically significant 
association with pre-eclampsia. Of all risk factors from African based studies, 
HIV is the only risk factor that has been explored using a cohort design that is 
able to establish a temporal association between exposure and outcome. 
Most of my retrieved articles were case-control and thus faced this 
methodological pitfall.  
Most of the papers were not able to categorise the examined risk factors 
based on early and late onset pre-eclampsia. This shortfall may have 
contributed to misclassification of the risk factors and hence underestimation 
of the association. There is also a potential for these studies to have 
misclassified pre-eclampsia outcome with other HDP. Table 3 shows the 
sample size, the measure of association and the comments of the study’s 
results. Most of the case-control studies were small studies, with insufficient 
power in the multivariable analysis, as reflected in the wide confidence 
intervals of some multivariable analysis results. Larger and focused studies 
for early and late pre-eclampsia could generate results with improved validity.  
The scoping review study on risk factors for pre-eclampsia in Africa identified 
several gaps and highlighted the feasibility for a systematic review. The first 
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gap observed was that the association of malaria infection and pre-eclampsia 
was not conclusive from the retrieved studies. Based on the observed gaps 
from the scoping review, I decided to address this gap by carrying out a 
systematic review to examine the association of malaria and pre-eclampsia 
(see Chapter Four). The second gap observed was that most studies did not 
differentiate between early and late onset pre-eclampsia in designing their 
analysis to identify risk factors for pre-eclampsia in Africa. In addressing this 
gap, I planned to conduct a secondary analysis study in one of the LMIC 
settings, taking into account early and late onset pre-eclampsia in identifying 
risk factors. Another observed gap is that none of the studies had attempted 
to build prediction models using identified risk factors to predict the outcome 
of pre-eclampsia. I, therefore, decided to explore biomedical risk factors in 
relation to early and late onset pre-eclampsia. A woman’s biomedical 
parameters can conveniently be measured in hospital settings. In addition, 
these parameters are often recorded in patient notes. Thus, in future, these 
parameters may be used to develop prediction models that can easily be 
applied in hospital settings, unlike models that incorporate complex, 
expensive and hard to measure biomarkers as predictors. These more 
complex prediction models are not feasible in resource-poor settings in 
LMICs. 
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3.5 Summary  
A history of hypertension, previous pre-eclampsia pregnancies and low levels 
of serum calcium and magnesium have consistently been shown to be 
associated with the development of pre-eclampsia across studies.  
Interventions could target these risks to improve screening detection and 
focused prevention services.  
Larger studies examining many variables are needed in Africa to address the 
gaps of scarcity of evidence in this area. So far, there are few countries 
where the risk factors for pre-eclampsia have been studied, mostly using a 
case-control design. Further studies using cohort design would improve our 
understanding of the risk factors and their temporal relationship with pre-
eclampsia.  
Malaria infection is a potential risk factor for the development of pre-
eclampsia. However, evidence from small studies has not been conclusive. 
In the next chapter, I explore this relationship further by conducting a 
systematic review and meta-analysis to aggregate the available evidence 
from observational studies.  
It is relevant to analyse risk factors under the consideration of early and late 
onset pre-eclampsia to avoid potential misclassification. Most previous 
studies were unable to do so; my secondary data analysis in Tanzania aims 
to address this issue (see Chapter Five). 
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Chapter 4 Systematic review and meta-
analysis on the association of 
malaria infection and gestational 
hypertension. 
4.1 Background  
Hypertensive disorders of pregnancy account for 14 % of global maternal 
mortality (Say et al. 2014). Pre-eclampsia and gestational hypertension (GH) 
are closely related subcategories of hypertensive disorders of pregnancy. 
Pre-eclampsia is characterised by a rise in blood pressure and protein loss in 
urine (proteinuria), with an onset at 20 weeks of gestation and onwards. GH 
is also characterised by a rise in blood pressure, with an onset of 20 weeks 
of gestation and onwards, but without proteinuria. The main difference 
between pre-eclampsia and GH is thus that pre-eclampsia involves multi-
organ damage, characterised by the proteinuria feature. As explained in 
Chapter Two of this thesis, however, the fact that a significant proportion of 
women develop severe pre-eclampsia without proteinuria being detectable 
(Barton et al. 2001). This finding prompted the ISSHP to revise its definition 
of pre-eclampsia to include the presence of severe features with or without 
proteinuria ( Tranquilli et al. 2014). 
The aetiology of these conditions is not clearly understood; so far, there are 
several theories for their occurrence and different risk factors and 
mechanisms of action are being explored, as described earlier in this thesis. 
The scoping review in the previous chapter summarises the observational 
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epidemiological research evidence on pre-eclampsia risk factors in African 
populations. This identified inconclusive evidence on the association between 
malaria infection and pre-eclampsia. Some of these studies also showed that 
malaria infection was associated with GH. This suggests that malaria 
infection is a shared risk factor for both pre-eclampsia and GH. This 
understanding tallies with other studies that have shown that pre-eclampsia 
and GH share cardiovascular risk factors (Egeland et al. 2016). Following 
these observations, I set out to conduct a systematic review and a meta-
analysis with the aim of aggregating available evidence on the relationship 
between malaria infection and the combined outcome of pre-eclampsia and 
GH. 
Malaria is a protozoan blood infection that primarily affects and destroys red 
blood cells thus causing a release of endotoxin that triggers an inflammatory 
reaction (Verdecchia et al. 2016). Malaria is a common disease in tropical 
countries that accounted for 405,000 deaths globally (WHO 2019b). Over 11 
million pregnant women are estimated to be exposed to malaria infection in 
2018 while about 24 million children were also infected with malaria (WHO 
2019b). In 2017, it was estimated to cause 34,000 (95 % CI 20,000 - 53,000) 
maternal death among 15 - 49 years females in Sub-Sahara Africa (IHME 
2017). Malaria alone is estimated to cause 2.1 million deaths (95 % CI 1.6 – 
3.2) of 1 - 49 month children globally (Liu et al. 2016). Its potential 
contribution as a risk factor to pre-eclampsia and GH deserves attention, in 
order to reduce pregnancy related mortality and morbidity.  
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What mechanisms have been proposed linking malaria infection with pre-
eclampsia and GH? To date, a dysfunctional placenta is the basis of most 
theories for the cause of pre-eclampsia (Ahmed and Ramma 2015). Malaria 
infection may develop into placental malaria during pregnancy. Placental 
malaria changes the environment in the intervillous space of placenta. This 
occurs as a result of malaria infected erythrocytes binding to 
syncytiotrophoblast, a specialized epithelial layer that covers the interior of 
the villous of the placenta. Malaria infected erythrocytes bind on ST receptors 
known as chondroitin sulphate A (CSA) and hyaluronic acid. This binding 
leads to the sequestration of infected erythrocytes in the intervillous space of 
the placenta. Sequestration leads to secretion of chemokines resulting in 
inflammatory cells recruitment and cytokine production which is associated 
with poor pregnancy outcomes (Kidima 2015). Several studies suggest that 
placental malaria infection is associated with pre-eclampsia and GH, the 
hypothesised mechanism being that of a dysfunctional placenta affected by 
malaria parasites (Ndao et al. 2009, Adam et al. 2011).  
This is not, however, the only proposed mechanism linking malaria to GH 
and pre-eclampsia. A newly proposed mechanism hypothesises that malaria 
infection may cause hypertension via inflammatory reaction on the 
endothelial lining in blood vessels. It is hypothesised that inflammatory 
processes on the endothelium due to malaria infection may play a role in 
causing hypertension (Verdecchia et al. 2016). Studies in Asia that examined 
maternal serum iron and ferritin have suggested oxidative stress caused by 
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free iron radicals may play a role in causing pre-eclampsia (Rayman et al. 
2002, Zafar and Iqbal 2008). Thus, the inflammatory and oxidative stress due 
to malaria toxin and red blood cell (RBC) destruction may lead to pre-
eclampsia. We also know that malaria infection on its own may induce 
proteinuria (Ehrich and Horstmann 1985). Therefore, an alternative pathway 
mechanism may exist where malaria infection during pregnancy may be 
causing both hypertension and proteinuria, which are the main features that 
define pre-eclampsia, without placental pathway involvement. It is also 
possible that malaria infection will only induce hypertension without 
proteinuria, to resemble gestational hypertension.  
In this regard, it is worth examining the association of malaria and 
hypertension during pregnancy (with or without proteinuria) to identify its total 
effect on the burden of hypertensive disorders of pregnancy. From this point 
onwards in this chapter, I have regarded gestational hypertension to imply 
the combination of both, pre-eclampsia and gestational hypertension proper 
i.e. high blood pressure with an onset from 20 weeks of gestation without 
proteinuria. Therefore, my systematic review and meta-analysis regards my 
outcome of gestational hypertension to imply both conditions hypertension 
without proteinuria or with proteinuria (pre-eclampsia).  
Earlier studies suggest an association between malaria infection in the rainy 
season and increased maternal mortality due to pre-eclampsia (Etard et al. 
2003). Women are prone to develop malaria throughout pregnancy, but the 
peak period seems to occur before the onset of pre-eclampsia (Brabin 1983, 
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Moore et al. 2017). The peak incidence of malaria during pregnancy has 
been shown to occur at 13 -16 weeks of gestation, which is prior to the onset 
of the GH which commences at 20 weeks of gestation onwards (Brabin 
1983). In Thailand, the peak of initial malaria infection occurred at 5 – 6 
gestation weeks while the peak for recurrent malaria infection occurred at 14 
weeks for falciparum malaria and 20 for vivax malaria (Moore et al. 2017). 
This sequential timing of the malaria risk factor and the occurrence of the 
disease suggests a temporal relationship between the risk factor and the 
outcome. 
Malaria infection could be an important contributing factor to GH in tropical 
countries where malaria is prevalent. About 25 million pregnant women from 
Sub Saharan Africa are at risk of malaria infection every year, while 
approximately 25 % have been found with evidence of placental malaria 
infection at delivery (Desai et al. 2007). Understanding the association of 
gestational hypertension with malaria infection can inform prevention 
strategies in malaria endemic regions. Even a weak association between 
malaria and gestational hypertension will likely have a high population 
attributable risk (PAR), due to the high prevalence of malaria in these 
settings. PAR is the product of the magnitude of the risk (relative risk of the 
exposure) times the incidence of the exposure in the population. In other 
words, it is the incidence of the disease in the population that would be 
eliminated if the exposure was eliminated. I, therefore, set out to conduct a 
systematic review and meta-analysis with the aim to aggregate the available 
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evidence on this association. Evidence on the association between malaria 
infection and GH is likely to attract further studies to investigate causality. 
4.2 Methods  
REVIEW QUESTION 
What is the association of malaria infection and gestational hypertension in 
malaria endemic area?  
DATABASE SEARCHES 
The following databases were searched: MEDLINE, WHO Global Index 
Medicus, Google Scholar, EMBASE. I extended my search to include grey 
literature and hand searching of referenced studies. The search date was 9th 
week of 2018. 
KEYWORDS 
Malaria, Placental malaria, Hypertension-pregnancy-induced (pre-eclampsia, 
eclampsia, HELLP) 
The above keywords were used to search in the medical subject heading 
(MESH) and as keywords in the respective databases. Exposure keywords 
(malaria or placental malaria) were combined using the Boolean word AND 
with outcome keywords (gestational hypertension, pre-eclampsia). Keywords 
were modified to fit the respective databases. 
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I restricted my search to full articles, English language, and human studies. I 
did not apply limits on the year of study.  
TYPE OF STUDIES 
I explored observational studies for the association between malaria infection 
and gestational hypertension. I included case-control, cross-sectional, clinical 
trials and cohort studies, while excluding case report, case-series and 
ecological studies. 
POPULATION 
All pregnant women, who live in malaria endemic countries of Africa. 
EXPOSURE 
Women diagnosed with malaria during pregnancy, or post pregnancy 
diagnosis of placental malaria formed the exposed group. Malaria Infection is 
diagnosed clinically by signs and symptoms accompanied by a blood test 
(rapid blood test for malaria or blood slide for microscopy). Malaria infection 
during pregnancy can invade the placenta to cause placental malaria, which 
can be confirmed after delivery by examining the placenta tissue. In my 
study, I considered either malaria infection during pregnancy or placental 
malaria confirmed after delivery as my exposure of interest. The sensitivity 
and specificity of light microscopy in detecting malaria varies; in maternal 
blood the sensitivity is 41 % and specificity is 100 %, in placental blood the 
sensitivity is 35 % and specificity is 100 %, while in placenta tissue the 
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sensitivity is 33 % and specificity is 95 % (Campos et al. 2011). This shortfall 
in diagnostic tools present potential misclassification.  
COMPARATOR 
Women free of malaria diagnosis during pregnancy or free from post-
pregnancy diagnosis of placental malaria were regarded as the unexposed 




The outcome of interest was a diagnosis of gestational hypertension (pre-
eclampsia and GH proper). Women with this outcome were examined for the 
exposure of malaria infection or placental malaria infection. 
INCLUSION AND EXCLUSION CRITERIA 
• All observational studies that examined the association of malaria and 
gestational hypertension were eligible for inclusion. 
- Ecological, case series and case report studies were 
excluded.  
- Studies that did not ascertain the diagnosis of malaria by a 
laboratory test were excluded. 
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SELECTION PROCESS 
The retrieved papers from the searched databases were exported to Endnote 
X7 software. Duplicates were removed first by the software and then followed 
by manual search. Titles and abstracts of identified studies were screened for 
relevance. Those not considered relevant were excluded.  
Additional papers were selected from grey literature sources such as relevant 
institutions’ repositories (e.g. universities). Reference lists of the selected 
papers were examined to identify additional papers.  
A full-text review of the selected articles identified the eligible articles based 
on my inclusion and exclusion criteria. The selection process followed the 
preferred reporting items for systematic reviews and meta-analysis (PRISMA) 
guideline. (PRISMA flow diagram as shown in figure 2 below)  
 
QUALITY ASSESSMENT 
Critical appraisal skills programme (CASP) checklist tools were used to guide 
the quality assessment of the observational studies. In case-control and 
cross-sectional studies, this tool was used (https://casp-uk.net/wp-
content/uploads/2018/01/CASP-Case-Control-Study-Checklist-2018.pdf). 
While in cohort studies, this tool was used (https://casp-uk.net/wp-
content/uploads/2018/01/CASP-Cohort-Study-Checklist 2018.pdf). Each 
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paper was assessed for its weakness and strength based on the checklist 
questions. The tool assessed eleven aspects of the paper: 
1. Did the paper have a focused question?  
2. Did the paper use the appropriate method to answer the question? 
3. How was the overall recruitment process? 
4. How was the recruitment of cases done?  
5. How were the controls recruited?  
6. Was the exposure accurately measured? 
7. Were relevant confounding factors accounted for in the design and 
analysis? 
8. What are the results of the study? 
9. How precise are the results?  
10. Do you believe the results (internal validity)?  
11. Can the results be applied to the local population (generalizability)?  
12. Do the results of this study fit with other available evidence? 
The selected studies satisfied all the above quality assessment questions. 
Studies that did not address confounding factors in analysis and design were 
excluded. The CASP tools assess the quality of a paper in a holistic manner, 
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thus it does not use the scoring of points in the above twelve questions to 
justify a paper’s eligibility in terms of its quality. The detailed analysis of each 
paper is presented on annex 7, table 55 at the end of this thesis.  
POTENTIAL BIAS 
Malaria infection can be subclinical; hence it can be undiagnosed leading to 
misclassification of the exposure status in the unexposed group. 
Misclassification of this sort will shift the association towards the null. My 
attempt to reduce this bias was by ascertaining the diagnosis of malaria 
when it was supported by a laboratory test: peripheral blood smear for 
malaria parasite, rapid diagnostic test for malaria or placenta histology for 
malaria. I set criteria to include studies that had ascertained the lack of 
malaria exposure by a laboratory test. 
There is also a potential misclassification of the outcome of gestational 
hypertension (pre-eclampsia and GH proper), which may bias my results. To 
minimise this bias, I restricted my selection to only include studies that used 
the outcome of pre-eclampsia or GH proper, where both share the 
characteristic of hypertension with the onset of 20 weeks and onwards. 
However, there is always a challenge of ascertaining the gestation age of 20 
weeks and detecting the new onset of hypertension, especially in low 
resource settings. This challenge presents the potential misclassification bias 
in the primary studies that we cannot eliminate.  
DATA EXTRACTION 
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I extracted key information from the articles; author, year, study design, 
country of study, sample size and univariable odds ratios and confidence 
interval (unadjusted). Where it was available, multivariable (adjusted) odds 
ratio and confidence interval were extracted together with the list of variables 
used in the adjustment model.  
DATA ANALYSIS 
A narrative synthesis was done to summarise the evidence from the gathered 
papers. Odds ratios or relative risks from the selected studies were directly 
extracted from the available data. I then assessed the heterogeneity of the 
included papers to determine the feasibility of a meta-analysis. I had pre-set 
to accommodate moderate heterogeneity (I2 = 30 %) due to the expected 
population variability of the exposure outcome association. I had anticipated 
the association between malaria and gestational hypertension to vary widely 
across study populations; hence, I used the random effects model 
(DerSimonian and Laird 1986) to estimate the pooled effect in the meta-
analysis. RevMan 5 software was used to aggregate the odds ratios from 
selected studies. Inverse variance weighting was used to compute the pooled 
odds ratio and its confidence interval. The inverse variance method estimates 
the amount of variation across studies by comparing each study’s result with 
an inverse-variance fixed-effect meta-analysis result. I used a forest plot to 
display my study results. I also used a funnel plot to assess the publication 
bias of the selected papers. 
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4.3 Results  
The results of my literature search, the screening of articles based on the 
inclusion and exclusion criteria, followed by a quality assessment, was in 
accordance to the preferred reporting items for systematic reviews and meta-
analyses (PRISMA) guidance. The figure below outlines findings in the 
identification, screening and eligibility stapes. 
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My search identified 483 papers, 462 were excluded based on title and 
abstract, 13 were duplicates. Eight papers were assessed for eligibility only 
four were suitable for the meta-analysis. These four papers were case-
control studies and are approximately 1 % of all identified papers from my 
search strategy. There were two cohort studies and two case-controls that 
were excluded due to lack of addressing confounding factors in the design 
and analysis. 
 
4.3.1 Narrative synthesis 
My preliminary narrative synthesis paves the way for the meta-analysis of the 
selected studies. It describes the context of the methods and results of the 
meta-analysed papers. In exploring the association between malaria infection 
and gestational hypertension, my systematic review has identified four good 
quality studies that satisfied the CASP checklist (See annex 7 table 55). 
Studies that have adequately measured the association of malaria and 
gestational hypertension. All four studies showed that malaria infection 
increases the odds of gestational hypertension. However, some of the 
findings were not statistically significant, while some had a wide confidence 
interval of their estimates. Three studies were conducted in West Africa 
(Senegal and Ghana) and one in the horn of Africa (Sudan). All these 
countries have a tropical climate, which favors the endemicity of malaria 
infection. These few studies inadequately represent the African population, 
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which is very diverse. However, the similarity in the measure of association 
across these studies (homogeneity) suggests the effect of malaria on 
gestational hypertension is narrow in range and possibly is a fixed value 
across all populations. 
These four studies were hospital-based, thus are prone to some selection 
bias on their study participants. The cases and controls were selected from 
the same hospital in an attempt to ensure controls are as similar as cases 
except having the disease. However, the exposure odds in the control group 
could not be ascertained to be equal to that of a general population, thus 
setting a possibility of bias in estimating the association.  
The selection criteria of the study participants applied a restriction to some 
population groups that were thought to have the potential to confound the 
association, such as women with twin pregnancies and those with diabetes. 
Table 4 shows the groups that were excluded in the selection of the 
individual studies. Other studies attempted to match the controls with the 
cases using age, parity and prematurity factors known to confound the 
association. However, they did not do a matched analysis rather they 
adjusted for these factors in the analysis using a logistic regression model. 
Overall, all four studies had adjusted for maternal age, the number of 
previous pregnancies and history of hypertension. Two studies (Adam et al. 
2011, Ephraim et al. 2014) had adjusted for body mass index (BMI) and 
diabetes. This provides sufficient confidence of adjustment of key 
confounders in my pooled estimates. 
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 The ascertainment of exposure status was based on confirmation of malaria 
diagnosis through histological examination of the placenta remains after 
delivery. This ensured a minimum possibility for misclassification of disease 
outcome in exposed and unexposed groups, which could dilute the strength 
of the association. If a woman had acquired placental malaria in the course of 
her pregnancy, then her placenta would reveal histological changes to detect 
past malaria infection on the placenta. The diagnosis of placental malaria is 
not a routine test as it involves the collection of a sample from the placenta at 
the time of delivery; this may explain why few studies have embarked on 
exploring this relationship in these LMIC, where laboratory services are often 
limited. However, these few studies used appropriate laboratory tests to 
diagnose placental malaria. Giemsa staining test of placenta blood and 
placenta histological section were the methods used.  
All the four studies have relatively small sample sizes ranging from 252 to 
463 participants (see table 4). Most of the studies lacked detail on how they 
calculated their sample size. The relatively small sample sizes generate wide 
confidence intervals for the final estimates thus contributing to some studies 
giving non-statistically significant estimates, as seen on the forest plot.  
These selected studies were able to adjust for the necessary confounding 
variables. Table 4 lists the variables that were adjusted for in the relationship. 
The results of these studies are more credible because the researchers were 
able to minimise the confounding effect by applying restriction and matching 
techniques in the selection and the unmatched logistic regression analysis. 
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All the studies adhered to the definitions of the outcome, gestational 
hypertension proper and pre-eclampsia. All studies used the same definition 
of raised blood pressure, where the cutoff was a rise of blood pressure 
≥140mmHg (systolic) and ≥90mmHg (diastolic). However, there was some 
variation in the cut off point for proteinuria, ≥ 2+, >2 and ≥ “1+” in Ndao et al. 
(2009), Adam et al. (2011), Ephraim et al. (2014) studies respectively. This 
classification is key to segregate between the pre-eclampsia cases from 
gestational hypertension proper cases. A pregnant woman with raised blood 
pressure and proteinuria value = 2 would be regarded by one study as 
having pre-eclampsia while the other study would regard her as having 
gestational hypertension. This difference in cut off points on the severity of 
proteinuria across studies was likely to introduce misclassification in their 
outcome variable i.e. women with pre-eclampsia or GH.  
The potential misclassification in the outcome of gestational hypertension 
(pre-eclampsia and GH proper) in the primary studies may still have an 
influence on our finding. We know that it is a challenge to ascertain the 
characteristic of a new onset of raised blood pressure above 140mmHg 
(systolic) and 90mmHg (diastolic) starting from 20 weeks of gestation, 
especially in poorly resourced settings. In these settings, there is high 
illiteracy thus some women may not recall their last menstrual date correctly.  
4.3.2 Meta-analysis 
Table 4 Overview of the included studies 
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This forest plot shows the odds ratio of the individual studies and their pooled 
effect in the association between malaria infection and gestational 
hypertension. The individual studies are weighed by the inverse variance 
method. The pooled odds ratio is 2.67 with 95 % CI [1.58 - 4.53]. This 
suggests women exposed to malaria during pregnancy had 2.67 times (95 % 
CI 1.58 to 4.53) the odds of gestational hypertension compared to women not 






Figure 4. Funnel plot of the meta-analysed studies 
This funnel plot shows that studies with large and small variance had similar 
estimates of the effect of malaria infection on gestational hypertension. 
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4.4 Discussions  
The association between malaria infection and gestational hypertension has 
long been explored by different small studies in Africa (Sartelet et al. 1996, 
Etard et al. 2003). My meta-analysis has been able to show an overall 
statistically significant association between malaria infection and gestational 
hypertension, a pooled odds ratio of 2.67 (95 % CI 1.58 - 4.53). This 
association was drawn from 1,281 women (518 malaria cases and 763 
controls). My outcome of interest was gestational hypertension with 
proteinuria (pre-eclampsia) or without; both being referred as gestational 
hypertension in my chapter. Malaria infection is a common infection in Africa, 
especially during pregnancy. My result suggests that it is associated with 
gestational hypertension. This association places malaria infection as a 
potentially important risk factor for gestational hypertension in malaria 
endemic regions. 
One of the strengths of this review unlike other studies is that it explores the 
association of malaria infection to a broader spectrum outcome of two related 
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subcategories of hypertensive disorders of pregnancy: pre-eclampsia and 
gestational hypertension. Since malaria infection can be prevented and 
cured, this association sheds light on the potential benefit to maternal and 
infant health if this single risk factor of malaria is identified and addressed.  
The search process produced four good quality papers. I used the critical 
appraisal skills program (CASP) checklist tool to assess the quality of the 
papers. (See table 55 at annex 7) These papers had a focused research 
question to explore the relationship between malaria infection and gestational 
hypertension. These studies were able to adjust for possible confounders 
through restriction, matching and analysis. All four studies had adjusted for 
parity, which confounds the association between malaria and GH. Thus, the 
aggregate result of my meta-analysis was able to give a credible result on the 
nature of the overall association.  
A potential limitation may be due to residual confounding even after adjusting 
most of the common factors shown in the literature. Another limitation is the 
few studies that met my selection criteria thus necessitating further studies in 
the area. 
The measure of heterogeneity I2 was 0 %; this was different from my earlier 
assumptions. The value of I2 shows the variability between study groups that 
is not explained by chance alone. A higher value of I2 shows the between 
study groups difference is significant and hence the study groups are 
inherently different from each other. My analysis assumed the relationship 
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between malaria and gestational hypertension to vary widely across societies 
and thus I adopted the random effects model, which often produces a higher 
measure of heterogeneity. My findings appear to suggest that there is a 
constant effect of malaria on gestational hypertension across African 
populations because the between study groups difference is explained by 
chance, hence not inherently different. Three of my selected studies were 
from West Africa and one from Sudan. However, my analysis included only a 
few studies, so this limitation may have produced the observed low I2 value. 
The 95 % confidence interval of my pooled odds ratio estimate was 1.58 to 
4.53, from the random effects method (DerSimonian and Laird 1986). If I 
were to use the fixed effects method then this 95 % confidence interval would 
have been narrower, closer to my point estimate of 2.67. This provides 
assurance that changing the method would not have resulted in a wider 95 % 
confidence interval. 
Although my analysis involved a small number of studies, the funnel plot 
seems to suggest that studies with high variability in their standard errors 
produced similar effect sizes to studies with less variability. There is no 
asymmetry on the funnel plot, a feature that indicates publication bias; all 
studies are centred close to the common effect. This observation may be due 
to chance or absence of sufficient published papers from diverse populations. 
Therefore, it does not provide sufficient evidence to rule out the absence of 
publication bias. 
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The evidence from these studies is supported by other ecological studies that 
suggested an association between an increase in pre-eclampsia death during 
the rainy malaria seasons (Etard et al. 2003, Anya 2004). Dorman et al. 
(2002) also showed that malaria infection was affecting the uterine blood 
flow, this being a step closer in showing the effect of malaria infection on the 
placenta. Placenta dysfunction has been one of the theories linking malaria 
to pre-eclampsia. 
This meta-analysis has aggregated evidence for the small studies that 
examined the association of malaria and gestational hypertension and, thus 
produced a more credible result of the existing association. If malaria is 
causal to GH, then my findings have potential policy implications on disease 
prevention, as it links infectious disease (malaria) prevention to potential 
benefit in preventing gestational hypertension, a non-communicable disease 
(NCDs). Therefore, reducing malaria during pregnancy may have a broader 
impact beyond that of reducing the direct effects of malaria on the mother 
and the unborn baby. Molecular studies exploring this causal relationship 
could improve our understanding and identify intervention points on the 
theorised causal pathways. 
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4.5 Summary  
Malaria infection is associated with gestational hypertension in tropical Africa. 
This association appears to be similar in different African contexts, having 
fixed effects, across the studied populations. If malaria is causal to 
gestational hypertension, enhancing malaria control efforts on pregnant 
women could have immediate indirect benefits during pregnancy on averting 
hypertension and in long-term cardiovascular diseases. Molecular studies are 
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Chapter 5 Analysis of risk factors for pre-
eclampsia in Tanzania. 
This chapter builds on the findings from the two previous chapters. Chapter 
Three, the scoping review, summarised the evidence of explored risk factors 
in the African continent. Out of the many suggested risk factors from the 
scoping review, I selected malaria infection and further explored it by carrying 
out a systematic review and meta-analysis. The results are presented in 
Chapter Four. Chapter Five analysed data from Tanzania with the aim of 
estimating the incidence of pre-eclampsia in urban settings. This was 
performed using trial dataset with 3,767 women from the commercial capital 
city of Dar es Salaam, Tanzania. The remaining analysis in this chapter was 
performed using a dataset with 16,432 women from northern Tanzania. With 
this dataset, I described the sociodemographic characteristics of women with 
pre-eclampsia. This was to get an understanding of pre-eclampsia’s 
distribution along sociodemographic groups. Then I embarked on identifying 
risk factors that are associated with early and late onset pre-eclampsia. In my 
analysis, I had a large sample size, and sufficient confounding variables, 
unlike most other studies, which lacked methodological rigour. I focused on 
exploring maternal biomedical characteristics as risk factors from pre-
eclampsia. These maternal biomedical characteristics are collected routinely 
in the health information system. Furthermore, I used the statistically 
significant maternal risk factors to develop logistic regression prediction 
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models. These models were developed for all deliveries and for term and 
preterm deliveries subgroup. This was to account for the aetiological 
difference between early and late onset pre-eclampsia. The developed 
prediction models were used to classify the likelihood of a woman to develop 
pre-eclampsia outcome. The area under the curve (AUC) and maximum 
sensitivity and specificity values were computed for each model. Overall, all 
the three models performed satisfactorily in terms of the AUC, sensitivity and 
specificity. Moreover, there is room for further improvement in their 
performance, if biomarkers are integrated as predictors in these models. 
There is a growing interest to understand the long-term effects on newborns 
from pre-eclampsia pregnancies. Thus, the final piece of this analysis 
describes the pregnancy outcome of women with pre-eclampsia pregnancies. 
The results show newborns of pre-eclampsia pregnancies have far worse 
indicators of physical and mental wellbeing than their counterparts.  
5.1 About Tanzania  
My study has analysed secondary data from Tanzania, which has a 
population of 44,928,923 (NBS-Tanzania 2012b) spread out in a geographic 
area of 947,303 square kilometres (NBS-Tanzania 2012a). Tanzania is 
among the LMIC, its gross domestic product (GDP) per capita is 960.15 USD 
and ranks as the 158 poorest out of 187 countries. (IMF 2016). 
The Tanzanian population is growing quickly, with a high fertility rate of 5.5 
births per woman (NBS-Tanzania 2015). It is also a rapidly urbanising 
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country. Dar es Salaam is the main commercial city of the country with a 
population of 4,364,541 (NBS-Tanzania 2012b). These population changes 
have not been met with a corresponding growth in the health system. 
Tanzania has a low physician population density of 0.399 per 10,000 people. 
It trails behind its neighbouring countries of Kenya (1.988 per 10,000 people) 
and Uganda (0.908 per 10,000 people) (WHO 2014). The situation is very 
different in the developed counties; the United Kingdom has a physician 
population density of 28.058 per 10,000 people (WHO 2014).  
Being a tropical country, Tanzania is prone to most common tropical 
diseases such as malaria and helminthiasis, which lead to anaemia and other 
adverse consequences, especially during pregnancy. 
The maternal mortality ratio (MMR) is still high, estimated to be around 556 
maternal deaths per 100,000 live births (UNICEF 2017). MMR is the number 
of maternal related deaths during a given period per 100,000 live births 
during the same period. MMRs in Sub-Sahara Africa range from 119 
maternal deaths per 100,000 live births in South Africa to 1,150 maternal 
deaths per 100,000 live births in South Sudan (World Bank 2017). A few 
studies have estimated the burden of pre-eclampsia in Tanzania, which is 
thought to contribute to the high maternal mortality. The incidence of pre-
eclampsia in northern Tanzania was estimated to be 3.5 % among women in 
their first pregnancies through a hospital-based study (M J. Mahande et al. 
2013). The incidence of pre-eclampsia in some African counties was reported 
to range from 1.1 % in the Ivory coast to 9.3 % in South Africa (Abalos et al. 
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2013). Furthermore, this study was also hospital-based, utilizing a hospital 
register. Thus, both studies may underestimate the burden since a 
substantial proportion of women in rural settings still deliver at home and 
hence their information is never captured in the health system. Another study 
done in Dar es Salaam (an urban setting) examined the incidence of 
eclampsia amongst the hospitalised and non-hospitalised population. The 
incidence was 200/10,000 and 67/10,000 respectively (Urassa et al. 2006). 
These methodological limitations in the above studies show the uncertainty in 
our estimation of the burden of pre-eclampsia /eclampsia, which is a 
condition of public health concern.  
Some potential risk factors for pre-eclampsia in Tanzania have also been 
documented by several reports. The prevalence of HIV is around 4.7 % (95 
% CI 4.3 to 5.0) (NBS-Tanzania 2017b) while that of malaria, which is 
measured among children aged 6 to 59 month is 7.3 % (NBS-Tanzania 
2017a).  
Cardiovascular diseases, which share similar risk factors to pre-eclampsia, 
have been explored in rural and urban settings in Tanzania. Walker et al. 
(2010) showed the yearly stroke incidence rates were 108.6 per 100,000 (95 
% CI 89.0 – 130.9) in Hai (rural Tanzania) and 315.9 per 100,000 (281.6 – 
352.3) in Dar es Salaam (urban Tanzania). The rural rate was similar to that 
in northern Manhattan, USA study which showed the incidence of stroke to 
be 93 per 100,000 in white people and 223 per 100,000 in black people, but 
the urban rate of stroke in Tanzania was higher than the northern Manhattan 
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study (Walker et al. 2010). He suggested that this could be a result of a 
difference in the prevalence of risk factors. He, therefore, emphasised the 
importance of screening for hypertension, which is a precursor of stroke. 
Improving our understanding of risk factors for pre-eclampsia in African 
populations has the potential of providing appropriate care to the high-risk 
women and mitigate catastrophic outcomes of pregnancies complicated with 
pre-eclampsia. 
Access and utilisation of reproductive health services is still a challenge in 
Tanzania as in many other LMIC. A study done in rural Tanzania estimated 
the proportion of home deliveries to be 58 % (Mrisho et al. 2007).  The low 
proportion of hospital deliveries contributes to high maternal and infant 
mortality due to a lack of emergency care at home. On the other hand, child 
immunisation coverage is high in Tanzania, ranging from about 100 % BCG 
vaccine coverage for TB to 97 % coverage for DPT-H influenza and Hepatitis 
B vaccine (USAID 2017). This could indicate that there is public willingness 
to utilise health services if made accessible by outreach services that bring 
the services close to the doorsteps of these women.  
5.2 Problem statement  
There is limited understanding of the range and interactions of risk factors for 
pre-eclampsia in African countries. My scoping review study shows that few 
studies have been done in Africa and those that have been conducted often 
exhibit methodological limitations. The literature suggests there is 
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considerable variation in risk factors, some being more predominant in 
certain geographical regions while others may be universal. Genetic risk 
factors are also thought to play a role in the aetiology of pre-eclampsia 
(Williams and Morgan 2012). Black women have been shown to be at an 
increased risk of developing pre-eclampsia compared to white women 
(Knuist et al. 1998). Certain risk factors have been associated with different 
pregnancy outcomes in different ethnic groups. Obesity has been associated 
with gestational hypertension/pre-eclampsia in Australian born women while 
being associated with only shoulder dystocia in South Asian born women 
(Davies-Tuck et al. 2016). Therefore, it appears that particular risk factors 
may produce different outcomes in different populations and certain risk 
factors may only apply to a specific population.  
The scarcity of literature that has explored the risk factors of pre-eclampsia in 
African populations warrants further research to examine the relationship 
between risk factors and pre-eclampsia outcome. This study will explore 
globally known risk factors such as chronic hypertension and body weight 
alongside potentially locally important risk factors, such as malaria infection. 
Several small studies have suggested that placental malaria is associated 
with pre-eclampsia (Ndao et al. 2009, Adam et al. 2011). However, the 
results of these studies were not conclusive. Unlike previous small studies 
that lacked methodological rigour, my analysis has utilised data sets that are 
large, enough to explore the association of risk factors routinely captured in 
the Tanzanian health information system. From the reviewed literature, there 
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is a lack of evidence on the utility of these risk factors in predicting pre-
eclampsia in African populations. Hence, I am also interested in assessing 
the performance of a prediction model that utilises these risk factors in 
classifying pre-eclampsia outcome.  
My scoping review shows that most studies that explored risk factors for pre-
eclampsia did not differentiate early and late onset pre-eclampsia. My study 
will focus on identifying appropriate risk factors for early and late onset pre-
eclampsia in Tanzania, with the potential to produce separate results for the 
two distinct disease subgroups.  
At the outset of this analysis, I anticipated several potential challenges: with a 
rare outcome such as pre-eclampsia, including challenges in identifying risk 
factors and modelling the outcome and challenges due to missing data and 
potential misclassification of the outcome when relying on routine hospital 
data. On the other hand, the use of routine data for this research problem 
provides results that are generalizable to these settings.  
There is some evidence to suggest an increasing trend in the incidence of 
pre-eclampsia among pregnant women in both high, low and middle-income 
countries (Wallis et al. 2008, Vata et al. 2015), although the picture is mixed: 
a large international comparative study by Roberts et al. (2011) suggests a 
decrease in some European counties but not Massachusetts, USA. 
Unfortunately, we lack sufficient evidence to establish the trend of pre-
eclampsia in LMIC. The apparent observed rise from the Vata et al study 
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could be a result of increased utilization of health services or improvements 
in diagnostics and recording in the medical services.  It is possibly due to a 
corresponding increase in the trends of associated risk factors such as 
obesity, diabetes and chronic hypertension (Wang et al. 2008, WHO 2017a). 
With this uncertainty in mind, my study sets to determine the incidence of 
pre-eclampsia in Dar es Salaam, an urban setting of Tanzania. I envisage 
that rapid urbanisation and lifestyle transformation may predispose this 
population to a higher incidence of pre-eclampsia. There is a lack of historical 
data to establish the trend of pre-eclampsia from the past years, since pre-
eclampsia diagnosis is not routinely reported in the health information 
system. However, my study’s findings could set a reference for comparing 
with future incidence studies to establish the future trend of the disease in 
Tanzania. In this objective, I set to estimate the incidence in an urban setting 
of Dar es Salaam, Tanzania. 
In addition to estimating the incidence of pre-eclampsia, I will also describe 
the sociodemographic characteristics of women with pre-eclampsia. This 
information will provide an understanding of pre-eclampsia distribution in the 
population subgroups. Although the distribution of pre-eclampsia along 
sociodemographic characteristics has been described in several studies in 
Africa (Endeshaw et al. 2016a, Endeshaw et al. 2016b), each country has its 
own socioeconomic dynamics, thus distribution results from one country may 
not apply to another country. A comprehensive epidemiological 
understanding of the incidence, distribution, risk factors and disease 
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outcomes will facilitate the design of appropriate prevention interventions 
targeted at this population. 
Several studies have revealed the potentially devastating effects on infants 
born from pre-eclampsia pregnancies. Fetal programming in utero is thought 
to mediate their later life health impairment. A cohort study in the Netherlands 
showed that first trimester growth restriction was associated with increased 
risk of developing CVD in school age children (Jaddoe et al. 2014). This fetal 
programming effect is thought to be mediated through fetal growth restriction 
in the first trimester, birth weight and altered offspring blood pressure 
(Palinski 2014). Women born preterm or with inappropriate weight for 
gestational age were found to be at increased risk of gestational diabetes 
and pre-eclampsia in their adult life (Rogvi et al. 2012). Little is known of 
pregnancy outcomes from women with pre-eclampsia in LMIC. In addition to 
causing perinatal mortality, we want to know about the condition of the 
surviving offspring from pre-eclampsia. My study aims to describe 
characteristics of surviving offspring of pre-eclampsia using indicators of 
mental and physical wellbeing at birth. These indicators contribute to the 
wellbeing trajectory of these offspring in later life. 
5.3 Rationale  
Studies have shown that risk factors interact differently across ethnic groups 
(African American, Hispanics and Caucasian) due to environmental and 
genetic factors (Knuist et al. 1998, Makgoba et al. 2012, Davies-Tuck et al. 
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2016). Therefore, identifying risk factors for early and late onset pre-
eclampsia in Tanzania, may inform the design of effective intervention 
strategies. This research will contribute new knowledge on the status of 
evolving risk factors such as obesity, smoking, anaemia and malaria during 
pregnancy in Tanzania.  
Most developing countries’ health systems rely solely on maternal risk factors 
to identify women with a high risk of pre-eclampsia. I am interested to know 
how well these risk factors can classify the outcome. I have therefore 
developed and assessed the performance of pre-eclampsia prediction 
models in using maternal risk factors. This modelling is unique because it 
utilises local risk factor (malaria infection), in an attempt to achieve improved 
prediction suitable and focused to the Tanzanian population. 
A comparative description of the pregnancy outcomes between women with 
and without pre-eclampsia demonstrated the contribution of pre-eclampsia to 
the burden of poor pregnancy outcomes in Tanzania. This study also shines 
a light on birth indicators of offspring of women with pre-eclampsia, these 
indicators contribute to wellbeing in adult life. This comparative description of 
pregnancy outcomes has also made a comparison of the subgroups of 
preterm and term deliveries. This was done to account for the difference in 
pregnancy outcome as a result of difference in the duration of the pregnancy 
before delivery. Therefore, pre-eclampsia women with preterm deliveries 
were compared with non-pre-eclampsia women who also had preterm 
deliveries. 
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This study will also estimate the incidence of pre-eclampsia among women in 
Dar es Salaam, Tanzania. This finding will enable us to establish the baseline 
of the magnitude of the condition, which will serve in future comparison when 
evaluating the trend of the condition in the country. I envisage that the 
evolving lifestyle-related risk and the changing prevalence of other risk 
factors in this setting necessitate periodic estimation of the burden of the pre-
eclampsia. High cost attached to reforming health information systems is 
likely to continue to prevent integration of pre-eclampsia and other 
hypertensive disorders in the routinely monitored conditions in the health 
system. Therefore, LMIC like Tanzania will have to rely on periodic research 
to inform the burden of the condition. The incidence of pre-eclampsia in Dar 
es Salaam city is also important in raising awareness and for mobilizing 
resources to address this problem. Unlike previous incidence studies, which 
were based in tertiary hospital, my study utilised data from lower level public 
health facilities across Dar es Salaam, where access to maternal health 
services is free of charge, hence making my incidence estimate more closely 





The importance of this study: 
• It highlights the burden and the sociodemographic distribution of 
pre-eclampsia in LMIC. which is relevant in raising awareness and 
targeting prevention efforts. 
• It has identified relevant risk factors in LMIC settings which are 
useful in risk stratification and prediction for population health 
management in LMIC 
• It has shown the adverse health outcomes of newborns of pre-
eclampsia deliveries in LMIC settings, calling on the need for 
intervention to mitigate pre-eclampsia in these settings 
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5.4 Objectives  
The key objective of this study is to determine the incidence, risk factors and 
pregnancy outcomes for pre-eclampsia among women in Tanzania. 
Specific objectives are: 
1. To determine the incidence of pre-eclampsia among women in Dar es 
Salaam, Tanzania from 2007 to 2009. 
2. To describe the sociodemographic characteristics of women with pre-
eclampsia in northern Tanzania from 2006 to 2010. 
3. To identify risk factors for pre-eclampsia, term and preterm deliveries 
subgroups, among women in northern Tanzania from 2006 to 2010.  
4. To describe the pregnancy outcomes characteristics of women with 
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5.5 Methods  
5.5.1 Study design 
I have used cross-sectional study design to address my four objectives. This 
study utilises two Tanzanian data sets.  
1. The first dataset is sourced from the Kilimanjaro Christian Medical 
Center (KCMC) maternal register; KCMC is a tertiary level hospital, 
serving the Northern region of Tanzania. Its maternal register collects 
all the vital information on women’s deliveries. I used this data set to 
identify the risk factors for pre-eclampsia in term and preterm 
deliveries and to describe the sociodemographic and pregnancy 
outcome characteristics of women with pre-eclampsia pregnancies. 
[Objective 2,3 and 4]  
2. The second dataset is sourced from a clinical trial of nutritional 
supplements to newborns (Child 2, NCT.00421668), conducted in Dar 
es Salaam, Tanzania. This Child 2 trial recruited a cohort of pregnant 
women at antenatal clinics and collected background and pregnancy 
outcome data of the recruited women. I used this data set to estimate 
the incidence of pre-eclampsia in Dar es Salaam, Tanzania. [Objective 
1] 
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5.5.2 KCMC register data set 
The KCMC is among four tertiary level hospitals in Tanzania and caters for 
the northern regions of Tanzania. My dataset from this centre covers from 
2006 to 2010 and has records of 16,342 women. The register is 
computerised and uses access software that applies field restrictions i.e. you 
must enter data in all the specified entry fields on the screen. Some entry 
fields provide selection options, these mechanisms enhance completeness 
and valid data entry. The dataset includes information about the women 
during the antenatal period and at delivery. The hospital has skilled staff and 
equipment to facilitate an accurate diagnosis. Despite these assurances, I 
cannot rule out misclassification due to sensitivity and specificity limitations of 
diagnostic tools.  
5.5.2.1 Study population and sampling for objective two, three and four 
 KCMC is a tertiary level hospital that caters for the northern regions of 
Tanzania (Kilimanjaro, Arusha and Tanga). The population from these 
regions is around 5,379,602 (NBS Tanzania, 2012). Most maternal cases 
attending this hospital were referred from lower level health facilities from 
these regions. Antenatal and delivery services are offered free of charge in 
Tanzania. My sample data was drawn from the register based in this hospital, 
where all singleton deliveries from 2006 to 2010 were extracted. It represents 
the characteristics of women with pre-eclampsia in the northern region. 
However, this hospital-based dataset is not ideal in estimating the incidence 
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of pre-eclampsia in a population. To achieve this, I have sought the dataset 
from the clinical trial in Dar es Salaam solely for this purpose. 
5.5.2.2 Study variables 
Independent variables  
Table 5 Maternal antenatal variables 
This table lists all the maternal variables that my analysis utilised to assess 
whether they are associated with the occurrence of pre-eclampsia. These 
variables were selected out the KCMC maternal register dataset. The 
complete list of all the variables in the KCMC dataset is listed in annex 1. 
Variables stating history of a condition or use of item means the woman had 
experienced that disease or used that item prior to her current pregnancy. It 
does not show the duration or how may time in the past she had used the 
item or experienced the condition. However, some chronic diseases once 
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eclampsia among the exposed (obese) was 6.5 % and in the unexposed 
(normal weight) was 2.5 %. Using these findings and a set alpha level (α = 
0.05) and power at 80 % (β = 0.2), The Kelsey method gives the required 
sample size is 886 i.e. [222 exposed (obese) group, 664 unexposed (normal 
weight) group]. I did not get data from prior studies in Tanzania to enable me 
to estimate the different sample size needed to satisfy the set alpha level and 
power for each of the variable (risk factors) I intend to explore. However, my 
estimated sample size of 886 women for the risk factor of obesity serves to 
show that my available sample size of 16,342 women is likely to meet the 
required sample size for all the other risk factors I plan to explore.  
5.5.3 Child 2 clinical trial data set 
Muhimbili University of Health and Allied Sciences (MUHAS) in collaboration 
with Harvard School of Public Health conducted a clinical trial on the effect of 
zinc and multivitamin supplementation to infants of HIV Negative mothers in 
Dar es Salaam, Tanzania (Registration no NCT.00421668). The trial 
recruited a cohort of pregnant women from antenatal clinics, randomised 
their infants from 2007 to 2009, and followed them up for 18 months until 
2011. The trial was designed to study infants, but it had to recruit mothers 
first and provide standard antenatal care during their pregnancy period. In 
this process, data were collected about their pregnancy state and progress.  
Recruitment plan 
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Mothers of potentially eligible infants were recruited into the study in one of 
two ways: 
1. Pregnant women ≤ 34 weeks gestation presenting at one of the three 
prenatal clinics (Sinza, Magomeni and Amtulabai health centres) in 
Dar es Salaam were informed about the study and consented 
prenatally or 
2.  Women were recruited from the labour ward of Muhimbili National 
Hospital within 12 hours of delivering a healthy singleton baby.  
A mother was considered enrolled after signing the consent form for the 
study. An infant was not enrolled until he/she was randomised. 
Eligibility criteria for mothers 
A woman eligible for enrollment must:  
• be pregnant with a singleton fetus 
• be ≥ 18 years old 
• be ≤ 34 weeks gestation (as measured by last menstrual period) 
• be HIV negative 
• be willing to remain in Dar es Salaam for 2 years after the child’s 
birth 
• Must not have had a previous child enrolled in Child 2 
  [Risk factors for pre-eclampsia] 
[Analysis of risk factors]  129 
 
 Measurements and tools 
Pre-eclampsia diagnosis 
The study used the standard definition of pre-eclampsia. Pre-eclampsia was 
defined as persistent high systolic (≥ 140 mmHg) or diastolic (≥ 90 mmHg) 
blood pressure and proteinuria (≥0.3 g/24 hours or a dipstick result of ≥ 1+, 
equivalent to 30 mg/dl in a single urine sample or spot urine protein/ 
creatinine ratio ≥ 30 mg protein/mmol creatinine) of new onset after 20 weeks 
of gestation (Kleinrouweler et al. 2012).  
Blood pressure was measured using a sphygmomanometer and a 
stethoscope. The systolic value was recorded on the first knocking 
(Korotkoff) sounds and the diastolic value was noted when the knocking 
sound disappears. The correct size of blood pressure cuff was used during 
blood pressure measurement.  
Protein in urine was measured by dipstick and results recorded as Nil, Trace 
(5-20mg/dl), + (30mg/dl), + + (100mg/dl), + + + (300mg/dl) and + + + + (> 
300mg/dl) (Kallen and Watson 2015).  
Data collection  
Double entry of data was conducted to minimise entry errors. Two data clerks 
monitored by a supervisor collected, coded and entered the trial data. All the 
information was stored on secure computers in the data centre. Data 
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The nonresponse rate includes women who were eligible to join the study but 
did not consent and women who consented to join the study but did not join 
for whatever reason.  
5.5.3.2 Sample size estimates 
In estimating the incidence of pre-eclampsia using the trial dataset, I used the 
formula estimating the proportion of a dichotomous outcome in a single 
population. My estimated incidence of pre-eclampsia among northern 
Tanzanian women attending ANC was 3.5 % (M. J. Mahande et al. 2013). I 
set the margin of type I error of my estimate at 1 % (α = 0.01), and a 99 % 
confidence interval. The calculated sample size using the Kish Leslie formula 
is 2,248 (Leslie 1965). My dataset from the clinical trial has records of 3,767 
pregnant women, which surpasses the required sample size for a 99 % CI. 
5.5.4 Data analysis 
Statistical Package for Social Science (SPSS) software version 25 was used 
for analysis. I used the Kish Leslie formula to calculate the sample size for 
pre-eclampsia incidence estimation in Dar es Salaam (Leslie 1965). To 
calculate the required sample size for estimating risk factors for pre-
eclampsia, I used the Kelsey (1986) formula for sample size estimation of 
unequal group of exposure/risk factor, while setting the power at 80 % and 
alpha level (α = 0.05). 
Objective 1: (Using the child 2 trial dataset). The incidence of pre-eclampsia 
was determined by counting the frequency of new pre-eclampsia cases in the 
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cohort population in Dar es Salaam. The crude incidence was adjusted by 
age to give an adjusted incidence, and then a 95 % CI was estimated. 
Objectives 2 and 4: (Using KCMC register dataset). Sociodemographic 
characteristics were compared between women with and without pre-
eclampsia. Similarly, pregnancy outcome variables (stillbirth, Apgar score 
and prematurity.) were compared between women with and without pre-
eclampsia. Significance testing was done using Chi square (χ2) or Fisher’s 
exact test. Continuous variables were compared by mean difference between 
pre-eclampsia and non-pre-eclampsia groups. T-test was done for statistical 
significance testing.  
Objective 3: (Using KCMC register dataset). In determining risk factors for 
the development of pre-eclampsia in all deliveries, term and preterm 
subgroups, I split the dataset with 16,342 cases into 80 % for training and 20 
% for testing my models. Assessment of missing data was done to explore 
the pattern of missing-ness to inform selection of appropriate assumptions for 
my analysis. There was no missing value in the outcome variable of pre-
eclampsia, so the imputations were only done on some of the predictor 
variables. I imputed missing data in selected continuous variable using linear 
regression model. I first did a complete case analysis to develop my first set 
of prediction models using logistic regression. Then I imputed the missing 
dataset with single imputation method and developed a second set of logistic 
regression models. I compared the first (without imputed data) and second 
set (with imputed values) of logistic regression models. The second set 
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models (with imputed values) were not better than the first set models 
(without imputation i.e. complete case analysis). The models from complete 
case analysis were then internally validated on the 20 % testing dataset 
spared for this role. The performances of these models during validation 
were compared to their performance on the training datasets. The area under 
the curve (AUC) and its 95 % confidence intervals were used to assess the 
model classification performance. I used the following steps in developing my 
models: I conducted a univariable analysis for each biomedical risk factor 
with a logistic regression model. I added predictor variables with statistically 
significant (p values < 0.05) to a multivariable logistic regression model. I 
specified these predictors using “Enter method” in SPSS, when adding them 
to the multivariable logistic regression. I explored clinically plausible 
interaction terms in an attempt to fit the best multivariable model. I developed 
three different multivariable prediction models to predict pre-eclampsia 
outcome among all deliveries and in preterm and term deliveries subgroups. 
The best fitted model for each of these three outcome models is reported in 
the results section. 
I tested the assumptions of logistic regression modelling. The assumption of 
independent observations was tested by using a generalised estimating 
equation model (GEE) and the result compared with that from a logistic 
regression model. This consideration resulted from the fact that a woman 
may have delivered multiple times during the period of 2006 to 2010. This 
possible correlation of pre-eclampsia outcome within a cluster of each 
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individual woman was addressed by using GEE model and then compared 
with the results of logistic regression models. The logistic regression 
modelling was done with the assumption that each pregnancy was an 
independent outcome, even if it was from the same woman, since she would 
be having different risk profile in each pregnancy.  
5.5.5 Ethical considerations 
Ethical approval was obtained from the owners of the two datasets: 
1. The clinical trial, a trial of zinc and multivitamins to the infant of HIV 
unexposed pregnant women in Dar es Salaam, Tanzania (Registration 
no NCT.00421668).  
2. The KCMC maternal register. 
The owners of these datasets had already received ethical approval from the 
relevant ethics bodies prior to carrying out the primary studies. My request for 
approval is for secondary analysis of these datasets. 
Neither data set contains patient names or other identifiers to ensure 
confidentiality of participants’ identity. Level one, self-audit form was filled in 
and signed under by the principal research supervisor. This is in accordance 
with the University’s ethical approval procedures. A letter from the 
university’s ethical review committee was issued, affirming that the study was 
a level one. Annex 8 shows the approval letters from owners of the datasets 
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and the approval letter from the University of Edinburgh (Usher Institute 
Research and Ethics Committee). 
 
5.5.6 Study limitations 
Incidence estimation of pre-eclampsia 
Because the child 2 clinical trial was designed to focus on infants, rather than 
on pregnancy outcomes of their mothers, there are limitations based on the 
enrolment criteria of excluding HIV positive pregnant women. However, 
systematic review evidence shows no conclusive evidence of HIV being 
associated with pre-eclampsia (Adams et al. 2016). Therefore, the incidence 
of pre-eclampsia among HIV negative women is unlikely to be different from 
those who are HIV positive. Thus, it is reasonable to assume that my 
estimate is representative of the whole population of pregnant women in Dar 
es Salaam.  
Chance 
I used an alpha level of 5 % in my analysis in my four objectives thus 
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Power 
My study had sufficient sample size to detect a clinically meaningful 
difference in proportion between unequal groups with a power of 80 % and 
an alpha level of 0.05. (See sample size estimates sections above) 
Selection bias 
The clinical trial in Dar es Salaam recruited women based on the eligibility 
criteria (see annex 3). The recruitment was also voluntary (nonprobability 
sampling) hence may not represent the target population. Recruitment was 
carried out among pregnant women attending public antenatal clinics. These 
women are likely to differ in their risk of pre-eclampsia compared to more 
affluent pregnant women who are attending private antenatal clinics. This 
aspect may bias us to have a lower estimate of the incidence of pre-
eclampsia in Dar es Salaam. 
Non-response bias 
Non-response bias occurs when participants chosen for the study are 
unwilling or unable to participate and this may result in the respondents to 
differ from non-respondents in relation to the characteristic under 
investigation. There were 4,650 eligible women, out of which 3,767 were 
enrolled in the child 2 clinical trial, giving a nonresponse rate of 19 %. It is 
assumed that those who enrolled did not differ in their characteristics from all 
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those who were eligible, thus making the dataset representative of the target 
population; however, this is an untested assumption, which may not be true.  
 
Misclassification bias 
My study’s validity depends on the quality of the datasets in terms of how the 
variables were measured, recorded, and coded in the clinical trial and the 
KCMC hospital maternal register. In this process, there is a possibility for 
misclassification of the variables. This may impair identifying associations in 
the analysis. In order to minimise this challenge, I inspected all variable 
values in my datasets to detect obvious errors. I am not able to do a 
diagnosis audit to validate the assigned diagnosis because my data was from 
past years; it would be difficult to retrieve the case files of the patients for 
validation. Carrying out a diagnosis quality audit at the present time would 
not reflect the situation in past years when the data were generated. A 
diagnosis quality audit checks the diagnosis status of patients in a hospital 
and compares the results to what has been documented in the patient’s 
diagnosis. It offers a measure of agreement between the documented 
diagnosis and the true diagnosis. 
Confounding factors 
Confounding variables such as maternal age, parity and gestational age at 
delivery were recorded and were used in the multivariable analysis to adjust 
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the strength of associations. However, other confounding variables such as 
change of paternity and previous abortions were not available or accurately 
captured to enable adjusting for their effects. Therefore, my results may still 
have a limitation of residual confounding.  
5.5.7 Summary 
This chapter introduces the context of Tanzania, one of the low-income 
countries in Africa. Data from this country is used for the secondary analysis 
of risk factors for pre-eclampsia. This chapter also outlines the problem 
statement highlighting the gaps from literature. The rationale and objectives 
of my study are presented in this chapter. Then a detailed plan of methods 
for analysing the data are presented for the respective objectives. The ethical 
approval process is discussed with respect to the dataset acquisition. The 
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Chapter 6 Results of pre-eclampsia risk factor 
analysis in Tanzania. 
Chapter Six provides the results from the planned analysis presented in the 
previous chapter. The results are organised according to the four objectives 
of the data analysis. 
•  Objective one has estimated the incidence of pre-eclampsia in Dar es 
Salaam, to be 1.9 %, 95 % CI 1.3 % to 2.2 %. 
• Objective two has shown sociodemographic distribution of pre-
eclampsia in northern Tanzania to be more prevalent among women 
aged above 35 years, single and women with tertiary education. 
• Objective three has shown there is a difference in risk factors that 
explain term and preterm pre-eclampsia. The identified risk factors for 
all types of pre-eclampsia we’re; maternal age, mother’s weight before 
pregnancy, history of hypertension, HIV treatment, contraceptive IUD 
use, a diagnosis of malaria and a diagnosis of infections. Prediction 
models developed using these risk factors, were able to satisfactorily 
classify women with and those without pre-eclampsia outcome. 
• Objective four has shown pre-eclampsia is associated with a high 
proportion of stillbirths. Furthermore, the surviving newborns from pre-
eclampsia pregnancies have far worse indicators of physical and 
mental wellbeing.  
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Adjusting the crude incidence of pre-eclampsia by maternal age produced 
the incidence of pre-eclampsia of 1.9 % [95 % CI (1.3 % - 2.2 %)]. This is 
similar to the world estimates of the incidence of pre-eclampsia, which is 2 % 
to 8 % of all pregnancies (WHO 2011). 
6.2 Results for objective two  
Objective two describe the sociodemographic characteristics of women with 
pre-eclampsia in northern Tanzania. The table below shows the comparison 
of the sociodemographic characteristic among women with and without pre-
eclampsia. It shows this comparison in all deliveries and in the subgroups of 
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The proportion of pre-eclampsia increases linearly across the maternal age 
ordinal categories. This is observed among all deliveries and in both 
subgroups of term and preterm deliveries. 
There is a linear increase in the proportion of pre-eclampsia across mother’s 
education ordinal categories. This trend is observed in all pre-eclampsia 
deliveries and in the preterm and term delivery subgroups. 
The proportion of women with pre-eclampsia does not differ significantly 
across the marital status categories. This applied to all deliveries and in the 
term and preterm subgroups. 
There is an increase in the proportion of pre-eclampsia across gravidae 
categories. This trend was observed on all pre-eclampsia and term 
deliveries. However, this trend was not observed in the preterm delivery 
subgroup. 
Pre-eclampsia is associated with abortion/miscarriages in all deliveries and in 
preterm deliveries. Odds ratio (abortions/miscarriages vs normal pregnancy) 
1.5 [95 % CI (1.1 - 1.9)] and 1.9 [95 % CI (1.3 - 2.8)] respectively. This 
association was not observed in the term delivery subgroup, odds ratio 1.00 
[95 % CI (0.7 -1 .5)]. 
The proportion of pre-eclampsia differs across the nominal categories of 
mother’s occupation. The proportion of pre-eclampsia was highest among 
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professional mothers. This was observed in all deliveries, and in term and 
preterm deliveries subgroups.  
The proportion of pre-eclampsia was not different across the nominal 
categories of father’s occupation. 
The overall social demographic comparison of women with and without pre-
eclampsia shows women with older age, single, higher education level, 
history of abortion/miscarriage, professional occupation and with a higher 
number of pregnancies were more likely to have pre-eclampsia. On the other 
hand, father’s occupation categories were not associated with having pre-
eclampsia. 
I further analysed these sociodemographic characteristics to explore if they 
explained the occurrence of pre-eclampsia in all deliveries, after adjustment. 
The table below shows the result of a multivariable logistic regression model 
for sociodemographic characteristics only. I did not find any evidence of 
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Variables B S.E. Wald Sig. Odds 
Ratio 
(OR) 
95 % C. I. for Odds 
Ratio 
Lower Upper 
26-30 -0.11 0.17 0.37 0.54 0.89 0.63 1.27 
31-35 0.32 0.18 2.87 0.09 1.37 0.95 1.99 











  7.57 0.10  
  
2 -0.24 0.12 3.54 0.06 0.78 0.60 1.01 
3 -0.09 0.15 0.37 0.54 0.91 0.67 1.22 
4 -0.03 0.18 0.04 0.84 0.96 0.67 1.38 





reference) 0.26 0.14 3.50 0.06 1.30 0.98 1.72 
Constant -3.66 0.18 382.1 <0.0
1 
0.02   
 
The above model for pre-eclampsia outcome among all deliveries suggests 
that being single, maternal age and tertiary education are the only jointly 
statistically significant sociodemographic factors that are associated with the 
outcome, after adjustment. A possible explanation is that women with tertiary 
education have a lifestyle that predisposes them to be more at risk than their 
counterparts. Single women may not have gained enough exposure to their 
partner’s sperm. 
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6.3 Results for objective three  
Objective three aimed to identify risk factors for pre-eclampsia, term and 
preterm deliveries subgroups, among women in northern Tanzania. This 
result section contains key findings in the development and validation of the 
prediction model using maternal biomedical risk factors. My original dataset 
contained 16,342 cases form KCMC hospital. I then randomly split the 
dataset into two parts, 80 % (13,113 cases) for the training set and 20 % 
(3,229 cases) for internal validation. I did not have access to another dataset 
with similar predictor variables coming from an African setting, which I could 
use for external validation.  
My analysis was focused primarily on modelling for the outcome of pre-
eclampsia for all deliveries, then I went on to carry out two sub-analyses by 
modelling for the outcome of pre-eclampsia among term deliveries followed 
by pre-eclampsia among preterm deliveries.  
The first set of the abovementioned models was developed using complete 
case analysis of the training dataset under the assumption of missing 
completely at random. Then the above models were applied on the same 
training dataset after single imputation since most of them were dichotomous 
in nature (yes or no for a disease). There was no improvement on the 
model’s performance in classifying pre-eclampsia outcome when applied on 
the imputed training dataset. The beta coefficients of the predictors and their 
standard errors did not reasonably differ between the complete case and 
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imputed analysis outputs. The complete case analysis models developed 
initially were then internally validated using the 20 % data that were spared 
for validation purposes.  
I used the Statistical Package for Social Science (SPSS) version 25 to carry 
out my analysis.  Binary logistic regression modelling was used in my 
analysis. Univariable analysis was carried out for each of the biomedical 
factors. The results of the univariable association are presented in Tables 13, 
17 and 21 (all pre-eclampsia, pre-eclampsia among term deliveries and pre-
eclampsia among preterm deliveries respectively). 
The statistically significant variables were then added to a multivariable 
model using the Enter method in SPSS. The multivariable model was revised 
to exclude manually non statistically significant variables in the model. The 
final prediction models are presented in tables 15, 19 and 23 (all pre-
eclampsia, pre-eclampsia among term deliveries and pre-eclampsia among 
preterm deliveries respectively). The performance of the developed models 
was determined by the area under the receiver operator curve (ROC), 
presented in figures 9, 10 and 11 (all pre-eclampsia, pre-eclampsia among 
term deliveries and pre-eclampsia among preterm deliveries respectively). 
My dataset had missing values. SPSS software omits all cases with missing 
variables in the analysis; therefore, my complete case analysis had a 
reduced sample size. In order to address this gap, I applied single imputation 
for missing values in my training dataset and developed similar models to the 
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above developed models (seen in tables 15, 19 and 23). I then compared 
their classification performance and beta coefficient values of the predictors. 
The results of the models developed on imputed training datasets are 
presented in tables 25, 26 and 27 (all pre-eclampsia, pre-eclampsia among 
term deliveries and pre-eclampsia among preterm deliveries respectively). 
However, there was no improvement in the classification performance from 
the models developed from the imputed training dataset (see figure 12, 13 
and 14). The beta coefficients of my predictors did not reasonably differ from 
that of complete case model output. The standard errors were slightly smaller 
in the imputed models outputs due to an increase in sample size after 
imputing all missing values. 
I carried out validation of the developed models. These models performed 
satisfactorily on the 20 % validation dataset. There was an increase in the 
standard error of the beta coefficients in all the models because the 20 % 
validation dataset is of a smaller sample size. This increase in the standard 
error of the beta coefficient rendered some predictor variables to have a wide 
confidence interval and thus become non statistically significant. However, 
there was little change in the values of most beta coefficients point estimates 
in the models developed. The results of the validated models are presented 
in tables 28, 29 and 30 (all pre-eclampsia, pre-eclampsia among term 
deliveries and pre-eclampsia among preterm deliveries respectively). The 95 
% CI of the area under the curve (AUC) of the model’s performance on the 
validation dataset was similar to that in the complete case analysis. The 
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results of the AUC are presented in figure 15, 16 and 17 (all pre-eclampsia, 
pre-eclampsia among term deliveries and pre-eclampsia among preterm 
deliveries respectively)  
I also performed diagnostics checks for the logistic regression models; I 
tested the impact of potential correlation of my outcome within the cluster of 
each individual women by modelling the pre-eclampsia outcome using 
generalised estimating equation (GEE). The results of GEE univariable 
analysis (see table 14, 18 and 22) and later the multivariable results of GEE 
are presented side by side with the results of logistic regression, see table 
16, 20 and 24 (all pre-eclampsia, pre-eclampsia among term deliveries and 
pre-eclampsia among preterm deliveries. 
6.3.1 Exploration of data 
I explored my data to understand the nature of the relationship between the 
predictor variables and the outcome. I am citing one example, where I 
explored the nature of the relationship between maternal age and the risk of 
pre-eclampsia expressed in percentage. A study by Kumari (2016) showed 
maternal age had a J- shape relationship with pre-eclampsia. However, this 
study did not factor the difference brought about by the number of 
pregnancies (nulliparity and parity), which is an important confounder of this 
relationship.  
Figure 6: The relationship between women age and proportion of pre-
eclampsia for all women. 
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missing values in numerical data. In one variable (mother’s height), I imputed 
the mean value of mother’s height. 
*- denotes the variables that were modified to reduce missingness. There 
was no systematic pattern to the missingness of these values 
Table 11 Percentage of missing values in my sociodemographic and 
predictor variables. 
Predictor variables 
Variable list Valid Missing 
Maternal age 16338 4 
Number of pregnancies 15391 951 
Gestational age in weeks LMP*  14783 1559 (9.5 %) 
Body weight at admission 16276 66 
Highest educational level of mother 16318 24 
Mothers occupation 16314 28 
Marital status 16328 14 
Fathers age 16229 113 
Fathers education 16295 47 
Fathers occupation 16306 36 
Hx Diabetes 16342 0 
Hx Hypertension 16342 0 
Hx Heart disease 16342 0 
Hx Epilepsy 16342 0 
Hx Malaria 16342 0 
Hx Anaemia 16342 0 
Hx Liver disease 16342 0 
Hx Kidney disease 16342 0 
Hx Sickle cells 16342 0 
Mothers weight before pregnancy** 13321 3021(18.5 %) 
Mothers height*** 13604 2738 (16.7 %) 
p-pills 16342 0 
injections 16342 0 
implant 16342 0 
Number of ANC visits 16095 247 
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*  Missingness reduced to 2 %, using a model with R2 = 26.7 %. 
** Missingness reduced to 7.7 %, using a model with R2 = 57.7 %. 
***  Missingness reduced to 0 %, imputed mean height = 160.4cm to 2758 missing 
values out of 13,584 cleaned values. 
**** No imputation done, variable not used at all instead we used the below variable, HIV 










Chewing tobacco  16320 22 
Chewing tobacco during pregnancy? 16316 26 
Do you Smoke 16312 30 
Smoking during this pregnancy 16329 13 
Do you drink alcohol beverage 16260 82 
Alcohol during this pregnancy 16321 21 
Result of HIV-test**** 14822 1520(9.3 %) 
HIV treatment 16308 34 
Diagnosis of Gest diabetes 16342 0 
Diagnosis of diabetes 16342 0 
Diagnosis of Hypertension 16342 0 
Diagnosis of Pre-eclampsia 16342 0 
Diagnosis of eclampsia 16342 0 
Diagnosis of epilepsia 16342 0 
Diagnosis of leeding 16342 0 
Diagnosis of anaemia 16342 0 
Diagnosis of hyperemsis 16342 0 
Diagnosis of malaria 16342 0 
Diagnosis of heart disease 16342 0 
Diagnosis of infections 16342 0 
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Table 12 Percentage of missing values in my pregnancy outcome variables 
Pregnancy outcome variables 
Variable list Valid Missing 
Mothers health after delivery 16309 33 
sequence for twins 16342 0 
Childs status 16316 26 
Sex of the child (neonates) 16284 58 
birth weight 16308 34 
birth length* 16104 238 
head circumference** 16090 252 
Mode of delivery 16323 19 
Apgar 1min 16300 42 
  
*Missingness reduced from 1.55 % to 1.4 % after imputing with a model R2 = 
45.6 % suing birthweight and head circumference. There was no significant 
reduction (only 0.15 %) in missingness using these variables as they also 
had missing values.  
**I did reduce missingness in this variable since it would result in a non-
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Figure 9: Logistic regression model performance on a receiver operator 
curve. The above model predicts overall pre-eclampsia outcome. 
 
*Area under the curve 0.694 
The predicted probability cut off point that maximises sensitivity and 
specificity is 0.035. Youden’s Index yields a sensitivity of 65 % and specificity 
of 63 %. 
Model classification at Youden’s index 
  Predicted  
  Non pre-eclampsia Pre-eclampsia  
Observed Non pre-eclampsia 7351 4317 Specificity 63% 
Pre-eclampsia 156 290 Sensitivity 65% 
Overall classification percentage   63% 
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Figure 10: Logistic regression model performance on a receiver operator 
curve. The above model predicts pre-eclampsia outcome among term 
deliveries. 
 
*Area under the curve 0.712 
The predicted probability cut off point that maximises sensitivity and 
specificity is 0.026. Youden’s index yields a sensitivity of 65 % and specificity 
of 65 %. 
Model classification at Youden’s index 
  Predicted  
  Non pre-eclampsia Pre-eclampsia  
Observed Non pre-eclampsia 6312 3398 Specificity 65% 
Pre-eclampsia 179 97 Sensitivity 65% 
Overall classification percentage   64% 
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Figure 11: Logistic regression model performance on a receiver operator 
curve. The above model predicts pre-eclampsia outcome among preterm 
deliveries. 
 
*Area under the curve 0.669 
The predicted probability cut off point that maximises sensitivity and 
specificity is 0.107. Youden’s index yields a sensitivity of 59 % and specificity 
of 66 %. 
Model classification at Younden’s index 
  Predicted  
  Non pre-eclampsia Pre-eclampsia  
Observed Non pre-eclampsia 713 495 Specificity 66% 
Pre-eclampsia 59 85 Sensitivity 59% 
Overall classification percentage   59% 
 
Positive likelihood ratio = 1.73; Negative likelihood ratio = 0.62. 
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Figure 12 Model performance on a receiver operator curve. The above model 
predicts pre-eclampsia outcome using imputed data. 
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Model goodness of fit (Hosmer and Lemeshow test) χ2=4.018, d.f 8, P value 
0.855. 
 
Figure 14 Model performance on a receiver operator curve. The above model 
predicts pre-eclampsia outcome among preterm deliveries using imputed 
data. 
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Model classification at Youden’s index 
  Predicted  
  Non pre-eclampsia Pre-eclampsia  
Observed Non pre-eclampsia 1896 933 Specificity 67% 
Pre-eclampsia 41 76 Sensitivity 65% 
Overall classification percentage   67% 
 










Area Under the Curve 0.689  
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Model Classification at Youden’s index 
  Predicted  
  Non pre-eclampsia Pre-eclampsia  
Observed Non pre-eclampsia 174 106 Specificity 62% 
Pre-eclampsia 17 27 Sensitivity 61% 
Overall classification percentage   62% 
 










Area Under the Curve 0.672  
95 % Confidence Interval 0.585 - 0.758 
  [Risk factors for pre-eclampsia] 
[Analysis of risk factors]  195 
 
6.3.6 Diagnostics of the models 
Independent observation assumption 
In this logistic regression analysis, I have regarded the KCMC register data 
as a cross-sectional study design assuming that all the recorded pregnancies 
on my dataset (16,342) at KCMC hospital register from 2006 to 2010 were 
independent of each other. They were all singleton deliveries that were 
recorded on the register. This assumption was derived from the idea that 
each pregnancy separated in time, even if from the same mother, would be 
linked to different values of predictor variables. Even if the woman was the 
same, her age would differ between subsequent deliveries, so it is likely that 
her weight, hypertension status, infection status and other predictor variables 
might also differ.  
However, I made an effort to reanalyse the KCMC dataset using generalised 
estimating equation (GEE). This modelling technique can model datasets 
with cluster-correlated measurements, thus removing the possible correlation 
that results from the same women coming in for two or more subsequent 
deliveries in KCMC hospital. I used the hospital ID number to identify women 
who may have been delivered multiple times and recorded in the maternity 
register. 
The result from the generalised estimating equation modelling is presented 
side by side with the result of the logistic regression model for complete case 
analysis, all deliveries and in term and preterm subgroups. There was no 
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meaningful difference between the results of the two models i.e. logistic 
regression and generalised estimating equation. 
 
Linearity assumption 
My analysis includes conducting diagnostics for my models. Figures 18, 19 
and 20 show the relationship between the continuous predictor variables and 
their Logit outcome in a univariable regression model. This analysis tests the 
assumption of my model that the predictor variable has a linear relationship 
with the logit of the outcome. My continuous predictor variables were 
maternal age, mother’s height and mother’s weight before pregnancy, while 
my outcome variable is a diagnosis of pre-eclampsia. 

























Maternal age against Logit (Y)
Logit(Y)
Linear (Logit(Y))
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This figure suggests there is a linear relationship between maternal age and 
the logit of pre-eclampsia 
 
Figure 19 Mother’s height against the Logit (Y) 
 
This figure suggests that there is an approximately linear relationship 
between the mother’s height and the logit of pre-eclampsia. However, the 
linear relationship seems not to hold on extreme levels of mother’s height 



























Mothers height against Logit (Y)
Logit Y
Linear (Logit Y)
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Figure 20 Mother’s weight against the Logit (Y) 
 
This figure suggests that a mother’s weight before pregnancy has a linear 
relationship with the logit of pre-eclampsia. 
I attempted to resolve the nonlinearity observed in figure 19 by creating a 
composite variable of body mass index (BMI) which aggregates mother’s 
weight and height variables. The diagnostic of this new BMI variable is shown 
below. There is a non-monotonic relationship in the low values of BMI, 
suggesting BMI lower than 25 corresponds with negative logit of Y i.e. 
decreased log odds of pre-eclampsia. While BMI higher than 25 increases 
the log odds of pre-eclampsia.  



















Mothers weight before pregnancy quartiles





















Mothers BMI categories vs Logit Y
Logit Y
Linear (Logit Y)
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Since BMI did not show to have a better linear relationship with pre-
eclampsia compared to mother’s weight and mother’s height separately. I did 
not fit BMI in my prediction model rather I continued to use the weight and 
height variables independently. 
Residual analysis 
Figure 22 Residual analysis of the model predicting all pre-eclampsia 
outcomes, complete case analysis  
 
*Expected normal residual trend in orange line  ___ 
This figure suggests the residuals from the model do follow the expected 
normal trend. A normalised residual is a ratio: the difference between the 
observed count and the expected/predicted count and the standard deviation 
of the expected count. Homoscedasticity is not an assumption of logistic 
regression. 
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Variable Tolerance VIF 
Diagnosis of diabetes 0.586 1.706 
Diagnosis of hypertension 0.977 1.024 
Diagnosis of anaemia 0.989 1.012 
Diagnosis of hyperemesis 0.992 1.008 
Diagnosis of malaria 0.968 1.033 
Diagnosis of heart disease 0.993 1.007 
Diagnosis of infections 0.965 1.037 
 
Goodness of fit of the models 
Goodness of fit of the models was assessed by the Hosmer and Lemeshow 
test. The results of each model are presented below the respective model 
tables. None of the fitted models failed the test i.e. p value < 0.05.  
Improving the model performance based on diagnostic findings 
I attempted to improve my prediction model for pre-eclampsia among all 
deliveries (first model) by substituting mother’s weight with my composite 
variable BMI. However, the performance of this new BMI model (see table 32 
and 33 below) was not significantly better compared to my first model in table 
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6.3.7 Comparison of the final models; (first model) all 
deliveries, (second model) term deliveries and (third 
model) preterm deliveries 
 
Table 34 Comparison of the final models for predicting pre-eclampsia in all 
deliveries and in term and preterm deliveries subgroups. 






1st Model OR 2nd Model OR 3rd Model OR 
Maternal age 
(1year unit) 
1.035 1.05 1.036 
Number of pregnancies                
(1 pregnancy unit) 
- 0.86 - 
History of hypertension          
(Yes) 
(No)                        
5.896 4.74 6.308 
HIV treatment(Yes) 
                        (No) 
0.470 0.37 - 
Diagnosis of Malaria 
(Yes)                                   
(No) 
0.493 0.48 - 
Diagnosis of infections 
(Yes) 
0.370 0.37 0.405 
(No)                                        
Contraceptive IUD use 
(Yes) 
1.577 2.05 - 
(No)                                      
Mothers weight before 
pregnancy (1kg unit) 
1.030 1.03 1.029 
Area Under the Curve 0.694 0.712 0.669 
*Variable not in the model (-) 
Area Under the Curve classification scores are interpreted as follows: 
0.5 – < 0.6 = Failure; 0.6 – < 0.7 = Weak classifier; 0.7 - <0.8 = Moderate 
classifier; 0.8 - < 0.9 = Good classifier and 0.9 – 1 = Excellent classifier. 
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Table 35 Internal validation of the models on the testing dataset. 
 
Key findings 
The strength of the association shown for each predictor should be 
interpreted as the change in odds of pre-eclampsia outcome for a unit 
change in the predictor variable, conditional on the other variables in the 
models. The findings obtained from the logistic regression models are to be 
interpreted as the average population values of the odds ratio for each 
predictor variable. This means any woman picked at random from the study 
population will have the stated odds of developing pre-eclampsia. Therefore, 
according to results in table 34 above: 
1. A five-year increase in mothers age increased the odds of pre-
eclampsia on average by 18 % [95 % CI (9 - 29) %], 27 % [95 % CI 
(10 - 40) %], and 19 % [95 % CI (2 - 38) %] among all deliveries, term 
deliveries and preterm deliveries subgroups respectively. The five 
years increase in odds ratio was obtained from the one-year increase 
in odds ratio raised to the power of five. i.e. (1.035)5 = 1.187, 
Performance of models in the validation dataset 
Pre-eclampsia 1st Model 2nd Model 3rd Model 
Area Under the Curve 0.689  0.695  0.672  
95 % Confidence 
Interval 
0.636 - 0.743 0.620 -0.769 0.585 - 0.758 
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equivalent to a 18 % increase in odds for a five-year increase in 
maternal age. 
2. A positive history of hypertension increased the odds of pre-eclampsia 
by 489 % [95 % CI (236 - 933) %], 374 % [95 % CI (124 - 899) %] and 
530 % [95 % CI (121-1698) %] among all deliveries, term deliveries 
and preterm deliveries subgroups respectively. 
3. A ten-kilogram increase in mother’s weight increased the odds of pre-
eclampsia by 34 % [95 % CI (25 - 43) %], 34 % [95 % CI (21 - 48) %] 
and 33 % [95 % CI (18 - 50) %] among all deliveries, term deliveries 
and preterm deliveries subgroups respectively. 
4. A mother on HIV treatment was at a decreased odd of pre-eclampsia 
by 53 % [95 % CI (16 - 74) %] and 63 % [95 % CI (15 - 84) %] among 
all deliveries and term deliveries respectively. However, HIV treatment 
was not a significant predictor among preterm deliveries. 
5. A positive diagnosis of malaria decreased the odds of pre-eclampsia 
by 51 % [95 % CI (33 - 64) %] and 52 % [95 % CI (29 - 68) %] among 
all deliveries and term deliveries respectively. However, malaria 
diagnosis was not a significant predictor among preterm deliveries. 
6. The number of pregnancies was only a significant predictor on the 
term deliveries model, where an additional pregnancy to a mother 
reduced the odds of pre-eclampsia by 14 % [95 % CI (4 - 23) %]. 
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7. The three models produced an area under the curve of 69.4 %, 71.2 
% and 66.9 % in all deliveries, term and preterm deliveries 
respectively (see table 34 above). 
8. The performances of all the three models were internally validated 
using the 20 % testing dataset and their area under the curve 
performance results, seen in table 35, was similar to the AUC results 
in the training dataset (table 34). The point estimates of the AUC of 
the training dataset were contained within the 95 % confidence interval 
of the AUC results in the validated dataset. 
9. The results from the GEE models on all deliveries, term and preterm 
subgroups was similar to that shown from above logistic regression 
models. Thus, suggesting the potential correlation was not altering our 
conclusion on the strength of association of our predictors and pre-
eclampsia outcome. 
10. The positive likelihood ratio values of my models were weak likelihood 
in separating true positives over false positives. Approximately in 
every two true positives, there was one false positive. The same was 
observed of the negative likelihood ratio values, they were also weak 
in separating false negatives over true negatives. Approximately, for 
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Pearson Chi-square test 44.2, d.f. 1, p value < 0.001. OR = 2.8, 95 % CI 2.0 
– 3.9. 
Key findings 
The proportion of children with poor health indicators was higher among 
women with pre-eclampsia compared to women without pre-eclampsia. This 
outcome worsened among women with pre-eclampsia and preterm 
deliveries. 
1. The relative risk of stillbirth was higher among women with pre-
eclampsia compared to women without pre-eclampsia was 4.4, 2.5 
and 2.3 in all deliveries, term and preterm deliveries subgroups 
respectively. The association of pre-eclampsia and stillbirth appear to 
be partly mediated through prematurity. Controlling for prematurity 
dropped the strength of association. The odds ratio was 4.8, 95 % CI 
3.7 – 6.3 (All deliveries). It dropped to 2.6, 95 % CI 1.6 – 4.3 and 2.9, 
95 % CI 2.0 – 4.1 in term and preterm deliveries. 
2. Similarly, the relative risk of neonatal deaths was higher among 
women with pre-eclampsia compared to women without pre-
eclampsia. It was 1.6 in all deliveries and preterm deliveries. 
Examination of the strength of association between pre-eclampsia and 
these poor pregnancy outcomes showed stillbirth were strongly 
associated with pre-eclampsia pregnancies (odds ratio = 4.8, 95 % CI 
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3.7 – 6.3, p value < 0.001) while there was no association between 
neonatal death and pre-eclampsia pregnancy. 
3. There was no difference in the sex proportions of children born from 
all women with pre-eclampsia and term women with pre-eclampsia. 
However, there were more girls born from women with pre-eclampsia 
in the preterm delivery subgroup (OR = 1.4 95 % CI 1.0 – 1.9, P value 
0.014). 
4. The proportion of assisted deliveries (vacuum, CS elective, CS others 
and assisted breech) was higher in women with pre-eclampsia among 
all deliveries (OR = 1.38, 95 % CI 1.17 - 1.64, p value < 0.001). 
However, this association was only statistically significant in preterm 
deliveries subgroup (OR = 1.42, 95 % CI 1.06 – 1.9, p value = 0.018) 
and not in term deliveries subgroup (OR = 1.2, 95 % CI 0.97 – 1.49, p 
value = 0.081). 
5. The relative risk of children with poor Apgar (0 – 3) scores in the first 
minute of life was higher among women with pre-eclampsia compared 
to women without pre-eclampsia. It was 3.8, 2.3 and 2.2 in all 
deliveries, term and preterm deliveries subgroups. Apgar score of 4 -
10 was considered normal and the reference group in calculating the 
odds ratio. There is a strong association between pre-eclampsia and 
low Apgar score (OR = 4.3 95 % CI 3.4 – 5.4). When stratified into 
term and preterm subgroups, the odds ratio was 2.343, 95 % CI 1.5 – 
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3.5 and 2.8, 95 % CI 2.0 – 3.9 respectively. This suggests part of the 
effect of pre-eclampsia on Apgar score is partially mediated through 
prematurity. 
6. The relative risk of children with “very low” birthweight was higher 
among women with pre-eclampsia compared to women without pre-
eclampsia. It was 10, 16 and 3.2 in all deliveries, term and preterm 
deliveries subgroups respectively. Similarly, the relative risk of children 
with “low” birthweight was higher among women with pre-eclampsia 
compared to women without pre-eclampsia by 3, 2.8 and 1.5 times in 
all deliveries, term and preterm deliveries respectively. Upon 
combining the very low birth (< 1500gm) and low birth (1500 - < 
2500gm) categories into one category of low birth weight ( < 2500gm), 
the new low birth weight category was strongly associated with pre-
eclampsia (OR = 6.4, 95 % CI 5.3 – 7.6). When this effect was 
stratified in the term and preterm subgroups, the strength of the 
association was odds ratio of 3.6, 95 % CI 2.7 – 4.7 and 6.4, 95 % CI 
4.4 – 9.3 respectively. An interesting note from my result is that pre-
eclampsia was apparently associated with high birth weight ( > 
4000gm). The odds ratio was 2.04, 95 % CI 1.3 – 3.2, p value = 0.002 
and 2.07, 95 % CI 1.3 – 3.3, p value = 0.002 among all deliveries and 
term deliveries respectively. This association was lost in the preterm 
delivery subgroup OR = 2.4, 95 % CI 0.3 – 19.2, p value = 0.362. 
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7. Mean head circumference of children born from women with pre-
eclampsia was smaller than in children of women without pre-
eclampsia among all deliveries (33.3 cm ± 0.11 SD vs 34.3cm ± 0.01 
SD, p value < 0.001).The mean difference was 0.9 (0.75 - 1.22), P < 
0.001 in all deliveries. The mean difference was 2.02 (1.44 - 2.59), P < 
0.001 in preterm deliveries. However, this difference was not 
statistically significant in term deliveries 0.09 (-0.04 - 0.24), P = 0.15. 
8. The mean fetal length of children born of women with pre-eclampsia 
was shorter than in children born from women without pre-eclampsia 
in all deliveries (46.3 cm ± 0.18 SD vs 48.3 cm ± 0.01SD, p value < 
0.001). This was the case for children born of women with pre-
eclampsia with both preterm and term delivery subgroups (42.6 cm ± 
0.28 SD vs 46.3 cm ± 0.1 SD, p value < 0.001) and (48.1 cm ± 0.11 
SD vs 48.5 cm ± 0.01SD, p value < 0.001) respectively. The mean 
difference was 1.9 (1.5 - 2.2), P < 0.001in all deliveries. The mean 
difference was also observed in term deliveries 0.4 (0.1- 0.6), P < 
0.001 and was more pronounced in preterm deliveries 3.7 (2.8 - 4.6), 
P < 0.001. 
9. The proportion of women with pre-eclampsia was higher among 
preterm than term deliveries, 11.9 % and 2.7 % respectively. This 
difference in proportion was statistically significant (Pearson chi-
square test = 296.7, d.f = 1, p value < 0.001).  
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The mean gestation age at delivery was 33.9 weeks for the preterm 
subgroup and 39.6 weeks for the term subgroup. The overall gestation age at 
delivery was 38.9 weeks.  
6.4.1 Summary 
This chapter starts by showing the results of the estimation of the incidence 
of pre-eclampsia in Dar es Salaam, Tanzania. The data used for this 
estimation was drawn from Child 2 clinical trial that was conducted in Dar es 
Salaam. In northern Tanzania, a hospital registry data was used to sample 
singleton deliveries for secondary analysis. The analysis shows that maternal 
age ≥ 35 years, single and education level are the sociodemographic factors 
that are jointly associated with pre-eclampsia outcome. In objective three, 
which identifies risk factors for pre-eclampsia; maternal age, history of 
hypertension, history of contraceptive IUD use, HIV treatment, diagnosis of 
malaria, diagnosis of infections and mother weight before pregnancy are the 
statistically significant predictors in all deliveries. I observed a difference in 
the set of predictors in term and preterm deliveries subgroups, which 
supports the hypothesis of difference in aetiology between early and late 
onset pre-eclampsia. The above predictors were obtained from logistic 
regression modelling; similarly, a generalised estimation equation modelling 
was used to compare the results in an attempt to explore potential 
correlations in the dataset. AUC was used to assess and compare the 
classification ability of the developed logistic regression models. My models 
showed moderate classification performance of AUC scores around 0.7 (see 
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AUC reference scores at section 6.3.7 above). This modelling aspect of the 
analysis also included performing diagnostic tests for key model 
assumptions. Lastly, this chapter addresses the fourth objective which shows 
pregnancy outcomes of women with pre-eclampsia are worse that non pre-
eclampsia women. This comparison is done on perinatal survival indicators of 
stillbirth and early neonatal death. A comparison is also made on physical 
wellbeing indicators such as birth weight, head circumference and birth 
length. Apgar score comparison is also made which also suggests that 
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Chapter 7 Discussion on pre-eclampsia risk 
factor analysis in Tanzania. 
Chapter Seven discusses the results shown in the previous chapter. This 
chapter is also organised according to the four objectives of the analysis. 
• Objective one estimated the incidence of pre-eclampsia in Dar es 
Salaam to be 1.9 %, 95 % CI 1.3 % to 2.2 % after adjusting for age 
distribution of the urban population from the Tanzania Health 
Demographic Survey 2005 data. This finding was on the lower side of 
global estimates of pre-eclampsia, 2 % to 8 %. The estimates were 
based on the classical definition of pre-eclampsia, raised blood 
pressure with proteinuria. Adoption of modern definitions of pre-
eclampsia may uncover a higher estimate of the incidence of pre-
eclampsia. 
• Objective two showed the sociodemographic distribution of pre-
eclampsia to be more prevalent among women aged above 35 years, 
single and those with tertiary education. Tertiary education may be a 
proxy of unknown risk factor, thus requiring further studies to explore 
this observation. 
• Objective three has revealed several maternal characteristics to be 
associated with pre-eclampsia. These factors jointly can partly explain 
the variability in pre-eclampsia occurrence. There is a need to improve 
pre-eclampsia prediction. I propose to achieve this by using 
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biomarkers, by introducing new diagnostic methods to improve 
detection of conditions such as gestational diabetes.  
• Objective four shows pre-eclampsia is associated with stillbirth, 
neonatal deaths and poor indicators of physical and mental wellbeing 
among surviving newborns of pre-eclampsia pregnancies. Follow-up 
studies may be done to these newborns to observe the health 
implication of pre-eclampsia in their adult life. 
7.1 Discussion objective 1  
To determine the incidence of pre-eclampsia among women in Dar es 
Salaam, Tanzania. 
My study estimates the age adjusted incidence of pre-eclampsia in Dar es 
Salaam, from 2007 to 2009, was around 1.9 % (95 % CI 1.3 % - 2.2 %). This 
finding is within the lower range of global estimates. The eligibility criteria of 
my study participants posed a limitation that may have biased my estimates, 
as explained in more details below. The strength of my study is that I used 
cohort data with a sufficient number of participants, and I adjusted for age, a 
common confounder. Despite the limitations, my result showed pre-
eclampsia is a problem in urban settings of Dar es Salaam by affecting more 
than two percent of all women attending antenatal services.  
A systematic review involving around 39 million women from 40 countries, 
from  2002 through to 2010, showed a global point estimate of 4 % for the 
incidence of pre-eclampsia (95 % CI of 2 % to 8 %) (Abalos et al. 2013). My 
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estimates in Dar es Salaam of 1.9 % (95 % CI 1.3 % - 2.2 %) fall in the lower 
range of this global estimate. However, this global review study pointed out 
the challenges of estimating the incidence due to limitations in data from 
health systems of LMIC. A study in Mozambique estimated the incidence of 
pre-eclampsia to be 2.3% (Magee et al. 2018). This finding is comparable to 
my finding in Dar es Salaam 1.9 % (95 % CI 1.3 % - 2.2 %). 
My estimated incidence in Dar es Salaam was drawn from women 
participating in a clinical trial with the following eligibility criteria; being HIV 
negative, > 18 years, residents of Dar es Salaam for next two years. The 
recruited trial participants were from three public antenatal clinics in Dar es 
Salaam. This may not be the accurate reflection of the true incidence of pre-
eclampsia in the total population in Dar es Salaam because the women 
enrolled on the trial may differ in important respects from the general 
population. For example, women who attend public antenatal clinics are likely 
to be of lower socioeconomic status than those attending private antenatal 
clinics, which may impact on their risk of pre-eclampsia. Women with higher 
socioeconomic status are thought to live a sedentary lifestyle, which may 
predispose them to have a higher incidence of pre-eclampsia (Hoirisch-
Clapauch and Benchimol-Barbosa 2011). The limitation of not being able to 
include women from private antenatal clinics in Dar es Salaam may have 
underestimated the incidence of pre-eclampsia. I was not able to adjust for 
socioeconomic status because the information was not captured in my 
dataset. Contrary to this hypothesis, two studies in Ethiopia showed no 
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statistically significant difference in univariable analysis between income and 
pre-eclampsia (Endeshaw et al. 2016a, Endeshaw et al. 2016b). Another 
study in Senegal actually showed women with remunerative activity had a 
lower proportion of pre-eclampsia (Ndao et al. 2009). It is uncertain whether 
this potential bias resulting from not including women attending private 
antenatal would affect my estimate. This uncertainty about the direction of 
the association of socioeconomic status and pre-eclampsia in African 
populations may be explained by some risk factors such as; stress, 
hypertension and diabetes that are linked with both, high and low 
socioeconomic status.  
The incidence of pre-eclampsia in Tanzania has been estimated by a few 
studies. One hospital-based study done in a northern Tanzania referral 
hospital estimated the incidence to be as high as 3.5 % among women 
delivering in hospital (M J. Mahande et al. 2013). The limitation of this 
estimate is that women who were referred to deliver in this facility are likely to 
be more at risk for maternal complications including pre-eclampsia, thus 
overestimating the incidence. However, Mrisho et al. (2007) showed hospital 
delivery is still low, at 42 %, in Tanzania. Therefore, a sizable proportion of 
women in this population may have developed maternal complications, 
including pre-eclampsia, without being recorded on hospital data systems.  
The estimation of pre-eclampsia in Dar es Salaam was drawn from HIV 
negative trial participants. This may have biased my estimate. However, this 
potential bias is likely to be minimal because the prevalence of HIV positive 
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people aged 15 - 49 years in Dar es Salaam is only 4.7 %, 95 % CI 3.7 – 5.6 
(NBS-Tanzania 2017b). Furthermore, there is no conclusive evidence to 
suggest whether HIV positive women are at an increased or decreased risk 
of developing pre-eclampsia compared to HIV negative women. A systematic 
review by Adams et al. (2016) involving 13 studies, seven studies being from 
Africa, and 21,200 women showed an inconclusive association of HIV and 
pre-eclampsia. In this regard, it seems unlikely that the omission of HIV 
positive women would have significantly biased my estimate of the incidence 
of pre-eclampsia in Dar es Salaam.  
The strength of my estimated result is that I used data from a cohort of 
pregnant women who were recruited in a multicentre clinical trial. This 
provided quality data with a sufficient number of participants for estimating 
the incidence. This data set had a lot of missing values on maternal variables 
which made it unfit for modelling the risk factors. Unlike other studies that 
have estimated the incidence of pre-eclampsia using tertiary hospital data, 
which were likely to contain most women with obstetric complication, thus 
biasing their representativeness of the population estimates. The participants 
from my study were recruited from antenatal clinic of lower level health 
facilities, thus making my estimates closer to a population-based study. A 
total of 3,767 pregnant women were involved in my study. I also reweighted 
for maternal age, which could influence the incidence estimation in the 
population. Despite the uncertainty resulting from the inclusion of study 
participants, the incidence around two percent shows that pre-eclampsia is a 
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problem in Dar es Salaam-Tanzania, as in other urban settings of LMIC. The 
result provides the baseline reference for the years around 2007 to 2009. 
Having established this as a baseline, future studies will be able to compare 
the future incidence of pre-eclampsia in urban Tanzania. 
Further research could be done in urban settings of LMIC to estimate the 
incidence of pre-eclampsia using a broad systemic definition of pre-
eclampsia adopted by the International Society of the Study of Hypertension 
in Pregnancy (ISSHP) (Tranquilli et al. 2014). This will enable accurate 
estimation of the burden of the condition. However, an important limitation to 
the adoption of this definition in LMIC is its reliance on the use of modern 
technological equipment such as ultrasound and laboratory tests that are 
scarcely available at a population level in LMIC. The discrepancy between 
incidence estimates drawn using the two definitions of pre-eclampsia could 
inform the health system about the number of missed cases of pre-eclampsia 
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7.2 Discussion objective 2  
To describe the sociodemographic characteristics of women with pre-
eclampsia in northern Tanzania. 
My study has shown that there are sociodemographic differences between 
women with pre-eclampsia and those without pre-eclampsia in the northern 
Tanzania population. Further analysis showed that women with pre-
eclampsia in the subgroups of term and preterm delivery did not differ from 
one another in their sociodemographic characteristics. The reason for 
conducting this subgroup analysis was to explore the idea that early and late 
pre-eclampsia may arise from different mechanisms and hence may differ in 
their risk factors and present with different sociodemographic distributions 
(Kleinrouweler et al. 2012). In the northern Tanzanian population single 
marital status, mothers aged above 35 years and mothers with tertiary 
education level were significantly associated with pre-eclampsia occurrence. 
My findings add to the pool of knowledge from studies examining 
sociodemographic characteristics of women with pre-eclampsia in Africa. 
Some of my results agree, while other conflicts, with results from other parts 
of Africa.  
My initial results suggest that women with older age, history of 
abortion/miscarriage, tertiary education level and professional occupation are 
more likely to have pre-eclampsia. This observation is plausible in the 
Tanzanian setting, where women who pursue education to tertiary level are 
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likely to bear their first pregnancy at an older age than their less educated 
counterparts are. They also are likely to acquire professional occupations, 
which are associated with a sedentary lifestyle.  
Pre-eclampsia was associated with women with a history of 
abortion/miscarriage (OR = 1.5, 95 % CI 1.1 - 1.9) in a univariable analysis. 
In a multivariable analysis of all sociodemographic factors, history of 
abortion/miscarriage was non-significantly associated with pre-eclampsia 
(OR = 1.30, 95 % CI 0.98 - 1.72, p value 0.06). However, a cohort study 
involving 20,846 women in Norway showed two or more (spontaneous or 
induced) abortions reduces the risk of pre-eclampsia, OR = 0.73 (95 % CI 
0.55 – 0.97) after adjusting for maternal age, smoking in pregnancy, infertility 
treatment, pre-pregnancy BMI and education (Trogstad et al. 2008). 
Subgroup analysis showed two or more induced abortion reduces the odds of 
pre-eclampsia while two or more spontaneous abortion increased the risk of 
pre-eclampsia (OR = 0.26, 95 % CI 0.04 - 1.91 vs OR = 1.03, 95 % CI 0.62 - 
1.64 respectively). Although this subgroup analysis was not statistically 
significant, it shows opposite directions of association for the two types of 
abortions with pre-eclampsia. In the context of my study population in 
northern Tanzania, legal induced abortion services are limited. We are 
inclined to suggest that the self-reported history of abortion/miscarriage that 
is linked to increased odds of pre-eclampsia is predominantly due to 
spontaneous abortions/miscarriages.  
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Father’s occupation category showed a statistically significant difference in 
the proportion of women with pre-eclampsia (Pearson chi-square test, p 
value = 0.102 respectively). This may imply that the spouse socioeconomic 
status does not change women’s risk of pre-eclampsia in this population.  
Pre-eclampsia seemed to occur more with maternal age increase (Chi-
square trend p value < 0.001) and the number of children she has borne 
(Chi-square trend p value < 0.001).  
Upon combining, all the above sociodemographic variables in a multivariable 
logistic regression model, single marital status women, women with older age 
(≥ 36 years) and those with tertiary education were the only statistically 
significant sociodemographic variables that explained pre-eclampsia. Women 
aged 36 - 40 and ≥ 41 years were more associated with having pre-
eclampsia than younger women ≤ 20 years (OR = 1.8 [95 % CI, 1.2 – 2.8] 
and 2.6 [95 % CI, 1.4 – 4.6] respectively). Independent of age, women with 
tertiary level education were associated with having pre-eclampsia (OR = 
1.34, 95 % CI 1.0 - 1.6). 
Women who are single in marital status were associated with the 
development of pre-eclampsia. Their odds of developing pre-eclampsia were 
1.3 times those in all other marital categories combined (OR = 1.3, 95 % CI 
1.07 – 1.82). This finding was also observed in Ethiopia by Tessema et al. 
(2015). However, studies from Ethiopia (Endeshaw et al. 2016a, Endeshaw 
et al. 2016b) and Senegal by Ndao et al. (2009) did not find a statistically 
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significant association. A plausible explanation could be that women with 
single marital status may not have gained enough exposure to their partner’s 
sperms (Hutcheon et al. 2011). 
Maternal age was also associated with pre-eclampsia in different studies in 
Africa (Tessema et al. 2015, Endeshaw et al. 2016a, Endeshaw et al. 
2016b). One of these studies done in Sudan showed an OR = 1.4 (95 % CI, 
1.1 - 1.8) for women > 35 years after adjusting for parity, education level, 
prenatal care, anaemia and placenta praevia (Adam et al. 2013). This 
observation concurs with Framingham study that showed an increase in age 
is a risk factor for a wide range of cardiovascular diseases (Kannel and 
McGee 1979). My study showed that women with tertiary education were at 
increased odds of having pre-eclampsia independent of their age (OR = 1.34, 
95% CI 1.0 - 1.6). Contrary to my results, most studies in Africa showed that 
a low education level was associated with pre-eclampsia (Kiondo et al. 2014, 
Ajah et al. 2016). In Ethiopia Endeshaw et al. (2016b) showed that women 
who could not read or write had an increased odds of pre-eclampsia in a 
univariable analysis (OR = 2.18, 95 % CI 1.19, 4.62). However, this 
association was no longer statistically significant in multivariable analysis. My 
finding suggests that tertiary education in women of this population may be a 
proxy to some unknown risks. It also implies that unknown risk factors 
associated with having tertiary education outweigh the unknown risk factors 
associated with lower levels of education. This seems to be an interesting 
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area for further exploration in understanding the evolving dynamics of pre-
eclampsia distribution in sociodemographic strata in African populations. 
Furthermore, my study compared the sociodemographic characteristics of 
women with pre-eclampsia in the subgroups of term and preterm deliveries. 
The findings of this subgroup analysis showed that women with pre-
eclampsia differed from those without pre-eclampsia in a similar manner 
across the term and preterm deliveries subgroups. A study in Ethiopia 
showed similar results that women with early and late onset pre-eclampsia 
did not differ on sociodemographic characteristics (Endeshaw et al. 2016b). 
My study adds to our understanding of the sociodemographic relations with 
pre-eclampsia in northern Tanzania. Mothers aged above 35 years and those 
with tertiary education can be targeted by prevention strategies for pre-
eclampsia. Women can be informed of this evidence to enable them to make 
an informed decision on when they wish to have babies. Women with tertiary 
education may also be encouraged to avoid underlying risk factors such as 
sedentary lifestyle or stress to reduce their risk of pre-eclampsia. This study 
adds to the scarce body of knowledge on the understanding of early and late 
pre-eclampsia in an African population. My findings support an earlier study 
in Ethiopia that the sociodemographic relationship with pre-eclampsia is 
similar for early and late onset pre-eclampsia.  
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7.3 Discussion objective 3  
To identify risk factors for pre-eclampsia, term and preterm deliveries 
subgroups, among women in northern Tanzania.  
Theories on the aetiology of pre-eclampsia have suggested several 
mechanisms for its occurrence. Biological and medical risk factors have been 
explored in various populations. My study explored some of the maternal 
biomedical risk factors in the northern Tanzanian population. My findings 
show that maternal age, weight before pregnancy, history of hypertension, 
HIV treatment, contraceptive IUD use, diagnosis of infection and diagnosis of 
malaria significantly predicted the occurrence of pre-eclampsia in all 
deliveries. The subgroup analysis on term and preterm deliveries showed 
some differences in risk factors. Pre-eclampsia in term deliveries was 
predicted by maternal age, the number of pregnancies, weight before 
pregnancy, history of hypertension, HIV treatment, contraceptive IUD use, 
diagnosis of infection and diagnosis of malaria. Pre-eclampsia in preterm 
deliveries was predicted by maternal age, history of hypertension, diagnosis 
of infection and weight before pregnancy. To the best of my knowledge, this 
study is the first to develop and assess the performance of prediction models 
for pre-eclampsia, term and preterm deliveries subgroups, in an African 
population, relying only on maternal biomedical factors. 
The comparison of performance of the prediction models was assessed by 
the area under the curve (AUC) which is a relatively simple approach to 
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quantify the performance of a model (Hanley and McNeil 1982). AUC is 
obtained after plotting the sensitivity values against 1- specificity values of a 
test or model. The value of AUC summarises the overall probability of the 
model in correctly assigning high probability to cases and low probability to 
non-cases and thus, correctly classifying them. The fist model predicting pre-
eclampsia among all deliveries produced an area under the curve of 69.4 %. 
The second model predicting pre-eclampsia among term delivery was 71.2 
%, while the third model predicting pre-eclampsia among preterm deliveries 
was 66.9 %. The performance of my models was satisfactory when 
compared to findings from a similar study which had an area under the curve 
of 73 % (Myatt et al. 2012). This study was done in the USA and used 
biomedical factors plus biomarkers to predict pre-eclampsia outcome among 
low risk women. Biomarkers are known to be more accurate in measuring 
clinical parameters than biomedical factors gathered from participants’ history 
or self-reported. The study also used quality data from a clinical trial, where 
misclassification was expected to be minimal. Despite these assuring steps, 
their findings were not far superior to those of my models that only relied on 
biomedical factors. This suggests that the unexplained variability in predicting 
pre-eclampsia is likely due to genetic factors or unmeasured or yet unknown 
biomedical factors that were not examined in either their study or mine. 
Another study done in the United Kingdom showed an area under the curve 
of 80 % for early onset pre-eclampsia (< 37 weeks) and 74.5 % for late onset 
pre-eclampsia (≥ 37 weeks) when using maternal characteristics alone. 
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Later, they combined maternal characteristics and several biomarkers 
specific for gestation age of 11 - 13 weeks. This improved the area under the 
curve of the model to 90 % for early onset and 79.6 % for late onset pre-
eclampsia (O'Gorman et al. 2016). These results also pointed out that 
biomarkers levels were more pronounced among early onset pre-eclampsia 
cases than late onset cases, hence improved the prediction of early onset 
much greater than late onset pre-eclampsia. Contrary to their finding, my 
study showed maternal biomedical factors were slightly better in predicting 
late onset (AUC 71.2 %) than early onset (AUC 66.9 %) pre-eclampsia in my 
study population. However, this difference could be due to differences in 
sample sizes of term and preterm deliveries subgroups. 
The purpose of my prediction models is to classify women with and those 
without pre-eclampsia. I selected the Youden’s index, a point on the receiver 
operator curve for each model that would simultaneously maximise my 
prediction sensitivity and specificity values. In my first model that predicts 
pre-eclampsia among all deliveries, a cut-off point of 0.035 on my predicted 
probability resulted in a sensitivity of 65 % and a specificity of 63 %. My 
second model that predicts pre-eclampsia among term deliveries subgroup, a 
cut-off point of 0.026 on my predicted probability resulted in a sensitivity of 65 
% and specificity of 65 %. My third model that predicts pre-eclampsia among 
preterm deliveries subgroup, a cut-off point of 0.107 on my predicted 
probability resulted in a sensitivity of 59 % and a specificity of 66 %. I am not 
aware of similar studies that explored model performance on pre-eclampsia 
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prediction in African countries, to provide a comparison of results. My study 
contributes to the scarce literature on predicting pre-eclampsia using 
maternal biomedical factors in African populations.  
The above models were each subjected to a validation process using the 
internal validation dataset with 20 % (3,229) women. The performance of the 
first model (All deliveries) was similar to that observed above from the 
training dataset; the maximum sensitivity and specificity at a cut point of 
0.039 were 65 % and 67 % respectively. The performance of the second 
model (term deliveries) on the validation dataset produce similar results to 
that of the training dataset. At a cut of point of 0.025, the sensitivity was 66 % 
and the specificity was 66 %. The third model for preterm deliveries also 
produced similar results to that observed in the training dataset: at a cut of 
point of 0.13, the sensitivity was 61 % and specificity was 62 %. In the short 
time span of my research, I was not able to access a dataset from another 
African population to facilitate external validation of my models, a process 
that would have shown the extent to which my models were generalisable in 
other populations. 
The strength of my study is that we have used routinely captured data with its 
limitations in missing values and measurement errors to develop my models, 
unlike models developed using high quality trial data. Thus, my models 
portray a generalisable result of using these predictors elsewhere on 
Tanzanian health facilities to predict pre-eclampsia outcome. Furthermore, I 
have used simple linear relationships for my continuous predictors, such as 
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maternal age and number of pregnancies, in modelling the log odds of pre-
eclampsia outcome (as shown in my diagnostic section of these 
assumptions). Interaction of variables such as maternal age by the number of 
pregnancies, malaria and HIV treatment did not produce significant 
interactions. I acknowledge that a more complex relationship could be fit 
between my predictors and log odds of pre-eclampsia but this effort would 
likely improve slightly the overall performance at a cost of a more 
mathematically complex relationship.  
My models had moderate sensitivity and specificity values. This limitation is 
because it was developed in a low risk population, where the incidence of 
pre-eclampsia in my data was around 3.5 %. Therefore, these models are 
suited for predicting the outcome in low risk populations. Another limitation of 
my analysis is that some variables were self-reported, and this led me to rely 
on my clinical intuition to interpret the result of these variables based on the 
context. I interpreted the observed protective association of the variables 
diagnosis of malaria and diagnosis of infections on pre-eclampsia as having 
a history of ‘treated malaria and treated infections’ to be protective of pre-
eclampsia. Furthermore, I was unsuccessful at factoring in some known 
predictors such as diabetes mellitus, gestational diabetes and change of 
paternity, due to limitations in the hospital information system, from which my 
data was drawn. Therefore, my study results are likely to have a limitation of 
residual confounding since not all factors were accounted for in the 
modelling. 
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7.3.1 Predictor variables in my models 
The odds ratio output from my logistic regression and GEE models 
represents the population average change in odds of having pre-eclampsia 
per the respective predictor. This means, if all women in the population had a 
unit change in any given predictor then the odds of pre-eclampsia outcome 
would change by that amount for the whole population on average. This 
population average effect can also be expressed as the average change in 
odds of any women picked at random from that population. The magnitude of 
change in odds of pre-eclampsia as a result of a unit change of a predictor is 
to be regarded as a change that occurs when other predictors in that model 
are kept constant. There is an agreement on the role of age as a predictor 
across different studies. In my study’s first model (all deliveries) a five-year 
increase in age of any woman picked at random from this population was 
associated with an increase in the odds of pre-eclampsia on average by 16 
% (equivalent to OR = 1.03, 95 % CI 1.017 – 1.053, per year). In the second 
model (term deliveries subgroup) and third model (preterm deliveries 
subgroup) the five years increase in age increased the odds of pre-eclampsia 
by 28 % (equivalent to OR = 1.05, 95 % CI 1.02 – 1.07, per year), and 16 % 
(equivalent to OR = 1.03, 95 % CI 1.005 – 1.068, per year) respectively. 
Similar studies conducted in African populations showed that maternal age 
was associated with an increase in the odds of pre-eclampsia (Tessema et 
al. 2015, Endeshaw et al. 2016a, Endeshaw et al. 2016b). However, these 
studies analysed age as a categorical variable, making it difficult to compare 
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their results directly with mine in terms of the incremental change one year 
makes to the odds of pre-eclampsia. The understanding that age increases 
pre-eclampsia tallies with the Framingham cohort study, where the risk of 
cardiovascular disease was doubled among the older group (65 - 94years) 
compared to the young group (35 - 64 years) with the same systolic blood 
pressure (Vokonas et al. 1988). We cannot stop people from growing old, but 
in the case of pre-eclampsia reduction, we can recommend women to 
consider the risks of pregnancy at a relatively older age.  
My study found that having a positive history of hypertension was associated 
with an increase in the odds of pre-eclampsia. My first, second and third 
models showed the odds are increased by 489 % (OR = 5.89, 95 % CI 3.36 – 
10.33), 374 % (OR = 4.74, 95 % CI 2.24 – 9.99) and 530 % (OR = 6.30, 95 % 
CI 2.21 – 17.98) respectively. This finding tally with established clinical 
knowledge, where having chronic hypertension does increase one’s risk of 
developing pre-eclampsia (O'Gorman et al. 2016, NICE 2019).  
A ten-kilogram increase in mother’s body weight before pregnancy was 
associated with an increased odd of pre-eclampsia of 34 % (equivalent to OR 
= 1.03, 95 % CI 1.023 – 1.037, per kilogram) in my first model (all deliveries). 
The odds of pre-eclampsia were increased by 34 % (equivalent to OR = 1.03, 
95 % CI 1.02 – 1.04, per kilogram) in my second model (term deliveries) and 
33 % (equivalent to OR = 1.029, 95 % CI 1.01 – 1.04, per kilogram) in my 
third model (preterm deliveries). My findings are similar to studies done in 
Africa that have shown heavy body weight increases the risk of pre-
  [Risk factors for pre-eclampsia] 
[Analysis of risk factors]  243 
 
eclampsia; however, these studies used MUAC or body mass index obtained 
at delivery or during pregnancy. Different from them, my study has used pre-
pregnancy body weight as a predictor of pre-eclampsia. Pre-pregnancy body 
weight provides the advantage of identifying the risk group early on in 
pregnancy and even before pregnancy, thus providing room to modify this 
risk factor. Other studies that have used pre-pregnancy BMI in Asian 
populations and have echoed similar findings to mine (Savitri et al. 2016, 
Shao et al. 2017). A cohort study in Indonesia showed that pre-pregnancy 
BMI is associated with an increase odd of pre-eclampsia (OR = 1.09, 95 % 
CI 1.04 – 1.14). They further showed pre-pregnancy BMI determined the 
baseline SBP (0.25 mmHg/Kg/M2, 95 % CI 0.17 – 0.34) and DBP 
(0.18mmHg/Kg/M2, 95 % CI 0.13 – 0.24) but not their change during the 
pregnancy period. Another cohort study in China showed that pre-pregnancy 
BMI and excessive gestational weight gain (GWG) were two independent risk 
factors for pre-eclampsia. Women with pre-pregnancy obesity alone vs 
normal BMI were at increased risk for pre-eclampsia (OR = 1.81, 95 % CI 
1.37 – 2.39). Women with normal pre-pregnancy BMI and excessive GWG vs 
normal BMI and normal GWG were at increased risk of pre-eclampsia too 
(OR = 2.28, 95 % CI 1.7 – 3.05). Women with both obese pre-pregnancy BMI 
and excessive GWG vs normal BMI and normal GWG were at a much higher 
increased risk of pre-eclampsia (OR = 3.78, 95 % CI 2.65 – 5.41), thus 
speculating potential interaction between obese pre-pregnancy BMI and 
excessive GWG. We were unable to address this potential confounding 
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factor in my study because my data did not capture weight gain during 
pregnancy. However, based on the above findings, we can ascertain that 
pre-pregnancy weight is a risk factor irrespective of the pregnancy weight 
gain factor. 
Women with a positive diagnosis of malaria during pregnancy had a 
decreased odd of pre-eclampsia by 51 % (OR = 0.49, 95 % CI 0.36 – 0.67) 
among all deliveries and 52 % (OR = 0.48, 95 % CI 0.32 – 0.71) among term 
deliveries. Malaria diagnosis was not a significant predictor of pre-eclampsia 
among preterm deliveries. Malaria infection is prevalent in tropical countries 
thus placing women at risk of malaria related complications. It is estimated 
that 38.9 million pregnancies occur in Sub-Sahara Africa, out of which 11.1 
million pregnancies are infected with malaria annually (WHO 2019b). 
Therefore, malaria’s potential contribution towards pre-eclampsia is of 
considerable proportion in these populations. Malaria had been associated 
with pre-eclampsia in some observational studies in Africa but there was no 
conclusive evidence from the individual small size studies (Sartelet et al. 
1996, Ndao et al. 2009, Adam et al. 2011, Ephraim et al. 2014). My finding 
drawn from a sample of 16,342 pregnancies, adds up to the body of evidence 
linking malaria to pre-eclampsia among term deliveries. However, the 
direction of the association contradicts that of previous studies. My study 
suggests that malaria infection decreased the odds of pre-eclampsia, where 
the other studies (and my systematic review) have suggested that it does 
increase the odds of pre-eclampsia (Sartelet et al. 1996, Ndao et al. 2009, 
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Adam et al. 2011, Ephraim et al. 2014). A plausible explanation is that the 
reported malaria cases in my dataset were also treated for malaria and 
hence they had a decreased odd of pre-eclampsia compared to the control. 
Some of the control might have subclinical malaria and thus have a higher 
risk of placental infection that was undetected, which may have led to pre-
eclampsia than the cases who got treated for malaria and cleared the 
placental infection. The policy of giving two doses of Sulfadoxine 
Pyrimethamine (SP) for presumptive treatment for malaria infection to all 
pregnant women was adopted in Tanzania since year the 2000, this 
presumptive treatment factor could affect the observed relationship. An 
evaluation study done in Tanzania in 2015 showed 63 % of pregnant women 
were unwilling to take SP. Clinic results showed 54% of pregnant women (30 
– 40 weeks) took a single dose, 34 % took two doses. It was also found that 
SP was not administered under direct observed therapy in 86 % of women 
(Ayubu and Kidima 2017). In my analysis, I lacked the data of women who 
might have received the presumptive treatment for malaria infection. 
Therefore, SP treatment may have confounded the observed direction of the 
association.  
 My analysis was unable to show an association between malaria infection 
and pre-eclampsia among preterm deliveries (< 37weeks). Brabin (1983) had 
suggested that the peak incidence of malaria during pregnancy occurred at 
13 - 16 weeks of gestation, which is prior to early onset pre-eclampsia 
(arising from 20 – 34 gestation weeks). One plausible explanation is that 
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perhaps there is a wide window period from the time the placenta is infected 
with the malaria parasite to when pre-eclampsia manifests, therefore 
obscuring the link between malaria infection and early onset pre-eclampsia. 
An alternative explanation is that my subgroup analysis did not have 
sufficient power to detect an existing weak association. My preterm deliveries 
subgroups had 153 malaria cases and 1357 controls and yielded OR = 0.76, 
95 % CI 0.44 – 1.31, p value = 0.32 in a univariable analysis. I recommend 
further research studies to address these limitations by generating credible 
epidemiological evidence on the relationship between malaria and early 
onset pre-eclampsia. 
Women who had a diagnosis of infection during their pregnancy period were 
associated with decreased odds of pre-eclampsia by 63 % (OR = 0.37, 95 % 
CI 0.28 – 0.47) in all deliveries. This finding was also echoed in the subgroup 
analysis, in term deliveries the odds were decreased by 63 % (OR = 0.37, 95 
% CI 0.27 – 0.51) and in preterm deliveries by 60 % (OR = 0.4, 95 % CI 0.25 
- 0.64). My dataset did not unpack the diagnosis of infection to indicate the 
specific infections included. This became a challenge in comparing and 
interpreting my results in relation to the existing literature. A meta-analysis on 
maternal infections and pre-eclampsia by Conde-Agudelo et al. (2008) 
showed that urinary tract infection and periodontal disease were associated 
with pre-eclampsia. The review also cited trial studies from Germany (Fischer 
et al. 1970) and Croatia (Drazancić et al. 1989), which showed that treatment 
with antibiotics for urinary tract infection was associated with a reduced odds 
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of pre-eclampsia (OR = 0.22, 95 % CI 0.17 - 0.30 and OR = 0.36, 95 % CI 
0.20 - 0.64). With this evidence in mind, it is possible that the observed 
reduction in odds of pre-eclampsia from my analysis may imply that women 
who were diagnosed as having infection were also treated and hence they 
were at a reduced odds of pre-eclampsia compared to their counterparts 
(control group) who may have had a subclinical infection that went 
undiagnosed. Another possible explanation is that infections may lower 
maternal immunity thus lower the possibility of maternal fetal immune 
incompatibility, which is thought to cause pre-eclampsia (Kenny and Kell 
2018). In my review of African studies on pre-eclampsia risk factors, only one 
study in Ethiopia showed that urinary infection and periodontal disease were 
associated with pre-eclampsia (Endeshaw et al. 2016a). Therefore, 
contrasting this finding with my study’s finding it is not conclusive whether 
maternal infection increases or decreases the odds of pre-eclampsia in 
African populations. Further studies could explore this relationship by 
unpacking the specific infections and accounting for the immunological 
aspect of the relationship. 
My analysis revealed that use of an intrauterine contraceptive device (IUD) 
was associated with an increased odd of pre-eclampsia in all deliveries and 
in term deliveries (OR = 1.57, 95 %CI 1.07 – 2.30 and OR = 2.05, 95 %CI 
1.31 – 3.20 respectively). There is scarce evidence on the relationship 
between IUD and pre-eclampsia globally. A case-control study conducted in 
the United Kingdom by Parker et al. (2016) showed IUD decreased the odds 
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of pre-eclampsia (OR = 0.76, 95 %CI 0.58 – 0.98). The contrast observed 
with my study finding may be explained by the difference in types of IUD 
used in the UK and northern Tanzania. In the UK, copper containing IUDs 
and hormone releasing IUDs are both available while in northern Tanzania 
around the study period of 2006 to 2010, only copper containing IUDs were 
used. It is, therefore, necessary to conduct further studies to examine this 
potential association of pre-eclampsia and IUDs of both types. IUDs are 
growing in popularity as they offer a long-term reversible contraceptive option 
to most women in both developing and developed countries. 
Women receiving HIV treatment were at a decreased odd of developing pre-
eclampsia by 53 % (OR = 0.47, 95 % CI 0.26 - 0.84) among all deliveries and 
by 63 % (OR = 0.37, 95 % CI 0.16 – 0.85) among term deliveries. HIV 
treatment was not a significant predictor of pre-eclampsia among preterm 
deliveries. There have been conflicting results from studies whether HIV 
increases or decreases the likelihood of developing pre-eclampsia (Adams et 
al. 2016). My findings show that women on HIV treatment are at decreased 
odds of pre-eclampsia. The Tanzania HIV treatment guideline indicates, that 
women who test HIV positive are to be initiated on antiretroviral drugs (ARVs) 
to prevent mother to child transmission (NACP 2005). I cannot disentangle 
the source of the observed effect of a decrease in odds of pre-eclampsia, 
whether it results from having a positive HIV status, the HIV treatment or their 
interaction i.e. being positive and then receiving ARVs. I was also limited in 
my analysis while attempting to disentangle these components because of 
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the high correlation between women being HIV positive and simultaneously 
being on treatment, which brought a multicollinearity effect. 
Some studies have attempted to disentangle HIV status and HIV treatment in 
relation to pre-eclampsia. In South Africa, Frank et al. (2004) found no 
association between untreated HIV positive status and the risk of pre-
eclampsia., In a cohort of 2,600 women, the rate of pre-eclampsia was 5.2 % 
in HIV negative and 5.7 % in HIV positive women (p = 0.61). In Zambia, 
George et al. (2015) attempted to establish whether there was an association 
of HIV status, and/or HIV treatment with pre-eclampsia. In a cohort of 824 
women, neither HIV positive status (OR = 0.44, 95 % CI 0.1 - 3.2) nor HIV 
treatment (HAART) use was statistically significantly associated with the risk 
of pre-eclampsia (OR = 0.99, 95 % CI 0.1 - 8.9). However, this study had a 
small sample size, resulting in a wide confidence interval, and hence may 
have obscured a statistically significant association. Contrast to these 
findings my study shows; HIV treatment is statistically significantly associated 
with reduced odds of pre-eclampsia by 53 % (OR = 0.47, 95 % CI 0.26 - 
0.84) among all deliveries and by 63 % (OR = 0.37, 95 % CI 0.16 – 0.85) 
among term deliveries. 
Women with a higher number of pregnancies were associated with 
decreased odds of pre-eclampsia. One additional pregnancy was associated 
with 14 % (OR = 0.86, 95 % CI 0.77 – 0.96) decrease in the odds of the 
women developing pre-eclampsia. This finding is in line with the 
understanding that pre-eclampsia is predominantly a condition affecting the 
[Risk factors for pre-eclampsia] 
250  [Analysis of risk factors] 
first pregnancy (nulliparous women) (Hartikainen et al. 1998). The 
relationship between the number of pregnancies and pre-eclampsia is 
confounded by maternal age. Women on their first pregnancies tend to be 
younger while also women on their fourth or fifth pregnancy tend to be older. 
In addressing this potential confounding effect of maternal age on number of 
pregnancies, I included both variables in my modelling. My results showed an 
increase in the number of pregnancies is associated with decreased odds of 
pre-eclampsia after adjusting for maternal age. This relationship was 
statistically significant only among term deliveries (OR = 0.86, 95 % CI 0.77 – 
0.96). Several studies in African populations, that explored the relationship 
between the number of pregnancies and pre-eclampsia, have produced 
similar result showing the risk of pre-eclampsia is higher on first pregnancies 
(Adam et al. 2013, George et al. 2015, Ajah et al. 2016, Elmugabil et al. 
2016).  
7.3.2 Statistically non-significant predictors 
A series of variables have been shown to be statistically significant predictors 
of pre-eclampsia in literature. However, some of them have not been 
statistically significant in my models. In this section, I am discussing the 
possible explanation that rendered them non-statistically significant in my 
analysis. 
Diabetes mellitus and gestational diabetes are risk factors that have been 
shown to explain the occurrence of pre-eclampsia in numerous populations 
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(Tessema et al. 2015, Endeshaw et al. 2016a). My univariable analysis 
showed neither of these variables; a history of diabetes, a diagnosis of 
diabetes or a diagnosis of gestational diabetes was statistically associated 
with pre-eclampsia in all deliveries, term and preterm deliveries subgroups 
(See table 13, 17 and 21). This could be a result of very few cases with a 
positive history or diagnosis of diabetes. My dataset showed very few women 
had reported a history of diabetes (42 cases vs 16,298 control), a diagnosis 
of gestational diabetes (5 cases vs 16,333 control) or a diagnosis of diabetes 
(35 cases vs 16,307 control). The observed very low prevalence of self-
reported cases of history of diabetes and the number of diagnosed cases of 
diabetes and gestational diabetes can be explained by a weak health system 
to diagnose diabetes in these settings. A cross-sectional household study 
done in the same setting (Kilimanjaro region, northern Tanzania) by Stanifer 
et al. (2016) showed the prevalence of diabetes was 5.7 %; 95 % CI 3.3 - 9.4 
and that of glucose impairment was 21.7 %; 95 % CI 15.2 – 29.8. This 
population-based study had measured haemoglobin A1c in 481 adult 
participants from 346 urban and rural households. The study also reported a 
low awareness of diabetes (35.6 %) and low treatment uptake among 
diabetics (33.3 %) (Stanifer et al. 2016). 
Unlike the method used in this research study, the routine method used to 
screen pregnant women of diabetes in Tanzania is the urine dipstick test for 
sugar. The sensitivity of the urine test is low, and this may have led to 
misdiagnosis of diabetes cases. A systematic review involving five studies 
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concluded that urine dipstick test is insufficient to diagnose diabetes mellitus 
(Wei and Teece 2006). Currently, the Tanzanian government is in the 
process of adopting a new guideline that recommends routinely screening 
pregnant women using fasting blood glucose. In future, after this guideline 
has been implemented countrywide, it will warrant the revision of my 
prediction models for pre-eclampsia to incorporate the diagnosis of diabetes 
as a predictor in these models. Currently, it will be of no practical value to 
incorporate a predictor variable that is not measured sensitively enough to 
explain my outcome of pre-eclampsia in these settings. 
Smoking cigarettes has been documented in the literature as having a 
protective effect towards the development of pre-eclampsia. A systematic 
review involving six studies by Lucinda (2007) showed that smoking is a 
protective factor in pre-eclampsia. My analysis was not able to show an 
association of either smoking cigarettes or chewing tobacco with the 
development of pre-eclampsia. This observation may be attributed to the very 
low number of self-reported cases that professed to be smoking cigarettes (7 
cases/smokers vs 16,302 control/non-smokers) or chewing tobacco (5 cases 
vs 16,312 control) in my dataset. I was not able to find literature that has 
explored the prevalence of smoking among women of reproductive age in 
these settings, but I speculate that it has been under-reported in my dataset. 
This potential reporting bias could be caused partially by the hospital setup 
where the information was extracted: participants may not have felt at ease 
to disclose the information to their health care providers.  
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Other factors could have influenced my results of identified risk factors in this 
population.  
1. Change of paternity in subsequent pregnancies.  
This factor has been documented to influence the risk of a woman 
developing pre-eclampsia since the genetic makeup of the fetus is new to the 
mother’s immune system (Hutcheon et al. 2011). The feto-maternal immune 
incompatibility, because of changing a father, may lead to placenta 
dysfunction and hence pre-eclampsia. My dataset did not capture this 
variable, so I was unable to factor it in my analysis.  
 
2. Aspirin consumption during pregnancy. 
I did not have medical records that could enable me to identify women who 
may have consumed aspirin for other conditions. aspirin has been used to 
prevent pre-eclampsia in women at high risk of developing the condition 
(Bujold et al. 2010, Poon et al. 2017). However, it will be challenging for any 
study done in LMIC to account for this factor due to weaknesses in health 
systems. In most settings, it is possible to access aspirin without a 
prescription and even where it is prescribed, there is no central heath 
information system to enable tracking of the patient’s intake of such drugs in 
dispensaries and health centres across the region. 
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3. In vitro fertilization and interpregnancy interval 
The literature from developed countries has suggested factors such as In 
vitro fertilization (IVF) and inter-pregnancy interval to play a role as risk 
factors in their populations. I do not think these factors would have made a 
difference if explored in LMIC settings because IVF is a very rare 
intervention. Inter-pregnancy interval has been shown to matter after a ten-
year period of spacing pregnancies, where the risk of pre-eclampsia equals 
that of a nulliparous women (Skjaerven et al. 2002). Most LMIC are 
experiencing very high fertility rates. In Tanzania, the average fertility rate is 
five children per women. Given the fact that the reproductive age is from 15 
to 49 years, this high fertility rate can hardly be attained with interpregnancy 
spacing of more than ten years to make it worth factoring it into my analysis. 
My conclusion is that prediction models relying on maternal biomedical 
characteristics alone can be useful to predict the occurrence of pre-
eclampsia in LMIC, although with moderate sensitivity and specificity. The 
addition of biomarkers as shown in studies elsewhere is likely to improve the 
prediction performance. The predictors that have been statistically significant 
and adopted in my model to predict pre-eclampsia in all deliveries are; 
maternal age, weight before pregnancy, history of hypertension, HIV 
treatment, contraceptive IUD use, diagnosis of infection and diagnosis of 
malaria. My subgroup analysis showed there is a difference in the set of 
predictors that predict pre-eclampsia in term deliveries and preterm 
deliveries, thus, supporting a difference in aetiology of the two subgroups. My 
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findings differed from other studies since I was unable to include diabetes 
mellitus or gestational diabetes as predictor variables due to limitations in the 
health system in Tanzanian settings. Other predictors such as IVF that are 
often used in developed countries were not relevant in the context of LMIC. 
Currently, there are diagnostic challenges facing these potential predictors, 
diabetes mellitus and gestational diabetes. In future, I may revise these 
models to include gestational diabetes and diabetes mellitus to improve 
model prediction. Prediction models that rely on existing routine clinical data 
are likely to be affordable in LMIC and offer an opportunity of improving 
targeted care delivery to women at high risk of pre-eclampsia. 
 
7.4 Discussion objective 4  
To describe the pregnancy outcomes characteristics of women with pre-
eclampsia in northern Tanzania. 
Our understanding of the effects of pre-eclampsia on the unborn child has 
increased over the years. Pre-eclampsia has been reported to contribute 
fivefold to perinatal mortality in developing countries (López Jaramillo et al. 
2009). Furthermore, there is also a report of increased risk of stroke in adult 
life among the offspring of pre-eclampsia pregnancies, thus suggesting the 
possible long term effects of pre-eclampsia on the surviving offspring 
(Kajantie et al. 2009). The WHO is tracking the attainment of the SDG on 
child health through global health observatory data. The infant mortality data 
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showed 4.1 million deaths (75 % of under-five deaths) occurred in the first 
year of life. The infant mortality rate in Africa (51 death per 1000 live births) 
was six times that of Europe (8 deaths per 1000 live births), showing marked 
regional variation. The WHO also reported that 47 % of all under-five deaths 
were neonatal deaths, in the first 28 days of life (WHO 2017b). I have 
described the characteristics of pregnancy outcomes of women with pre-
eclampsia in comparison with women without pre-eclampsia using data from 
northern Tanzania. Furthermore, I have carried out a subgroup analysis for 
term and preterm deliveries subgroups to account for the difference in 
gestational age at delivery of the newborn. The gestational age at delivery is 
known to confound the survival and ill-being of the newborn (Osrin et al. 
2001). My overall finding has shown that pregnancy outcomes of women with 
pre-eclampsia are far worse than women without pre-eclampsia. This finding 
has remained valid even after accounting for the gestational age at delivery 
in my term and preterm subgroup analysis. The literature suggests that there 
is no difference in the pregnancy outcome of primiparous and multiparous 
women with pre-eclampsia (Badria and Amarin 2005). I have not made a 
distinction in characterizing the pregnancy outcomes of primiparous and 
multiparous women with pre-eclampsia. My findings are a combination of 
primiparous and multiparous pre-eclampsia women. 
My initial exploration of stillbirth outcome among women with pre-eclampsia 
in northern Tanzania showed that the rate of stillbirth was (74/587) 12.6 %, 
95 % CI 10 % - 15.2 % of pregnancies. This was similar to a rather small 
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study in the Lake zone of Tanzania that examined only eclampsia outcomes 
of 78 women, and showed stillbirth was 12.2 % (10/78) of all eclampsia 
outcome (Ndaboine et al. 2012). I then examined the strength of the 
association. The odds of stillbirth were 4.8 (95 % CI 3.7 – 6.3) times among 
women with pre-eclampsia than women without pre-eclampsia in all 
deliveries. Upon stratifying by term and preterm deliveries the odds were 2.6 
(95 % CI 1.6 – 4.3) and 2.9 (95 % CI 2.0 – 4.1) respectively. The drop in the 
strength of association appears to suggest that part of the effect of pre-
eclampsia on stillbirth is mediated by prematurity which is an integral 
outcome of pre-eclampsia. The overall association between pre-eclampsia 
and stillbirth finding is consistent with other research findings. A WHO multi-
country survey involving around 313,030 women by Abalos et al. (2014) 
showed pre-eclampsia (OR = 3.1, 95 % CI 2.7 - 3.5) and eclampsia (OR = 
3.9, 95 % CI 3.1 - 4.8) were both associated with fetal death (stillbirths). The 
observed strong association between pre-eclampsia and stillbirth outcomes 
may suggest the necessity to tackle pre-eclampsia as a probable root cause 
of stillbirth outcomes.  
I also examined neonatal death within 24-hours outcome among women with 
pre-eclampsia. Neonatal death was 0.5 % (3/587) of all deliveries among 
women with pre-eclampsia in KCMC hospital, northern Tanzania. Upon 
examination of the strength of the association, my finding showed pre-
eclampsia was not statistically significantly associated with neonatal death in 
all deliveries (p value =0.2), neither in term (p value =1) or preterm (p value 
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=0.2) deliveries subgroups. My finding was different from that drawn from the 
WHO survey where pre-eclampsia (OR = 2.7, 95 % CI 2.2 -3.2) and 
eclampsia (OR = 6.5, 95 % CI 4.9 – 8.8) were both associated with early 
neonatal death (Abalos et al. 2014). I may speculate that this lack of 
difference in early neonatal deaths within 24 hours between women with and 
those without pre-eclampsia is a result of quality neonatal care services or 
due to bias since children born with complications were transferred to the 
pediatric ward at my study Centre, KCMC hospital. The neonatal deaths that 
could have occurred in the pediatric ward could not be established from my 
data set. However, neonatal deaths may be worse in lower level health 
facilities. A small study in rural western Tanzania showed the proportion of 
neonatal death among women with severe pre-eclampsia and eclampsia was 
as high as 12.8 % (9/70) (Mooij et al. 2015).  
In addition to causing neonatal death and stillbirth, pre-eclampsia is 
associated with low Apgar scores of the surviving offspring. Low Apgar score 
at 1 minute is an indicator of the mental wellbeing of the newborn 
immediately after birth. Poor metal wellbeing at birth may lead to lifelong 
mental impairment in the surviving infant. My findings show pre-eclampsia is 
associated with a low Apgar score (OR = 4.3, 95 % CI 3.4 - 5.4) in all 
deliveries. The association was maintained in the subgroup of term and 
preterm deliveries (OR = 2.3, 95 % CI 1.5 – 3.5 and 2.8, 95 % CI 2.0 - 3.9 
respectively). Prematurity being an integral part of pre-eclampsia outcome 
appears to mediate part of the pre-eclampsia effect in causing a low Apgar 
  [Risk factors for pre-eclampsia] 
[Analysis of risk factors]  259 
 
score. A study in Ghana showed hypertensive disorders of pregnancy were 
associated with low Apgar score at birth, With an odds ratio of 1.8, 95 % CI 
1.1 – 3.1 after adjusting for maternal age, parity, number of antenatal visits, 
gestational age at delivery and mode of delivery (Adu-Bonsaffoh et al. 2017). 
This study did not present the association of pre-eclampsia with low Agpar 
score, a subcategory of hypertensive disorders of pregnancy, but showed the 
proportion of low Agpar score was higher among pre-eclampsia subcategory 
(45.7 %) compared to other subcategories combined (26.8 %). Therefore, the 
strength of the association between pre-eclampsia and low Apgar score is 
likely to be higher than the one presented for the entire group of hypertensive 
disorders of pregnancies. A larger multinational survey by Abalos et al. 
(2014) also echoed the proportion of low Apgar score was higher in 
newborns of pre-eclampsia (20.6 %) and eclampsia (25.5 %) compared to 
newborns of non-hypertensive women (5.3 %).  
The negative effect of pre-eclampsia on surviving offspring is also observed 
in the low birthweight (< 2500gm) indicator. Low birth weight, which often 
results from either preterm delivery or intrauterine fetal growth restriction or 
both, is thought to influence the survival of the newborn in the early days in 
life (Osrin et al. 2001). Low birth weight depicts fetal nutrition and is also a 
developmental indicator that has long term health effect on the sufferers in 
adult life (Barker et al. 1993, Lucas 1994). My result showed pre-eclampsia 
was strongly associated with low birth weight in all deliveries, term and 
preterm deliveries subgroups, with odds ratios of 6.4, 95 % CI 5.3 – 7.6: 3.6, 
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95 % CI 2.7 – 4.7 and 6.4, 95 % CI 4.4 – 9.3 respectively. I compared the 
strength of the association between term and preterm deliveries and 
observed that the strength is nearly double in the preterm subgroup 
compared to the term subgroup. What could explain this marked effect on 
low birth weight of pre-eclampsia newborns compared to non-pre-eclampsia 
newborns when both are born preterm? A plausible explanation for observing 
a much stronger association between low birth weight and pre-eclampsia in 
the preterm subgroup than in the term deliveries subgroup is due to some 
confounding factor. In my cases, the co-existence of IUFGR in the preterm 
deliveries with pre-eclampsia may be the confounding factor. A study by 
Sharma et al. (2017) showed IUFGR was associated with pregnancies with 
pre-eclampsia and preterm delivery compared with pregnancies with pre-
eclampsia alone. In the second paragraph below, I have embarked on 
exploring features of IUFGR among newborns of pre-eclampsia in term and 
preterm subgroups in order to substantiate this confounding relationship. 
The other side of the birth weight spectrum suggests that pre-eclampsia is 
associated with macrosomia (high birth weight > 4000gm) as well. The 
strength of the association was 2.0, 95 % CI 1.3 – 3.2 in all deliveries and 
2.0, 95 % CI 1.3 – 3.3 in term deliveries. In preterm the association was not 
statistically significant due to small sample size for the group, this is 
evidenced by the wide confidence interval (OR = 2.4, 95 % CI 0.3 – 19.2, p 
value = 0.36). This observation could suggest a number of plausible 
explanations, one of them being the confounding effect of IUFGR. If we 
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assume that pre-eclampsia is associated with macrosomia then we may 
expect in the preterm subgroup, where IUFGR related to pre-eclampsia 
strongly exists, will counter and nullify the effects that would result in 
macrosomia (high birth weight). Therefore, we are only able to observe the 
macrosomia effect of pre-eclampsia in the term subgroup where the IUFGR 
influence is reduced. A second explanation is that the relationship between 
pre-eclampsia and macrosomia is confounded by another factor. Both 
conditions may share the same risk factor such as gestational diabetes. 
There is scarce literature on this relationship between pre-eclampsia and 
macrosomia in LMIC. However, a study in Ghana by Adu-Bonsaffoh et al. 
(2017) demonstrated that macrosomia exists across the different 
subcategories of hypertensive disorders of pregnancy. Another study in the 
USA by Langford et al. (2011) suggested that macrosomia and pre-
eclampsia had a shared risk factor: overweight women who gained weight 
above 25 lb were more at risk of developing pre-eclampsia (RR = 1.7, 95 % 
CI 1.5 - 1.9) and macrosomia (RR = 2.1, 95 % CI 1.9 - 2.3) compared to 
those who gained recommended weight (15 - 25 lb). There is a need for 
more research to further explore this relationship between pre-eclampsia and 
macrosomia in LMIC populations.  
I examined features of intrauterine fetal growth restriction, head 
circumference and birth length, by comparing newborns of pre-eclampsia and 
non-pre-eclampsia deliveries in term and preterm subgroups. The average 
gestational age of preterm deliveries was 33.9 weeks, while that of term 
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deliveries was 39.6 weeks. The average head circumference for preterm 
newborns of pre-eclampsia women was smaller compared to those of their 
counterparts’ i.e. preterm newborns of non-pre-eclampsia women. The mean 
difference of head circumferences was 0.993 (0.758 - 1.227), p < 0.001 in all 
deliveries. The mean difference was 2.020 (1.444 - 2.597), p < 0.001 in 
preterm deliveries. However, this difference was not statistically significant in 
term deliveries 0.099 (-0.046 - 0.245), p = 0.153. 
These findings only show the comparison of average head circumference 
between newborns of women with and without pre-eclampsia. They do not 
offer a comparison with the standard values of the fetal head circumference 
with respect to gestational age that is used to quantify intrauterine fetal 
growth restriction. A limitation to my analysis is that I was unable to compare 
the deviation of head circumference of newborns of pre-eclampsia women 
with the standard fetal head circumferences for the respective gestational 
age that range from 26 – 40 weeks. This analysis would enable us to show 
the deviation of pre-eclampsia newborns from the standard head 
circumferences across the range of gestational age. In future, I plan to focus 
no this analysis to be able to observe the presence and the extent of 
intrauterine fetal growth restriction experienced by newborns of pre-
eclampsia women in northern Tanzania.  
Similarly, I explored birth length, another feature of intrauterine fetal growth 
restriction, in relation to pre-eclampsia. My results showed that newborns of 
pre-eclampsia women were on average shorter in length than newborns of 
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non-pre-eclampsia women (46.3 cm ± 0.18 SD vs 48.3 cm ± 0.01SD, p value 
< 0.001). This finding was also observed in both preterm and term 
subgroups. (42.6 cm ± 0.28 SD vs 46.3 cm ± 0.1 SD, p value < 0.001) and 
(48.1 cm ± 0.11 SD vs 48.5 cm ± 0.01SD, p value < 0.001) respectively. The 
mean differences for birth length in all deliveries was 1.920 (1.548 - 2.292), p 
< 0.001. The mean difference was also observed in term deliveries 0.406 
(0.182 - 0.631), p < 0.001 and was more pronounced in preterm deliveries 
3.729 (2.831 - 4.628), P < 0.001. 
Unlike head circumference presented above, birth length has shown a 
statistically significant difference in all deliveries, term and preterm deliveries 
subgroup. Both indicators are measured using the same tool i.e. a measuring 
tape around the head in the case of head circumference and crown to heel in 
the case of birth length. A reason for the discrepancy observed by these two 
indicators of IUFGR may be measurement errors. This may mask an existing 
difference in head circumferences but be insufficient to mask the difference in 
birth lengths because the existing difference is inherently smaller in head 
circumferences than in birth length. Therefore, I suggest that birth length is a 
more sensitive indicator to detect IUFGR. 
The alliance for maternal and newborn health improvement study has shown 
that use of transcerebellar diameter measurement in late pregnancy can 
improve the estimation of gestation age with appropriate weight for gestation 
and those with small for gestation age in LMIC (B J Wylie et al 2020). This 
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valuable finding, if applied has the potential to accurately identifying IUFGR 
after ascertaining appropriate gestation age of a newborn. 
Pre-eclampsia appears to present a constraint in the health delivery system. 
This is such an important aspect especially in the LMIC, where resources for 
health care are scarce. I have observed that pre-eclampsia is associated with 
assisted deliveries in all deliveries (OR = 1.38, 95 % CI 1.1 – 1.6). This 
finding also implies that assisted delivery services are required preferentially 
to support pre-eclampsia women to deliver safely to mitigate the negative 
impacts of pre-eclampsia on the mother and the newborn. In the event such 
services are not available then the consequence in terms of stillbirth and 
neonatal deaths will be more severe for mothers with pre-eclampsia. The 
magnitude of the association between pre-eclampsia and these negative 
consequences (stillbirth, neonatal death, Apgar score etc.) is highly 
influenced by the quality of intervention services. Even the less obvious 
interventions seem to make a difference in the outcome. There is evidence 
from a study in India showing the maternal and fetal outcome of women with 
severe pre-eclampsia undergoing emergency cesarean section differed 
depending on the anaesthesia technique used in the surgery (Suman et al. 
2014). This underlines the contribution of interventions in influencing the 
extent and types of outcomes from pre-eclampsia pregnancies. My results 
are from a tertiary hospital in northern Tanzania where most of the 
comprehensive emergency obstetric services are available and accessible. 
The situation is likely to be much worse in rural health settings, where such 
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intervention services are absent or not timely accessed. A study in Nigeria 
showed both maternal and perinatal death due to eclampsia were worse 
when patients presented after 12 hours from the onset of convulsion 
(Yakasai and Gaya 2011). In light of this thinking, I advocate for investment 
in addressing pre-eclampsia in LMIC, where the magnitude of its 
consequences is likely to be more devastating than the presented picture of 
my results. My results also highlight the effects on the surviving offspring in 
terms of their developmental indicators such as Apgar score and birth weight. 
This further emphasises investing in pre-eclampsia to avert these 
developmental challenges to surviving newborns, thus giving them a lifelong 
benefit. 
7.5 Summary  
The analysis of secondary data from Tanzania aimed firstly, to estimate the 
incidence of pre-eclampsia in Dar es Salaam city, Tanzania. I estimated the 
incidence in the year 2009 to have been 1.9 %, 95 % CI 1.3 % to 2.2 %. This 
estimate serves as a baseline for future monitoring of the trend of the 
condition in this rapidly evolving urban setting of Tanzania. Secondly, I 
described the sociodemographic characteristic of women with pre-eclampsia 
in northern Tanzania. The observed results showed that pre-eclampsia was 
independently associated with pregnant women above 35 years, single and 
those with tertiary level education. The increased risk among women with 
tertiary education may be due to either lifestyle change or increased health-
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seeking behaviour. Qualitative studies could explore this social group to 
understand this dynamic relationship. Thirdly, I analysed the risk factors 
associated with pre-eclampsia in northern Tanzania, which revealed that 
different sets of risk factors explain term and preterm pre-eclampsia 
outcomes in this population. This tally with findings elsewhere, which also 
suggested different aetiology for early and late pre-eclampsia onset. In my 
analysis, pre-eclampsia in term deliveries was explained by maternal age, 
number of pregnancies, history of hypertension, a diagnosis of malaria, 
diagnosis of infection, contraceptive IUD use, HIV treatment and pre-
pregnancy body weight. In preterm deliveries, pre-eclampsia was explained 
by maternal age, pre-pregnancy body weight, diagnosis of infection and 
history of hypertension. The prediction of pre-eclampsia outcome using 
models including these risk factors yielded a Youden’s index with a sensitivity 
of 65 % and specificity of 63 % in classifying pre-eclampsia outcome in all 
deliveries. This raises the concern for the need to integrate modern markers 
and tools to improve the prediction of pre-eclampsia. Most LMIC rely on a 
similar list of risk factors to screen for pre-eclampsia. Integrating modern 
markers and tools in predicting pre-eclampsia may improve identification of 
cases and allow timely provision of prevention services. Fourthly, I described 
the characteristics of pre-eclampsia pregnancy outcomes. This revealed that 
women with pre-eclampsia experience higher percentage of stillbirth and 
neonatal death. Their surviving offspring also had worse Apgar scores and 
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birth weight, which are important indicators setting them into a poor 
developmental trajectory in later life.  
This work contributes to the scarce literature on risk factors for pre-eclampsia 
in LMIC. It also captures the aspect of difference in risk factors in early and 
late pre-eclampsia onset in the region. In an attempt to explore the local 
drivers, I examined malaria infection as a unique local risk factor for this 
region, alongside other risk factors. The revelation of an existing relationship 
between malaria infection and pre-eclampsia may encourage further 
research to explore this important factor in this region. The observed results 
of poor pre-eclampsia pregnancy outcome and moderate sensitivity of 
screening tools in the region calls for further investment in the health system 
to mitigate the impact of the disease, so as to attain the SDGs for improved 
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Chapter 8 Conclusion on pre-eclampsia risk 
factor analysis in Tanzania. 
8.1 Conclusion  
This section concludes the discussions of this thesis in line with its main 
areas of research: the scoping review study on risk factors of pre-eclampsia 
in Africa, the systematic review and meta-analysis of the association of 
malaria infection and gestational hypertension and lastly, the analysis of risk 
factors for pre-eclampsia from Tanzania. 
The scoping review showed that risk factors for pre-eclampsia have been 
under-researched in African populations, despite the fact that such 
populations are experiencing high levels of maternal and infant mortality. The 
risk factors associated with pre-eclampsia showed inconsistent results across 
populations. Malaria infection, a locally important potential risk factor, showed 
inconclusive results in its association with pre-eclampsia and gestational 
hypertension, thus compelling me to undertake a meta-analysis of the 
primary studies. I observed methodological limitations in the studies since 
most studies were case-control with small sample size. Very few cohort 
studies were able to examine the temporal relationship between the risk 
factor and outcome. There was scarce evidence that took into account early 
and late onset of pre-eclampsia in analysing risk factors. Furthermore, there 
were no assessments of model performance in classifying pre-eclampsia 
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outcome in these populations. Following identification of these gaps, I set out 
to address them in the systematic review and in my risk factor analysis study 
using data from Tanzania.  
The systematic review and meta-analysis of primary studies that examined 
the association of malaria and pre-eclampsia plus gestational hypertension in 
African populations revealed a strong association after adjusting for key 
confounding variables. The odds of having GH were more than double 
among women with malaria infection, compared to women without malaria 
infection. In this, meta-analysis pre-eclampsia and gestational hypertension 
proper were combined into one outcome of gestational hypertension. This 
approach enabled me to identify the contribution of malaria as a risk factor in 
the overall burden of hypertensive disorders of pregnancy, as it was linked to 
both the pre-eclampsia and gestational hypertension sub-categories. Malaria 
infection was observed to exert constant effects across the studied 
populations. The ongoing interventions that are controlling malaria infection 
on pregnant women could have an indirect benefit of reducing gestational 
hypertension and, in the long-term, cardiovascular diseases to women in the 
region. However, since my study only shows an association, there is a need 
for conducting molecular studies to further explore the causal mechanism. 
The analysis of secondary data from Tanzania showed the incidence of pre-
eclampsia in Dar es Salaam Tanzania in 2009 was 1.9 %, 95 % CI 1.3 % to 
2.2 %, which is similar to the WHO global estimates of between 2 % and 8 %. 
This estimate serves as a reference for future estimation of the incidence in 
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the evolving urban setting of Tanzania. The sociodemographic characteristics 
that were independently associated with pre-eclampsia in northern Tanzania 
were women aged 35 years and over, single and with tertiary level education. 
Further qualitative studies could examine the dynamics of this relationship 
between tertiary education level and pre-eclampsia to inform the public on 
prevention strategies. This analysis showed that different sets of risk factors 
explain term and preterm pre-eclampsia outcomes in the northern Tanzanian 
population. This tally with findings elsewhere, which also suggest different 
aetiologies for early and late pre-eclampsia onset. Pre-eclampsia in term 
deliveries was explained by; maternal age, the number of pregnancies, 
history of hypertension, a positive diagnosis of malaria infection, HIV 
treatment, contraceptive IUD use, diagnosis of infection and pre-pregnancy 
body weight. Pre-eclampsia in preterm deliveries was explained by maternal 
age, pre-pregnancy body weight, diagnosis of infection and history of 
hypertension. The prediction of pre-eclampsia outcome in all deliveries, term 
and preterm deliveries subgroups using models with these risk factors 
showed an AUC of 69.4 %, 72.1 % and 66.9 % respectively. The three 
models yielded Younden’s index with sensitivity values of 65 %, 65 % and 59 
% respectively and specificity values of 63 %, 65 % and 66 % respectively in 
classifying pre-eclampsia outcomes in the three groups. The AUC scores 
show the models were moderate (≥ 70 % - < 80 %) and weak classifiers (≥ 
60 % - <70 %) of the outcome. This finding prompts the need to integrate 
modern markers to improve the prediction of pre-eclampsia in LMIC, which 
  [Risk factors for pre-eclampsia] 
[Analysis of risk factors]  271 
 
continue to rely solely on maternal biomedical risk factors for screening. My 
analysis also revealed that women with pre-eclampsia experience a higher 
percentage of stillbirth and neonatal death. Their surviving offspring also had 
worse Apgar scores and birth weight, which are important indicators setting 
them to a poor developmental trajectory in later life.  
This work contributes to the scarce literature on risk factors for pre-eclampsia 
in LMIC. It also illustrates the difference in risk factors in early and late pre-
eclampsia onset in the region. The observed results of poor pregnancy 
outcome in pre-eclampsia deliveries and moderate sensitivity of prediction 
models calls for further investment in the health system to mitigate the impact 
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8.2 Recommendations  
As a result of this study, I have identified five key recommendations, as 
articulated below. 
1. The diverse populations in the African region will benefit from research 
with methodological rigour that aims to explore the risk factors of pre-
eclampsia in order to resolve the conflicting and the inconclusive 
results observed in the literature for some important risk factors. 
2. There is a need to conduct molecular studies to understand potential 
causal links between malaria infection and both pre-eclampsia and 
gestational hypertension. 
3. It is necessary to conduct studies periodically to estimate the 
incidence of pre-eclampsia, especially in urban settings where rapid 
lifestyle changes may result in an increasing trend in the condition. 
Alternatively, establishing accurate diagnostic procedures for pre-
eclampsia and efficient data recoding in the health information 
systems in most LMIC may provide a reliable means of monitoring the 
condition using routine data.  
4. It is important for LMIC to develop prediction models for pre-eclampsia 
that have higher sensitivity and specificity compared to my models that 
only relied on maternal biomedical characteristics because I was 
attempting to offer a cheap and feasible way to predict the outcome. 
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High sensitivity and specificity models may be achieved through 
incorporating biomarkers, suited to the target population. However, the 
end models ought to be affordable and feasible to implement in the 
region.  
5. The mortality and morbidity proportions of infants born from pre-
eclampsia women are unacceptably high from the Tanzania data. 
Indicators of wellbeing among surviving offspring of pre-eclampsia 
were poor, hinting at a poor health trajectory in their adult life. We do 
not know the long-term effects because of fetal programming on the 
surviving offspring. This calls for further studies to explore the impact 
in later life among offspring in LMIC. Establishment of routine data 
systems that can link maternal records and adulthood morbidity and 
mortality records will enable follow up studies that explore fetal 
programming effects in LMIC.  
8.3 Way forward  
I plan to collaborate with other researchers in Tanzania and incorporate pre-
eclampsia related questions in the ongoing surveillance studies to enable an 
up-to-date estimation of the incidence of pre-eclampsia and related risk 
factors in Tanzania. 
I plan to revise the developed prediction models by incorporating more risk 
factors, such as gestational diabetes after a new maternal health guideline is 
implemented in Tanzania. The guideline adopts the use of blood sugar test 
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rather than a urine sugar test in detecting gestational diabetes. This will 
enable better prediction of pre-eclampsia. 
I plan to disseminate my results through publications; I have earmarked the 
following areas of my thesis for publication. 
a. The systematic review and meta-analysis on the association of malaria 
infection and gestational hypertension. This paper has been submitted 
to the Journal of Global Health. Malaria association reviewers have 
reviewed it. Later on, I will embark on addressing the reviewer’s 
comments. 
b. The risk factors that explain pre-eclampsia occurrence in northern 
Tanzania. 
c. Description of pregnancy outcomes of women with pre-eclampsia in 
northern Tanzania. 
I plan to advocate for the process of developing a national guideline for 
preventing and managing hypertensive disorders of pregnancy in Tanzania. 
This will harmonise care delivery and promote necessary preventive 
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Annex 2: standard antenatal care 
According to the guidelines set by WHO and adopted by the Tanzanian 
Ministry of Health, all women and children seen in the public or private Clinics 
need to have some basic care standards met.  Study Clinics need to fall 
within these requirements of health care provision whether using the local 
Clinic system or via research activities. The provisions set forth here are 
those recommended by the WHO Model for Antenatal Care in Randomised 
Clinic Trials: 
• All women will get MCH care free of charge 
• All pregnant women will attend ANC monthly in accordance with Ministry 
of Health guidelines. 
• Women received Tetanus Toxoid vaccinations according to the following 
schedule: 
Dose #1:  First antenatal visit 
Dose #2:  after 4 weeks 
Dose #3:  after 6 months 
Dose #4:  after 1 year 
Dose #5:  after 1 year 
• Women are given malaria prophylaxis: Fansidar tablets at 20 weeks and 
30 weeks gestational age. N.B. Not to be administered during first 
trimester.  
• Women receive iron (60mg elemental iron) and folic acid (at least 0.25 
mg) to be taken daily as a FeFol combination tablet. 
• Women will be checked for syphilis and blood group typing during the first 
antenatal visit.   
• Urine will be tested at first ANC visit with a multiple dipstick for bacteriuria 
and proteinuria.  Repeat proteinuria (Albumin stick) test at second visit if 
client is nulliparous or has a history of hypertension, pre-eclampsia or 
eclampsia.  Continue to check for bacteriuria until infection is gone. 
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Annex 3: Enrolment to child 2 study 
A mother was considered enrolled when she signs the consent form for the 
study. An infant was not enrolled until he/she was randomised. 
The trial was a 2X2 factorial, double-blind, randomised controlled trial, 2400 
infants who were 6 weeks of age and born to HIV-negative mothers were 
randomly assigned to receive daily oral supplementation of Multivitamins 
(vitamin B complex and vitamins C and E), zinc, zinc + Multivitamins or 
placebo for 18 months. Study nurses assessed morbidity at monthly visits 
and by physicians every 3 month and/or when the child was acutely ill. 
Eligibility  
Eligibility was determined by the medical history information obtained, by 
physical exam, and by laboratory results. Subjects who fail to meet the 
eligibility criteria were informed by study staff and thanked.  Enrolled subjects 
whose eligibility was verified by the screening tests were informed by study 
staff and scheduled to return for an enrollment visit.   
Inclusion Criteria for Mothers 
Eligibility of women was evaluated using the Confirmation of Maternal Eligibility 
form. This form was completed at the Enrollment Visit (V1). 
 
A woman eligible for enrollment must:  
• be pregnant with singleton foetus 
• be ≥ 18 years old 
• be ≤ 34 weeks gestation (as measured by last menstrual period) 
▪ The original gestational age criteria were 28-34 weeks 
gestational age. I started enrolling women less than or 34 
weeks on 21 January 2008. 
• be HIV negative 
• be willing to remain in Dar es Salaam for 2 years after the child’s 
birth 
• Must not have had a previous child enrolled in Child2 study 
Inclusion Criteria for Children 
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Eligibility of children will be evaluated using the confirmation of eligibility form.  
This form will be completed at the Visit 11 appointment.   
Inclusion criteria for children: 
- Singleton, live-born infants  
- Born to HIV negative women  
- Mothers intend to stay in Dar es Salaam for at least 2 years after 
delivery  
- 5 to 7 weeks of age  
Exclusion criteria for children: 
- serious congenital anomalies (e.g., cyanotic congenital heart 
disease, spinal bifida, or other nervous system malformations) 
- serious medical conditions (e.g., Down syndrome, other genetic 
condition that would interfere with compliance with study 
procedures) 
- inability to comply with study regimen (e.g., inability to take oral 
supplement) 
- inability to comply with study procedures (e.g., mother unable to 
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Annex 4:  
Figure 23. Malaria diagnosis algorithm. 
Rapid Diagnosis test for malaria was performed during consultation with the 
doctor to diagnose malaria 
 
 
  [Risk factors for pre-eclampsia] 
[Analysis of risk factors]  307 
 
Annex 5: search strategy for scoping study risk 
factors for pre-eclampsia. 
 
A. EMBASE; 
1. exp risk factor/       
2. exp etiology/ 
3. exp contraceptive agent/ 
4. exp smoking/ 
5. exp anemia/ 
6. exp diabetes mellitus/ 
7. exp hypertension/ 
8. exp cholesterol/ 
9. exp placental malaria/ 
10. exp Human immunodeficiency virus/ 
11. 1 or 2 
12. 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 
13. 11 or 12 
14. exp pre-eclampsia/ 
15. exp eclampsia/ 
16. 14 or 15 
17. 13 and 16 
18. limit 17 to english language 
19. limit 18 to human 
20. limit 19 to full text 
 
B; WHO GLOBAL HEALTH LIBRARY. 
(etiology OR risk factor) AND (Pre-eclampsia OR pre-eclampsia) AND 
(instance:"ghl") AND ( db:("LILACS" OR "WPRIM" OR "IMEMR" OR 
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C; WEB OF SCIENCE. 
Set 
Web of Science Core Collection 
Search History - " final risk f preE" 
#8 
(#5 NOT #6) AND LANGUAGE: (English) 
Refined by: Open Access: (YES)  
DocType=All document types; Language=All languages; 
#7 
(#5 NOT #6) AND LANGUAGE: (English)  
DocType=All document types; Language=All languages; 
#6 
TS=animal$  
DocType=All document types; Language=All languages; 
#5 
(#4 AND #1) AND LANGUAGE: (English)  
DocType=All document types; Language=All languages; 
#4 
(#3 OR #2) AND LANGUAGE: (English)  
DocType=All document types; Language=All languages; 
#3 
TS=(smoking OR diabetes OR hypertension OR anemia OR malaria 
OR HIV OR contraceptive)  
DocType=All document types; Language=All languages; 
#2 
TS=("risk factor*" OR etiology OR cause*)  
DocType=All document types; Language=All languages; 
#1 
(TI=(pre-eclampsia OR pre-
eclampsia)) AND LANGUAGE: (English)  
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Database: Ovid MEDLINE(R) <1946 to February Week 2 2018> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     hypertension, pregnancy-induced/ or eclampsia/ or hellp syndrome/ or 
pre-eclampsia/ or pregnancy complications, 
cardiovascular/ or pregnancy complications, hematologic/ or pregnancy 
complications, infectious/        (87919) 
2     malaria.mp. or MALARIA/       (76629) 
3     pregnancy induced hypertension.mp. or Hypertension, Pregnancy-
Induced/         (5188) 
4     1 or 3          (88851) 
5     2 and 4          (1086) 
6     limit 5 to (english language and full text and humans)  (334) 
EMBASE 
Database: Embase <1980 to 2018 Week 08> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     malaria/ or malaria.mp.       (101474) 
2     pregnancy induced hypertension.mp. or maternal hypertension/ (16362) 
3     1 and 2          (95) 
4     limit 3 to (full text and human and english language)   (34) 
 
WHO GLOBAL INDEX MEDICUS 
Search date:03/03/2018       (20) 
(tw:(pregnancy induced hypertension)) OR (tw:(maternal hypertension)) OR 
(tw:(pre-eclampsia)) AND (tw:(malaria)) OR (tw:(placental malaria)) AND 
(instance:"ghl") AND ( db:("LILACS" OR "WPRIM" OR "IMEMR" OR 
"IMSEAR" OR "WHOLIS" OR "AIM" OR "BBO") AND type of study:("case-
control" OR "cohort" OR "systematic reviews" OR "clinical trials") AND 
limit:("humans") AND la:("en")) 
 
GOOGLE SCHOLAR 
Search date:03/03/2018       (94)  
("Pre-eclampsia" OR "pregnancy induced hypertension") AND ("malaria" OR 
"Placental malaria")








